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Resumen
"Estudio epidemiológico y evolutivo de los schwanomas vestibulares tras distintos
tipos de tratamiento"
1. Antecedentes
Los schwanomas vestibulares (SVs) son tumores intracraneales benignos que se originan
en las células de Schwann del nervio cócleo-vestibular; suponen el 80-90% de las masas
localizadas en el ángulo pontocerebeloso1,3,8,12,20,22,32.
El estudio histopatológico de los SV determina la existencia de dos tipos celulares, Antoni
“A” y Antoni “B”. Rubinstein (1989) describió que los cambios mucinosos y
microquísticos tienden a suceder en las células Antoni B20.
A medida que el tumor crece, lo hace en la dirección de menor resistencia, medialmente en
el APC o hacia el oído interno (formando un cordón en el CAI). Por ello, los SV pueden
tener componente extracanalicular, intra-extracanalicular o exclusivamente
intracanalicular. El SV bilateral es poco frecuente y se asocia generalmente con la
Neurofibromatosis tipo 2 (NF2). La aparición de SVs esporádicos y NF2 parece estar
asociado con una mutación de un gen supresor tumoral en el cromosoma 22q12. La base
biológica que explique los diferentes patrones de crecimiento permanece desconocida.
La presentación clínica de un SV es muy variable; incluye hipoacusia neurosensorial
unilateral en frecuencias agudas, acúfenos, desequilibrio, presión ótica, otalgia y vértigo.
Todos son resultado de la presión ejercida por el tumor sobre las ramas coclear y vestibular
del VIII par craneal. La hipoacusia es el hallazgo más frecuente; ocurre en más del 95% de
los pacientes en el transcurso de la evolución.35
Según algunas publicaciones, la incidencia de los SVs está aumentando52,53 mientras que el
tamaño del tumor en el momento del diagnóstico es cada vez menor y la edad media al
diagnóstico se mantiene estable130,132. Este incremento en la incidencia probablemente se
deba a un uso generalizado de la RM en la práctica clínica.
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Las modalidades de tratamiento incluyen vigilancia, radiocirugía (Gamma Knife or Cyber
Knife) y cirugía convencional. La elección de una u otra alternativa depende de muchos
factores: tamaño, edad del paciente y estado general, severidad de la hipoacusia, presencia
de síntomas neurológicos y preferencia del paciente.
1.1 Planteamiento del problema.
La tasa de crecimiento de los SVs es variable y difícil de predecir. El tamaño del tumor
puede permanecer estable, aumentar o disminuir. Cuando crece, habitualmente lo hace de
forma lenta. Sin embargo, algunos SVs se comportan de un modo distinto y pueden causar
signos neurológicos incluso mortales por compresión del tronco encefálico. Es necesario
identificar los tumores que representen una amenaza frente a los que no.
La ventaja principal de la cirugía convencional es la posibilidad de conseguir una
extirpación completa. Sin embargo, implica morbilidad potencial por complicaciones como
fístula de LCR, meningitis, daño en el nervio facial y lesiones vasculares.171,173,224
El tratamiento con radioterapia es cada vez más preciso, al mejorar las técnicas de
administración y disminuir las dosis de radiación. Aunque es generalmente bien tolerado,
persisten los interrogantes sobre el control del tumor a largo plazo y la morbilidad
potencial, incluyendo hipoacusia permanente, parálisis facial, hidrocefalia y daño del
tronco cerebral; su incidencia es menor que con cirugía convencional.139,190, 196,231.
2. Objetivos
Nuestro estudio tiene como objetivo comparar la actitud vigilante frente a la radiocirugía,
para ayudar en la toma de decisiones en el tratamiento conservador del SV. Planteamos los
siguientes objetivos específicos:
1. Realizar un análisis epidemiológico de los pacientes con VS diagnosticados en
nuestro Servicio.
2. Evaluar la utilidad de diferentes pruebas audiológicas y vestibulares en el
diagnóstico del SV.
3. Analizar la historia natural del SV, tanto en aspectos morfológicos como
funcionales.
Abstract
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4. Comparar la eficacia de dos estrategias terapéuticas diferentes (vigilancia y
radiocirugía) en el manejo SVs pequeños.
5. Establecer un protocolo terapéutico para SVs pequeños.
3. Material y métodos
Desarrollamos un estudio retrospectivo observacional de 107 casos consecutivos de SV
diagnosticados en el Servicio de Otorrinolaringología del Complexo Hospitalario
Universitario de Santiago de Compostela, desde febrero de 1992 hasta febrero de 2013. La
duración media del seguimiento fue de 56.52±10.79 (rango 25.02-71.74) meses. 57
pacientes (53.8%) eran mujeres y 50 (46.2%) varones; uno de los varones (0.9%)
presentaba un SV bilateral por NF2.
Se empleraron los siguientes equipos diagnósticos:
 Audiómetro - “Audiotest 340”
 Craneocorpógrafo (CCG) - Eymasa CCG600SE®
 Posturógrafo dinámica computerizado (PD) - Neurocom®
 Videonistagmógrafos - Nicolet Instrumental®, “Veonys”from Biodigital® y VNG
de “Intracoustics®”.
 Otoemisiones acústicas (OEA) - TEOAE “ILO 292
 Potenciales evocados auditivos (PEA) - “Nicolet Viking IV P System” de Nicolet
Biomedical, Inc.
 Potenciales evocados miogénicos vestibulares (VEMPs) - “Intelligent Hearing
Systems”
 Resonancia magnética (MRI) - magnetom symphony maestro class, siemens.
4. Resultados
En nuestra serie, el número de mujeres fue ligeramente mayor al de varones. En la mayoría
de los casos, 68 (64.1%), el síntoma principal fue hipoacusia, mientras que en 24 (22,1 %)
fue un acúfeno. En 11 (16,1%) de los 68 que debutaron con hipoacusia, ésta fue el único
síntoma en el momento del diagnóstico. Pero en 54 (59.0%) de los pacientes con
hipoacusia, los acúfenos y los síntomas vestibulares estaban también presentes. Sólo en un
caso (0.94%) de los 106 pacientes, el acúfeno fue el único síntoma al debut. Por el
Abstract
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contrario, en 23 (21.6%) casos, la hipoacusia o los síntomas vestibulares se asociaban al
acúfeno. El vértigo y la inestabilidad no se presentaron nunca como único síntoma de
debut. Sin embargo, en un enfermo (0,94%), el mareo fue el único síntoma inicial.
No se encontró una asociación entre el lado afecto y el sexo (p=0.87, test de Chi-
cuadrado). Entre los pacientes con SV intracanalicular, había 27 (65.8%) mujeres y 14
(34.1%) varones. No encontramos correlación entre la localización del tumor y el sexo
(p=0.09, Chi-cuadrado). Pero sí hallamos relación estadísticamente significativa entre los
síntomas iniciales y la localización del SV (p=0.01, Pearson y Spearman).
En las pruebas audiométricas, 51 (53.1%) mujeres tenían un umbral auditivo medio (PTA)
de 64.93 dB y 45 (46.8%) varones de 60.96 dB. Diez (8.4%) pacientes presentaban una
audición normal. El PTA medio fue menor en pacientes menores de 40 años (49.94±32.69
(Rango 12.50-120)) que en los mayores de esa edad (60.54±28.07 (Rango 13-120)). La
mayoría de los pacientes (63.5%) presentaban inicialmente una hipoacusia neurosensorial
con caída de graves a agudos, mientras que el 5.0% mostraban una mejora de graves a
agudos. Se observó hipoacusia pantonal en el 25 % de los casos. Otros patrones
audiométricas se hallaron en el 6,3 % de los pacientes.
Los valores medios del PTA no difieren significativamente entre hombres y mujeres
(p=0.47). Sin embargo, sí hubo diferencias significativas en función de la localización
(p=0.014, ANOVA). Asimismo, hubo diferencias estadísticamente significativas entre las
localizaciones intracanalicular e intra-extracanalicular (p=0.016, Bonferroni). Entre los
grupos extracanalicular e intra-extracanalicular (p=0.750) y entre los intracanaliculares y
extracanaliculares (p=0.200), no hubo diferencias significativas.
En los PEA, más del 80% de los pacientes presentaban alteraciones en las latencias I-V y I-
III (83.7%); encontramos una fuerte correlación entre el tamaño del tumor y el IT5 (p <
0.001, Chi-cuadrado).
En las OEA, los siete pacientes (6.5%) en los que estaban ausentes tenían un SV mayor de
20 mm, con localización extracanalicular o intra-extracanalicular; su PTA media fue 70.22
±28.66 (Rango 30-120) dB.
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El tamaño medio de los SV con craneocorpografía tipo IV era mayor que el de los que
tienen una craneocropografía tipo I (normal). No se encontró asociación significativa entre
localización y tamaño del SV, y la CCG. Tampoco entre la CCG y las manifestaciones
clínicas.
La PD era normal en 38 pacientes (63.3), siendo patológico el equilibrio medio en 22
(36.6%). Encontramos diferencia significativa entre hombres y mujeres en la condición 6
(p= 0.005) (t-Student).
En 67 pacientes (63.2%) se habían realizado pruebas calóricas. La mayoría de los que
tenían pruebas anormales (78.3%) correspondían a SVs intracanaliculares o intra-
extracanaliculares; su PTA media era 67,24±32.66 (Rango 12.50-120) dB. El tamaño
medio era de 16.82±10.02 (Rango 4-50 mm). Los pacientes con pruebas calóricas
normales tenían una PTA media de 49.13±21.78 (3.75-88.78) dB y un tamaño tumoral
significativamente menor (13.77 ±7.96 (2-32.50)). En cuatro casos (5.9%), las pruebas
calóricas mostraron arreflexia vestibular.
En 12/21 (57.14%) pacientes, los VEMPs estaban presentes en el lado afecto y en nueve
(42.8%) ausentes. No encontramos asociación entre VEMPs y localización del SV.
En cuanto a la RM, el tamaño medio del tumor es algo mayor en los varones (17.37 mm
(±9.05)) que en las mujeres (14.96 (±10.16)). Esta diferencia fue más pronunciada en
pacientes ≤ 40 años (21,7 ±12.21 (6-50 mm)). Las pruebas estadísticas (t-Student) no
mostraron diferencia significativa en el tamaño entre los dos sexos.
4.1. Grupos de tratamiento.
En 67 pacientes (63.2%) se realizó vigilancia del SV. 36 (53.2%) eran mujeres y 31
(46.3%) varones. La edad media era 59.21±14.35 (Rango 24-85) y el tamaño medio 12.68
±6.76 (Rango 2-35). El valor medio de la PTA era 57,30 ±28,53. 35 (52.2%) eran
intracanaliculares, 10 (14.9%) extracanaliculares y 22 (32.8) intra-extracanaliculares.
De los 27 (25.5%) pacientes sometidos a radiocirugía, 15 (55.67%) eran mujeres y 12
(44.4%) varones. El PTA promedio era 59.80±26,86; el tamaño medio, 16,13±7,56. La
edad media fue 56.82±14.30. El tamaño fue levemente mayor en las mujeres (14,86±8,06)
que en los varones (17,7±6,88) (p=0.064). La localización del SV en este grupo fue: 7
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intracanaliculares (25.9%), 9 extracanaliculares (33.3%) y 11 (40.74%) intra-
extracanaliculares.
El grupo de 12 (11.32%) pacientes sometido inicialmente a cirugía convencional, incluía 6
(50.0%) mujeres y 6 (50.0%) varones. La edad media era 43.78 ±9.28 (Rango 29.16–
57.85) años. La PTA promedio fue 66.40±35.84 y el tamaño medio 30.04±11.37. Cinco
(41.6%) pacientes presentaban SVs extracanaliculares y 7 (58.3%) intra-extracanaliculares.
4.2. Asociación entre grupos de tratamiento
Entre los grupos de vigilancia y radiocirugía, encontramos una diferencia estadísticamente
significativa en el tamaño tumoral (p=0.002), pero no en la PTA (p=0,33). Comparados
globalmente, las diferencias entre grupos fueron significativas (p<0.001, ANOVA). El
tamaño medio en el grupo de vigilancia (12.68±6.76) fue menor que en el de radiocirugía
(16.13±7.56) (p= 0.014). El tamaño medio del grupo de cirugía convencional (30.04
±11.37) fue significativamente mayor que el de los otros dos (p<0.001, Bonferroni).
4.2.1. Complicaciones del tratamiento.
Las complicaciones tras cirugía convencional son evidentes; por ello, hemos analizado
exclusivamente las complicaciones de la radiocirugía. Basándonos en los datos de
anamnesis y exploración en la primera revisión (un mes tras la radiocirugía), el 61.90%
(26/42) no presentaron ninguna complicación. Sin embargo, el 38.1% (16/42) sí. Entre
éstos, el 11.09% (5/42) sufrieron paresia facial, el 2.3% (1/42) parálisis facial, el 6.9%
(3/42) cofosis, el 2.3% (1/42) hipoacusia significativa (>10dB) y el 4.76% (2/42) vértigo
(que no presentaban previamente). El 4.76% (2/42) referían incremento del acúfeno. Un
enfermo (2.3%) aquejó de cefalea holocraneal continua una semana tras la radiocirugía,
presentando posteriormente atrofia del hemisferio cerebeloso.
4.3. Seguimiento
La primera consulta de seguimiento tras el diagnóstico se realizó a los seis meses; las
siguientes, al año, tres años y cinco años. El seguimiento medio fue de 56,52±10,79 meses
(vigilancia: 55,30±11,92; radiocirugía: 58,60±9,22; cirugía convencional: 58,70±5,7).
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En doce casos fue necesario cambiar la opción terapéutica a lo largo del seguimiento, por
aumento del tamaño tumoral o empeoramiento clínico. Concretamente, cinco pacientes
pasaron del grupo de vigilancia al de cirugía convencional y ocho del grupo de vigilancia
al de radiocirugía; cinco de ellos lo hicieron por empeoramiento de la clínica, aún sin
incremento en el tamaño. En tres casos, el cambio de opción de tratamiento se debió al
deseo del paciente, pese a mantenerse estable la situación clínica y el tamaño tumoral.
4.3.1. Resultados de la exploración en el paciente con NF2.
Los síntomas iniciales fueron hipoacusia, acúfenos, inestabilidad y cefalea holocraneal. La
audiometría mostró hipoacusia neurosensorial derecha (PTA: 51,25dB) y cofosis izquierda
(PTA: 120dB). LA RM detectó múltiples meningiomas intracraneales y SVs
extranaliculares puros bilaterales (tamaño máximo: 11mm en el lado derecho y 20mm en el
izquierdo). En febrero de 2006, recibió radiocirugía bilateral con una dosis única de 12Gy,
permaneciendo estable el tamaño tumoral en los siguientes controles. Sin embargo, en
junio de 2010 el paciente refería acúfeno, empeoramiento de los síntomas vestibulares y
parálisis facial izquierda. La RM mostró un crecimiento del SV hacia el CAI, por lo que
fue remitido al Servicio de Neurocirugía. En marzo de 2013, fue intervenido con un
abordaje retrosigmoideo. En el control postoperatorio en Otorrinolaringología, presentaba
atrofia de la hemilengua izquierda y parálisis del hipogloso izquierdo, con parálisis del
tensor del velo del paladar.
5. Discusión
5.1. Población y características clínicas.
En nuestra serie, hay una ligera diferencia en cuanto al sexo, con 57 (53.8%) mujeres
frente a 49 (46.2%) varones. Otros estudios con mayor tamaño muestral sugieren una
ligera predilección por el sexo femenino. En una serie de 1000 SV intervenidos, Samii
(1997) describe una distribución de 54.0% de mujeres y 46.0% de hombres.
La edad media al diagnóstico fue 57.0 años (rango 24-86). A pesar de que es infrecuente el
diagnóstico en la tercera década,236-240 hay estudios que comunican que los SVs se
diagnostican entre los 30 y los 68 años.246 En nuestra serie, sólo 4 (3.0%) pacientes se
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diagnosticaron en la tercera década de la vida; la mayoría estaban distribuidos entre la 5ª y
la 6ª décadas.
El síntoma otológico más frecuente es la hipoacusia.243-246 En nuestra serie, éste era el
síntoma inicial en 68 (64.1%) pacientes. La mayoría de los trabajos revisados coinciden en
que el acúfeno como síntoma de debut es el segundo más frecuente.240-246 En nuestros
pacientes, 24 (22.6%) lo presentaron como síntoma inicial y 43 (40.5%) asociado con otros
síntomas otológicos o vestibulares.
El SV era derecho en 55 (51.9%) enfermos e izquierdo en 51 (48.1%). No encontramos
correlación estadística en términos de frecuencia entre la afectación de un oído u otro. En
la serie de Edwards y cols., con 160 pacientes, la afectación del derecha era más frecuente
(59%) que la izquierda (41%).250 Otros autores (Christensen y cols., 2004; Takebayashi y
cols., 2006) no encuentran diferencias significativas entre los dos lados.251-252
En nuestra serie, el SV era intracanalicular en 41 (38.7%) pacientes, intra-extracanalicular
en 40 (37.7%) y extracanalicular en 25 (23.6). En la literatura, pocos artículos describen la
distribución de los SVs según su localización. Kwan y cols. (2004) analizaron 54
pacientes: 22 (40.0%) eran SVs intracanaliculares puros y 32 (59.2%) intra-
extracanaliculares.
En cuanto a la PTA, en el momento del diagnóstico, 96 (90,5%) pacientes presentaban
hipoacusia, con un PTA promedio de 58,8dB. No encontramos asociación entre la PTA y
el sexo. Hajioff y cols. (2007) presentaron 72 casos de SVs con diez años de evolución; el
promedio del PTA al diagnóstico era 43.8±17.5; no hacen referencia a la prevalencia por
edad o sexo, pero sí por la localización.257 Woodson y cols (2010) estudiaron la PTA pre y
post-tratamiento de 156 SVs; en su serie, la PTA media pre-tratamiento fue 29±13 dB259.
Un 63.5% de los pacientes mostraban hipoacusia neurosensorial con caída en agudos.
Suzuki y cols. (2010), desarrollaron un estudio retrospectivo de 500 pacientes con
hipoacusia neurosensorial asimétrica; el 2,6% tenían un SV.261 Postularon que una
neuropatía por compresión o un bloqueo en la conducción del nervio coclear producían una
hipoacusia en frecuencias graves.262
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En los PEA, en siete 7 (16.2%) de 43 pacientes fueron normales, pese a presentar
hipoacusia. En nuestra serie, el intervalo IA5 es el más sensible para diagnosticar SVs. Hay
bastante controversia en la literatura sobre el valor de los PEA en el diagnóstico de los
SVs; algunos autores consideran que no hay lugar para ellos en el manejo moderno de los
SVs263-264. Sin embargo, otros estudios defienden todavía su utilidad.
Gómez y cols. (2000) estudiaron la craneocorpografía en 21 pacientes con SV; pero eran
pacientes ya operados, por lo que no tiene valor diagnóstico.269 Claussen y cols (1989)
también analizaron 20 pacientes con SV tras cirugía270. Concluyeron que, como otras
pruebas vestibulares, la craneocorpografía no abarca todo el rango de patologías
vestibulares270-271.
Gouveris y cols. (2007) estudiaron la PD en 216 pacientes con SV, con una edad media de
54 años. Encontraron diferencias significativas en las condiciones 5 y 6 entre pacientes con
y sin síntomas vestibulares272. En nuestro caso, no encontramos una correlación clara entre
los resultados de la PD y el hecho de presentar o no síntomas vestibulares. No obstante,
hemos encontrado una diferencia significativa en la condición 6 entre varones y mujeres.
Así, aunque los pacientes con síntomas vestibulares tienen puntuaciones menores en las
condiciones 5 y 6 que los pacientes sin estos síntomas, las diferencias no permiten
discriminar a los pacientes entre estos grupos272.
En las pruebas calóricas, la proporción de normal vs patológico fue de 44.8:55.2. Diallo y
cols. (2006) analizaron el valor diagnóstico de las pruebas calóricas en 100 pacientes con
SV. El 61.0% eran normales y el 11% anormales. En el 28% de los pacientes, no pudieron
analizar la respuesta calórica.274 Algunos autores consideran que las pruebas calóricas son
los más frecuentemente alterados (77%) de los tests vestibulares, mostrando hiporreflexia o
arreflexia273.
Iwasaki y cols. (2005) estudiaron 811 pacientes con alteraciones del equilibro; 40 de ellos
(5%) tenían VEMPs anormales con pruebas calóricas normales. Ocho de estos pacientes
tenían SVs275. En nuestra serie, el valor medio de la amplitud de los 12 VEMPs normales
fue 33.94±24.0% (Rango 87-6.2%). Ushio y cols. (2009) desarrollaron un estudio
comparativo de los VEMPs y las pruebas calóricas en 78 pacientes con SVs. Los VEMPs
(con clicks) fueron anormales en 46 (59%) enfermos. En ocho (10.3%), las respuestas
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fueron normales bilateralmente y en los 24 restantes (30.8%) no se detectaron VEMPs en
ningún oído277. En su serie, la especificidad de los VEMPs fue del 52.7%, mientras que en
nuestro caso fue un poco menor (42.8%). Esta especificidad relativamente baja de VEMPs
y pruebas calóricas se debe a que no son pruebas selectivas para lesiones
retrococleares277-278.
En cuanto a la RM, los varones tenían SVs de un tamaño medio ligeramente mayor
(17.37±9.05) que las mujeres (14.96±10.16). Esta diferencia era mayor en los menores de
40 años. No obstante, las diferencias nos fueron significativas. Esto coincide con los datos
de otros trabajos con series más amplias. Por ejemplo, Harun y cols. (2012)279
desarrollaron un estudio retrospectivo en 1296 pacientes diagnosticados de SV unilateral;
los varones tenían tumores significativamente mayores que las mujeres (18.23 versus
16.81mm, p=0.031); curiosamente, en sus casos, esta diferencia también era más
pronunciada en los menores de 40 años.
Con respecto a la edad, encontramos que el aumento de edad se correlacionó
negativamente con el tamaño del tumor y positivamente con la hipoacusia, pero no predijo
la presencia de mareo. La PTA promedio en SVs intracanaliculares fue (48.87±25.47),
diferente a la de las otras dos localizaciones. Por el contrario, Massick y cols. (2000)
estudiaron la influencia del tamaño y localización del SV en la audición, en 21 pacientes;
no encontraron relación significativa entre la audiometría y las características tumorales281.
5.2. Seguimiento
Nos centramos en la comparación entre los grupos de vigilancia y radiocirugía. El
seguimiento medio del grupo de vigilancia fue de 55.30±11.92 (rango 25.02-71.21) meses;
el de radiocirugía, 58.80±9.22 (36.16-71.74).
La mayoría de las publicaciones revisadas255,257-258,281,287-289 describen un seguimiento
medio, en los pacientes bajo vigilancia, de 52,68±13,82 (Rango 43,2-80) meses; el número
medio de pacientes seguidos era de 79,28±87,64 (Rango 21-273). La mayoría de estos
autores deben enfrentarse al problema de los casos perdidos255, 257-258,281, 288.
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6. Conclusiones
El SV afecta por igual a ambos sexos y en todas las edades, aunque su incidencia es
máxima en la sexta década de la vida. En nuestros pacientes, el porcentaje de afectación
intra y extracanalicular es similar.
El síntoma más común en el momento del diagnóstico es la hipoacusia; el patrón
audiométrico más frecuente es la hipoacusia neurosensorial con caída en frecuencias
agudas. En nuestra serie, la hipoacusia era mayor en los casos intracanaliculares que en los
extracanaliculares.
Las pruebas instrumentales para evaluar la función vestibular tienden a estar alteradas en
pacientes que refieren síntomas vestibulares en el momento del diagnóstico y tienden a ser
normales en los que no los refieren. En el caso de SVs pequeños, las dos actitudes
comparadas (vigilancia y radiocirugía) son efectivas para controlar el crecimiento tumoral.
En los pacientes sometidos a radiocirugía, el deterioro auditivo observado durante el
seguimiento es mayor que en el grupo sometido a vigilancia. Sin embargo, la reducción del
tamaño tumoral es mayor en los pacientes sometidos a radiocirugía que en el grupo de
seguimiento.
En los pacientes con SVs pequeños, el protocolo de vigilancia es un enfoque terapéutico
correcto, que no empeora el pronóstico a medio plazo. Consideramos que esta actitud es
una herramienta adecuada para el manejo de los SVs en las primeras fases tras el
diagnóstico.
Palabras clave: Schwannoma vestibular, neurinoma del acústico, vigilancia del neurinoma
del acústico, Gamma Knife, Radiocirugía.
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1 Introduction
Anatomy of Vestibulocochlear nerve (CN VIII)1.1
The vestibulocochlear nerve or acoustic nerve is the eighth of twelve cranial nerves, and is
responsible for transmitting sound and equilibrium (balance) information from the inner
ear to the brain. It consists of the cochlear and the vestibular nerves which relay sensory
input regarding hearing and balance, respectively.1-3
The cochlear and the vestibular nerves courses together until they reach their respective
nuclei in the brain stem. Their entire pathway is discussed from peripheral to central. 3
The vestibular apparatus contains two sack-like structures, the utricle and saccule, and
three semicircular canals: superior, lateral, and posterior that are joined together in the
same fluid environment.4
The special sensory receptors are the hair cells. Signals from hair cells in the macula of the
utricle and from hair cells on the cristae of the superior and lateral semicircular canals
travel first to the superior vestibular ganglion. Impulses from hair cells of the macula of the
saccule and hair cells on the cristae of the posterior semicircular canal travel to the inferior
vestibular ganglion. The superior and inferior vestibular ganglia (Scarpa's) is located in the
vestibule.1, 3
Postganglionic fibers from Scarpa's ganglia become the superior and inferior vestibular
nerves that traverse the internal acoustic canal (IAC) in the posterosuperior and
posteroinferior compartments, respectively. Cadaveric investigations show that the
superior vestibular nerve is usually larger than the inferior vestibular nerve.2,4 The cochlear
nerve usually represents the most inferior part of the vestibulocochlear nerve near the brain
stem.2 In some occasions, even the superior vestibular nerve lies completely separated
from the remaining portion of the vestibulocochlear nerve.1,4
At the porus acousticus, the medial IAC, the superior and inferior vestibular nerves and co-
chlear nerves are more fused are sometimes seen as a crescent shape.1,3-4 The cochlear and
vestibular nerves are usually separated about 3 to 4 mm from the lateral end of the internal
auditory canal (e.g. see fig 1).3 The relationship between the cochlear and vestibular nerves
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changes from the lateral end of the IAC to the cerebellopontine angle (CPA); the two
nerves rotate 90° from the labyrinth to the brainstem. 3-4 Most of the rotation occurs within
the IAC. 4 Some histological researches show that if there is complete separation between
the two nerves, the cochlear nerve contains the variable number of vestibular fibers that are
characterized by a larger diameter.4 They course through the CPA cistern as two distinct
nerves surrounded by cerebrospinal fluid and enter its root entry zone in the brainstem at a
slight angle.1-4. The cochlear division is separated from the vestibular division by the
cerebellar peduncle.4
Figure 1. Internal aspect of temporal bone and contents of IAC
Source: http://www.studmed.ru/4/129.htm (11.11.2013)
In the brain stem, the vestibular nerves course medially to the root of the inferior cerebellar
peduncle located at the pontomedullary junction along the lateral floor of the fourth
ventricle. Just medial to the cerebellar peduncle, the vestibular nerve branches and
terminates in one of the four vestibular nuclei that make up the “vestibular nuclear
complex”or the flocculonodular lobe of the cerebellum. Axons from there nuclei travel in
the following ways: via the vestibulocerebellar tract to aid in coordination, via the
vestibulospinal tracts along the length of the spinal cord to modulate muscle tone, to the
Introduction
33
reticular formation to regulate consciousness, and via the medial longitudinal fasciculus in
the brain stem and upper cervical cord to the paired nuclei of cranial nerves III, IV, and VI,
thus, controlling the extraocular muscles.1
The nerve fibers originated from hair cells of the organ of Corti of the cochlea composed to
the cochlear nerve the central portion of which forms at the cochlear apex. From the apex
to the base of the cochlea, outer fibers converge centrally and complete the formation of
the nerve. Nerve fibers course toward the medial IAC where the cochlear and vestibular
portions of the vestibulocochlear nerve occupy anteroinferior and posterosuperior portions
of the canal, respectively and unite with the superior and inferior vestibular nerves and
become the vestibulocochlear nerve bundle. In the Magnetic Resonance Image (MRI)
image the nerve complex in this part is seen as a crescent shape.1, 4.
The cochlear nerve traverses the CPA cistern heading toward the brain stem at a slightly
oblique angle. The nerve enters the anterolateral brain stem at the pontomedullary junction.
Here the primary sensory neurons bifurcate and terminate in secondary cochlear neurons,
the dorsal and ventral cochlear nuclei. They lie superficially on the dorsal surface of the
upper medulla immediately lateral to the restiform body.2 From this point, the ascending
hearing pathway becomes complicated because there are multiple decussations at all levels.
Most nerve fibers from the ventral cochlear nucleus cross the midline and form the
trapezoid body, the major acoustic pathway decussation, located in the pontine tegmentum.
Neurons from the trapezoid body synapse with the contralateral superior olivary nucleus
(lateral pons) and lateral lemniscus. Most neurons from the dorsal cochlear nucleus tend to
extend directly to the contralateral lateral lemniscus. A few auditory fibers ascend in the
ipsilateral lateral lemniscus.4
Neurons from the dorsal cochlear nucleus tend to extend directly to the contralateral lateral
lemniscus. From the lateral lemniscus, neurons ascend into the tectal plate to the inferior
colliculus in the lower midbrain.7
At the inferior colliculus, some fibers cross back to the original side but the majority
continue upward to the medial geniculate body, located posterolaterally at the level of the
superior colliculus immediately lateral to the ambient cisterns. From the medial geniculate
body, the acoustic radiations ascend through the thalamus and sublenticular internal
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capsule and terminate in the transverse temporal gyry of Heschl of the superior temporal
gyrus (Brodmans area 41 and 42), the primary auditory cortex, and central processing area
where the conscious perception of sound occurs. Associative areas (Brodmans area 22) are
located nearby in the posterior transverse and superior temporal gyri.1
A small number of neurons from the superior olivary complex extend to the facial nucleus,
which provide for reflex contraction of the stapedius muscle.
Anatomic relationship of CN VIII1.2
The vestibulocochlear nerve travels from the brainstem towards the inner ear and passes
through CPA and IAC and makes up the vicinity with the important anatomic structures
like brain tissue, nerves and vessels. Therefore the anatomic considerations are divided into
sections dealing with the topographic relationships (e.g. see fig. 2, and 3). In general, in the
IAC, the facial nerve has a close relationship with the three components of the
vestibulocochlear nerve as the facial and vestibulocochlear nerves always run together
from the brain stem to the internal auditory canal.
.
Figure 2. Spatial anatomical relationship between the nerves traveling through the internal auditory canal is
shown. Source: http://emedicine.medscape.com/article/835286-overview#showall (11.11.2013)
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In general in the IAC, the facial nerve has a close relationship with the three components
of the vestibulocochlear nerve as the facial and vestibulocochlear nerves always run
together from the brain stem to the internal auditory canal.
The average number of fibres forming vestibular, cochlear, and facial nerves was not
constant during their courses within the IAC. The superior and the inferior vestibular
nerves showed an increase in the number of nerve fibres from the inner ear end towards the
brainstem end of the IAC, whereas the facial and the cochlear nerves show reduction in the
number of fibres (e.g. see fig. 3).
Source: Bhuta S, Hsu Ch, Kwan G. The Course of the Facial & Vestibulo-Cochlear Nerves through the
Temporal Maze: A Gazeinto Embryology, Anatomy& Common Pathology 2011; Power point presentation.
At the IAC in most of cases the facial nerve occupies the superior and anterior position to
the vestibulocochlear nerve or its branches and maintains its tubular shape throughout its
course in the canal.1, 5 Close to the transverse crest the facial and cochlear nerves moves
are farther anterosuperiorly and anteroinferiorly, respectively.3
Figure 3. MRI views of Facial and vestibulocochlear nerves within the IAC
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Figure 4. Posterior view to CN VIII, IX and X. Internal acoustic meatus drilled and dura mater removed.
Source: Seker Askin, Kilic Turker. Atlas of anatomical dissections: The Cerebellopontine angle. Marmara
University, Turkey, http://nsa.marmara.edu.tr/anatomy/6/Serebellopontin-Aci (11.11.2013).
Accordingly, in the lateral part of the IAC there are facial, cochlear and the inferior and
superior vestibular nerves. The position of the nerves is most constant in the lateral portion
of the canal, which is divided into a superior and an inferior portion by a horizontal ridge,
called either the transverse crest or the falciform crest.4 The facial and the superior
vestibular nerves are superior to the crest. The facial nerve is anterior to the superior
vestibular nerve and is separated from it at the lateral end of the canal by a vertical ridge of
bone, called the vertical crest. The vertical crest is also called Bill's bar in recognition of
William House's role in focusing on the importance of this crest in identifying the facial
nerve in the lateral end of the canal.3 The cochlear and inferior vestibular nerves run
below the transverse crest, with the cochlear nerve being located anteriorly. Thus, the
lateral meatus can be considered to be divided into four portions, with the facial nerve
being anterior superior, the cochlear nerve anterior inferior, the superior vestibular nerve
being posterior superior, and the inferior vestibular nerve being posterior inferior.
In the CPA, the filaments of the nervus intermedius are also stretched around the fibers of
the vestibulocochlear nerve (e.g. see fig. 4). The nervus intermedius is divisible into three
parts: a proximal segment that adheres closely to the vestibulocochlear nerve, an
intermediate segment that lies free between the eighth nerve and the motor root of the
facial nerve, and a distal segment that joins the motor root to form the facial nerve.7
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Some nerves adhere to the eighth nerve throughout in the posterior cranial fossa and can be
found as a separate structure only after opening the internal acoustic meatus. In most
instances, the nerve is a single trunk, but in some cases, it is composed of two to four
rootlets.3 The nerve most frequently arises at the brain stem anterior to the superior
vestibular nerve as a single large root and in the meatus, lies anterior to the superior
vestibular nerve. When multiple rootlets are present, they may arise along the whole
anterior surface of the eighth nerve; however, they usually converge immediately proximal
to the junction with the facial motor root to form a single bundle that lies anterior to the
superior vestibular nerve.4
The vestibulocochlear nerve in the level of brainstem makes up the vicinity with the
consistent set of neural, arterial and venous vessels which facilitate identification of the
nerves on the medial side of the tumour. In the medial side the pons, medulla, and
cerebellum are also closely related to the vestibulocochlear nerve. These structures are
helpful in guiding the junction of the facial nerve with the brain stem are the
pontomedullary sulcus; the junction of the glossopharyngeal, vagus and accessory nerves
with the medulla, the foramen of Luschka and its choroid plexus and the flocculus.6
Figure 5. Topographical relationship of the facial and vestibulocochlear nerves at four levels.
1. Near the brainstem; 2. At the CPA; 3. At the IAC; 4. At the midportion of the IAC.
TN- trigeminal nerve; Cbll - cerebellum.
Source: Kim Hyun-Sook, Kim Dong-Ik, Chung In-Hyuk, Lee Won-Sang, Kim Kyo. Topographic
relationship of the Facial and Vestibulocochlear Nerves in the Suparachnoid Space and Internal Auditory
Canal. Am J Neuroradiol 1998; 19:1155-1161
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The facial nerve arises from the brain stem near the lateral end of the pontomedullary
sulcus. This sulcus extends along the junction of the pons and the medulla, and ends
immediately in front of the foramen of Luschka and the lateral recess of the fourth
ventricle. The facial nerve arises in the pontomedullary sulcus 1 to 2 mm anterior to the
point at which the vestibulocochlear nerve joins the brain stem at the lateral end of the
sulcus. The interval between the vestibulocochlear and facial nerves is greatest at the level
of the pontomedullary sulcus and decreases as these nerves approach the meatus.2-3 Mean
distances between the exits of the VIIth and VIIIth are 4.7 ± 0.9 mm (e.g. see fig. 6),
between the VIIth and IXth 6.2 ± 1.2 mm and between the VIIIth and
IXth 5.5 ± 1.0 mm. 10
Figure 6. The neighboring structures of a CN VIII at CPA
Source: Seker Askin, Kilic Turker. Atlas of anatomical dissections: The Cerebellopontine angle. Marmara
University, Turkey, http://nsa.marmara.edu.tr/anatomy/6/Serebellopontin-Aci (11.11.2013).
The structures related to the lateral recess of the fourth ventricle which have a consistent
relationship to the facial and vestibulocochlear nerves are the foramen of Luschka and its
choroid plexus and the flocculus. The foramen of Luschka is situated at the lateral margin
of the pontomedullary sulcus, just dorsal to the junction of the glossopharyngeal nerve with
the brain stem, and immediately posteroinferior to the junction of the facial and
vestibulocochlear nerves with the brain stem. The foramen of Luschka is infrequently well
visualized.7,10 However, there is a consistently identifiable tuft of choroid plexus which
hangs out of the foramen of Luschka and sits on the posterior surface of the
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glossopharyngeal and vagus nerves just inferior to the junction of the facial and
vestibulocochlear nerves with the brain stem. 11
Another structure related to the lateral recess is the flocculus. It is a fan-shaped cerebellar
lobule that projects from the margin of the lateral recess into the CPA. The flocculus,
together with the nodule of the vermis, forms the primitive flocculonodular lobe of the
cerebellum.10,11 The flocculus is attached to the rostral margin of the lateral recess and
foramen of Luschka. It continues medially with the inferior medullary velum, a butterfly-
shaped sheet of neural tissue which forms on the surface of the nodule and sweeps laterally
above the tonsil to form part of the inferior half of the roof of the fourth ventricle. The
lateral part of the inferior medullary velum narrows to a smaller bundle, the peduncle of
the flocculus, which fuses to the rostral margin of the lateral recess and foramen of
Luschka.11-12 The flocculus projects from the peduncle of the flocculus into the
cerebellopontine angle just posterior to the site at which the facial and vestibulocochlear
nerves join the pontomedullary sulcus.
At the CPA, among the other structures, the blood vessels are closely related to facial-
vestibulocochlear complex 5. The arteries crossing the cerebellopontine angle, especially
the anterior inferior cerebellar artery, have a consistent relationship with the facial and
vestibulocochlear nerves, foramen of Luschka and the flocculus. After coursing near, and
sending branches to the nerves entering the acoustic meatus and the choroid plexus
protruding from the foramen of Luschka, the anterior inferior cerebellar artery passes
around the flocculus to reach the surface of the middle cerebellar peduncle and terminates
by supplying the lips of the cerebellopontine fissure and the petrosal surface of the
cerebellum.5, 6
The anterior inferior cerebellar artery usually bifurcates near the facial and
vestibulocochlear nerves to form a rostral trunk and a caudal trunk. The rostral trunk
courses along the middle cerebellar peduncle to supply the upper part of the petrosal
surface, and the caudal trunk passes near the lateral recess and supplies the lower part of
the petrosal surface 6.
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The trunk of the anterior inferior cerebellar artery is divided into three segments based on
its relationship to the nerves and the meatus: the premeatal, meatal and postmeatal
segments. 5
The premeatal segment begins at the basilar artery and courses around the brain stem to
reach the region of the meatus. The meatal segment is located in the vicinity of the internal
acoustic meatus. 3, 6 The postmeatal segment begins distal to the nerves and courses
medially to supply the brain stem and cerebellum. The meatal segment often forms a
laterally convex loop, the meatal loop directed toward or into the meatus. 1,3,6
In most cases, the anterior inferior cerebellar artery passes below the facial and
vestibulocochlear nerves as it encircles the brain stem, but it may also pass above or
between these nerves in its course around the brain stem. In some occasions it could be
displaced by tumours arising in this area. If the artery courses between the facial and
vestibulocochlear nerves, a tumour arising in the latter nerve will displace the artery
forward.
In the internal auditory canal, the IAA supplies the ganglion cells, nerves, dura and
arachnoid membranes. It then divides into two main branches, the common cochlear artery
and the anterior vestibular artery (e.g. see fig. 6 and 7). The common cochlear artery
further divides into the main cochlear artery and the vestibulocochlear artery, the latter
forming the posterior vestibular artery and the cochlear ramus. The main cochlear artery
supplies the apical three fourths of the cochlea, whereas the cochlear ramus irrigates the
basal one fourth.1,3 The anterior vestibular artery supplies the utricle, superior part of the
saccule, and ampullae of the anterior and horizontal semicircular canals. The posterior
vestibular artery is the source of blood supply to the inferior part of the saccule and the
ampulla of the posterior semicircular canal. The intraosseous branches or collaterals of the
vestibulocochlear artery and its vestibular branch are more abundant than those of the
anterior vestibular artery.1
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Figure 7. The branches of the anterior inferior cerebellar artery that arise near the facial and
vestibulocochlear nerves are the IAA arteries, which supply the facial and vestibulocochlear nerves.
Source: dizziness.webs.com/vestibularneuronitis.htm (11.11.2013)
The veins on the side of the brain stem that have a predictable relationship to the facial and
vestibulocochlear nerves are those draining the petrosal surface of the cerebellum, the pons
and medulla, and the cerebellopontine and cerebellomedullary fissures.3 The veins on the
medial side of the CPA are the vein of the pontomedullary sulcus, which courses
transversely in the pontomedullary sulcus; the lateral medullary vein, which courses
longitudinally along the line of origin of the rootlets of the glossopharyngeal, vagus, and
accessory nerves; the vein of the cerebellomedullary fissure, which passes dorsal or ventral
to the flocculus before joining the other veins in the cerebellopontine angle; the vein of the
middle cerebellar peduncle, which is formed by the union of the lateral medullary vein and
the vein of the pontomedullary sulcus and ascends on the middle cerebellar peduncle to
join the vein of the cerebellopontine fissure; and the vein of the cerebellopontine fissure,
which is formed by the union of the veins that arise on the petrosal surface of the
cerebellum and converge on the apex of the cerebellopontine fissure.6
All of these veins course near the lateral recess and the junction of the facial and
vestibulocochlear nerves with the brain stem. 1,3
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Physiology of CN VIII1.3
Physiology of the cochlear nerve1.3.1
The cochlear nerve as a sensory nerve conducts auditory information from the inner ear to
the brain.1,3,7,11
The cochlea of the inner ear is the system that converts the mechanical energy of the stapes
motion into electrochemical impulses that can be transmitted by the central auditory
nervous system to the auditory centers of the brain. 13
The first stage in this process is the conversion of the stapes motion into the motion of the
fluids of the cochlea and the subsequent creation of a traveling wave moving along the
basilar membrane. The induced movement of the basilar membrane affects the motion of
the stereocilia of the outer and inner hair cells. 1, 13
The outer hair cells provide an amplification function, increasing the amplitude of the
incoming sound wave, while the inner hair cells are sensory receptor cells, changing the
mechanical motion of the stereocilia into the release of a neurotransmitter chemical that
communicates with the auditory portion of the vestibulocochlear nerve. Therefore, the
sound reception process in the inner ear is an active process which dissipates some of its
energy in the form of otoacoustic emissions. 12, 14 The complex process by which the
cochlea breaks down the mechanical motion of the basilar membrane and translates it into
a series of nerve impulses that can be transmitted, reassembled, and interpreted has been
theorized for over a century but is still under investigation. 1, 12-14
The oval and round windows of the cochlea are both covered with elastic membranes that
can bulge in and out of the cochlea. An inward motion of the stapes into the scala vestibuli
causes movement of the incompressible perilymph from the scala vestibuli into the scala
tympani. After the fluid passes through the helicotrema at the apex of the cochlea, the
round window membrane bulges out to accommodate the increased amount of fluid in the
scala tympani.12 A motion of the stapes away from the scala vestibuli causes perilymph to
move from the scala tympani into the scala vestibule and the membrane of the round
window to consequently bulge inwards. The motion of the inner ear fluid caused by the
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inward and outward motions of the stapes creates a traveling wave motion along the basilar
membrane.12 The basilar membrane responds differently to sound stimuli of different
frequencies, making the location where it reaches its maximum displacement depend on
the frequency of the sound wave. There is a systematic shift in the point of maximal
vibration from the apex toward the base as the frequency increases. Thus, the basilar
membrane is said to be tonotopically organized.10,12
The traveling wave was first described by Békésy (1953- 1955), who worked with cadaver
ears and ear models. 13 He found that the point at which the displacement of the basilar
membrane was the greatest was dependent on the frequency of the sound wave and
considered the traveling wave mechanism to be responsible for the sound analysis done by
the cochlea. The theory of hearing, or of sound perception, based on this concept is called
the traveling wave theory.13,14
There is however another competing theory of hearing, called the resonance theory, that
views the basilar membrane as an array of sequentially tuned tiny resonators distributed
along the membrane. This theory was originally proposed by Helmholtz (1885) and states
that the tiny resonators of the basilar membrane are set directly into motion by sound
pressure changes in the perilymph without needing the traveling wave to set them off. 14
Both of these theories belong to a larger group of theories of hearing, called the place
theories, which support the tonotopic organization of the basilar membrane (e.g. see fig. 8).
Figure 8. View of uncoiled cochlea and the traveling wave
Source: Bear M.F, Connors B.W, Paradiso M.A. Neuroscience 2001. Exploring the Brain. Baltimore:
Lippincott, Williams and Wilkins. pp354-358.
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There are a number of experimental studies which support either the travelling wave or the
resonance theory of hearing, but there is still a lack of complete agreement in the literature
as to whether the traveling wave is directly responsible for the basilar membrane motion or
whether it is a secondary effect caused by the direct stimulation of basilar membrane’s
resonators by sound pressure propagating through the perilymph (Bell, 2004; Bell and
Fletcher, 2004). 14
Regardless of the theory behind the true manner in which the cochlea analyzes sound, the
basilar membrane is the element responsible for sound analysis, and its tonotopic
organization is mirrored within the auditory nervous system.1, 4, 12, 13
Sound waves and mechanical vibrations acting on the surface of the human head are
absorbed by the soft tissue and bones (Bone Conduction) of the head and propagate
through the head’s structures. They also induce complex physical vibrations of the skull
that can be transmitted to the brain and sensory organs of the head. Both these mechanisms
together can affect the hearing system and evoke auditory responses analogous to those
caused by sound waves arriving at the outer ear of the hearing system. 12-14
All important head resonances have frequencies below the transmission range of bone
conducted stimuli to protect supporting them mechanisms from potential harmful effects of
body vibrations and acoustic stimulation.14 They include, but are not limited to, eyeball
resonance, jaw resonance, neck resonance, and head and shoulder vibrations For the
human communication purposes only bone vibrations created by directly applied physical
vibrations (via a mechanical vibrator) have sufficient energy to be used as a carrier of
information. Sound waves arriving to the surface of the head are either captured by the
outer ear and delivered through the hearing system to the organ of Corti or are mostly
reflected back into the environment due to the impedance mismatch between the
impedance of the skull and the impedance of surrounding air.10
Sound waves can only be heard through bone conduction when the arriving sound has very
high intensity and the person’s ears are occluded by hearing protectors or head mounted
audio displays (audio HMD). 13, 14
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However in such cases, perceived sound often constitutes the harmful noise which leaked
to the hearing system by bone conduction pathways rather than a communication signal.
The first modern theory of bone conduction hearing was proposed by Herzog and Krainz in
1926. 14 According to this theory the bone conduction hearing is a combination of the
following two phenomena:
1. Relative motion of the middle ear bones caused by head vibrations
2. Compression waves in the cochlea resulting from the transmission of vibrations
through the skull.
The two landmark publications on bone conduction by Békésy (1932) and Barany (1938)
provided further evidence for and expanded this theory. Bekesy and Barany also provided
clear evidence that air conduction and bone conduction mechanisms were two different
hearing mechanisms resulting in the same excitation of the basilar membrane. 13, 14
The current theory of bone conduction hearing is mostly based on the comprehensive
studies by Tonndorf who expanded Herzog and Krainz’s work and identified seven
potential mechanisms which can contribute to human hearing.14,15
The four main mechanisms proposed by Tonndorf are the following:
1. Inertial Mechanisms
a. A middle ear inertial mechanism involving relative and delayed movement of the
ossicular chain in reference to the surrounding temporal bone (cochlear
promontory).
b. An inner ear inertial mechanism involving transmission of temporal bone
vibrations on the inner ear fluids.
2. Compression Mechanisms
a. An outer ear compression mechanism involving radiation of bone-conducted
energy from the osseous walls of the ear canal back to the ear canal.
b. An inner ear compression mechanism involving compression and decompression
of the inner ear fluids by compression vibrations of the bony cochlea. 13
The most dominant of the above mechanisms seems to be the inner ear inertial mechanism
although several other mechanisms contribute as well.
The effectiveness of the individual mechanism depends on the frequency of the signal,
place and direction of vibration application, and the status of the outer ear.
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The first two factors affect the modes of vibrations of the skull whereas the third depends
on the type and quality of the ear occlusion. The last factor dramatically affects the
effectiveness of the outer ear compression.14
The neural activity of the inner ear is dependent on electro-chemical processes and initial
electric potentials between the fluids occupying the various structures of the inner ear. An
electric potential is created when there is a difference in the electric charge between two
different locations. The area of higher charge is said to be positively polarized while the
area of lower charge is said to be negatively polarized. In a biological system, such as the
human ear, a difference in chemical charge between two areas is called the bioelectric
potential.11 When the two polarized areas are connected, the charged particles move from
one area to another. This occurs because of the electromotive force that is created by the
difference in electrical charge. Commonly charged particles in the human ear include
positively-charged potassium ions (K+), negatively-charged chloride ions (Cl-), positively-
charged sodium ions (Na+) and positively-charged calcium ions (Ca2+). In the inner ear,
the endolymph contains a large amount of potassium ions and the perilymph contains a
large amount of sodium ions. A static bioelectric potential that involves the separation of
charged particles by a cell membrane is called a resting potential. The resting potential of
the endolymph in the scala media, called the endocochlear potential (EP), is + 80 millivolts
(mV) in reference to the resting potential of the perilymph in the two other cochlear
channels. The resting potential of the inner hair cells is -40 mV and of the outer hair cells
is -70 mV compared with the perilymph. 15 Therefore, the difference in potential between
the endolymph and the inner hair cell is 120 mV and between the endolymph and the outer
hair cell is 150 mV. This 150-mV potential is a biological battery that supports all inner ear
processes. It is a very efficient system that consumes only approximately 14 microwatts
(μW) of power while carrying out the equivalent of approximately one billion floating-
point operations per second. 12, 13, 15
A dynamic bioelectrical potential that involves the movement of charged particles from
one area to another in response to a stimulus is called a stimulus related potential. There
are three stimulus related potentials that are commonly observed in the inner ear in
response to an auditory stimulus. The three stimulus related potential are the summating
potential (SP), cochlear microphonic (CM), and the compound action potential (CAP). The
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former SP and CM are generated by the hair cells and CAP is generated by the
vestibulocochlear nerve.11, 12, 15 The SP is a direct current potential that causes a positive or
negative change in the endocochlear potential for the duration of a signal. It is the driving
force for moving the charged ions through the stereocilia and membrane separating hair
cell from the surrounding endolymph. Both the CM and CAP are alternating current
potentials which vary in polarity based on changes in the phase of the signal. The CM is a
pre-neural electric potential that mimics the incoming sound signal; it is considered to be a
reflection of receptor currents flowing through the hair cells. The CAP is the actual event
related potential (ERP) that is generated when the auditory nerve “fires” (transmits a
signal) in response to a stimulus. The CAP results from the firing of the auditory portion of
the vestibulocochlear nerve in response to the release of the neurotransmitters from the hair
cells.13
Various ERPs and their changes in time and space can be measured in the central nervous
system using electroencephalography (EEG). One example of these measurments is the
mismatch negativity (MMN) potential generated in the auditory cortex and having a
latency of 150 to 250 ms post-stimulus. The MMN is a negative, task independent neural
potential generated in response to an infrequent change in a repetitive sound sequence.15
Up and down movement of the basilar membrane causes a shearing force to act on the cilia
of the hair cells of the organ of the Corti. The shearing force is a result of different points
of attachment of the basilar membrane and the tectorial membrane to the cochlear wall.
The force bends the cilia to the left and to the right of the basilar membrane axis.1
The stereocilia of a hair cell have gradually changing height and are held together by tip-
to-side links that cause the whole bundle to move together when stimulated.14 Tilting
movements of the stereocilia affect the tension on the fiber in the tip link. When the
stereocilia are bent toward the largest stereocilium, the tip-to-side links cause
mechanically-gated ion channels in the stereocilia membranes to open. The opening of the
ion gates allows positively-charged ions (K+) of potassium, which are the main cations in
the endolymph, to flow from the positively-charged endolymph into the negatively-
charged hair cell.15 As the fiber tension increases, the flow of ions into the hair cell also
increases. When the stereocilia bundle is bent in the direction away from the largest
stereocilium, the ion channels close and the excess of K+ in the cell is pushed out of the
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cell through a semipermeable membrane via active pumping processes restoring natural
negative polarization of the cell (Geisler, 1998). 7,14 However, the effects of stereocilia
bending and the in-and-out flow of K+ ions are different in the inner hair cells and the
outer hair cells. When the K+ ions enter the inner hair cell, they depolarize the content of
the cell, that is, they change to zero the difference in electric potentials between the areas
inside and outside the cell. As a result, when the gates are open, the cell becomes
depolarized (excited), and when the gates are closed, the cell becomes hyperpolarized or
inhibited (e.g. see fig. 9).
Figure 9. The inner hair cells response to the bending of the steriocilia.
Source: Emanuel D, Maroonroge S, Letowski T. The Hearing System 2009. Chapter 9. Physiology and
Function of the Hearing System p320
The transduction of the mechanical actions of the shearing of the stereocilia to the electro-
chemical signal transmitted by the nervous system begins when a neurotransmitter is
released from the base of the inner hair cell. 17 This neurotransmitter crosses the synaptic
cleft and binds to specialized receptor sites located on the post-synaptic membrane of the
peripheral processes of the nerve fibers connecting the inner ear with the brainstem. The
bundle of nerves connecting the inner ear with the brainstem is called the auditory nerve. If
a sufficient amount of neurotransmitters are released, the afferent nerve fibers will fire in
response, sending an electric signal down the length of the auditory nerve towards the
brainstem. 16, 17
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The response of single auditory nerve fibers to different stimuli has been measured in
many experiments. Most of them performed experimentally in which a microelectrode
placed in the nerve trunk to isolate the activity myelinated nerve fibers.17,20
The auditory nerve has approximately 30,000 fibers in humans and there are approximately
50,000 auditory nerve fibers in cats. Perhaps one of the most important research findings
was the observation that 90% to 95% of neurons (type I radial fibers) innervate to the outer
hair cells, whereas 5% to 10% (type II, outer radial fibers) innervate to the outer hair
radial cells. The radial cells have bipolar cell bodies in the spiral ganglion. Outer spiral
fibers are monopolar and unmyelinated.15,16,17
On the base of spontaneous discharge, the nerve fibers have been classified into the
following three categories: high (18 to 20 spikes per second), medium (0,5 to 18 spikes
per second), and low (0 to 0,5 spikes per second). Fibers with high rates of spontaneous
activity respond to auditory signals at low levels better than do the fibers with medium or
low rates that have thick dendrites which tend to determinate on the side of the inner hair
cells facing the outer hair cells. Fibers with low and medium spontaneous rates have thin
dendrites on the side of the inner hair cells facing the modeolus.11
According to some ongoing studies, the fibers with high rates of spontaneous activity have
different terminations in the auditory CNS (cochlear nucleus) than do fibers with low rates
of spontaneous activity. In other words, spontaneous activity of nerve fibers is not random
but is proving to be anatomically and functionally significant.11 The tuning curve of the
single auditory nerve fiber is perhaps the most basic measure of auditory nerve function.
When effectively stimulated by sound, the cochlear afferent responds with an increase in
the rate of discharge. At low stimulus intensities, such rate increases are evoked only by a
narrow range of stimulus frequencies.18
Auditory nerve fibers arrive at the brainstem by forming synapses with large groups of
neurons in the cochlear nuclei located in the border between the pons and medulla. The
fibers from each ear terminate on the nucleus located on the same (ipsilateral) side of the
brainstem from where most of the fibers cross to the opposite (contralateral) side of the
brainstem, and either connects to contralateral superior olivary complex or ascends directly
to contralateral inferior colliculus in the midbrain. Type I nerve fibers with large
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myelinated neurons are responsible for transporting the coded auditory signal from the
peripheral to the central nervous system. The function of the smaller and less numerous
type II fibers is still largely unknown.16,18
The neural cells in the cochlear nuclei have several complex firing patterns and wider
dynamic ranges than the neurons in the auditory nerve. In response to simple tonal stimuli,
several response patterns have been recorded in the various cells of the cochlear nuclei.
These response patterns include the following patterns: 1) a “primary”pattern that is
similar to that of the auditory nerve (“primary-like”neurons), 2) a “chopper”pattern that
consists of repeated bursts of firing followed by short pauses (“chopper”neurons). The
periodicity does not match the periodicity of the stimulus. 3) an “on”pattern, in which the
cell fires only when a stimulus begins “on”neurons, and 4) a “pauser”pattern in which the
cell fires only at the onset of the stimulus, pauses, and then continues until the stimulus is
turned off (“pauser”neurons).20
Examples of peristimulus (PST) histograms, i.e., the histograms of the times at which
neurons fire, as a function of latency following tonal stimuli (e.g. see fig. 10).
The firing patterns shown in figure 10 are the most commonly reported firing patterns.
However, there also are other firing patterns observed in response to simple stimuli.
Further, there are reports of many different subcategories of firing patterns under each of
the main categories, and the response of the cochlear nucleus to complex stimuli varies
from the response to simple stimuli.
The type of response recorded from the neurons in the cochlear nucleus depends on a
number of physical features associated with the cells (e.g. characteristics of the membrane,
type of cell), the connection between the auditory nerve and the cochlear nucleus cells (e.g.
many or few axon endings contacting many or few dendrites), and the presence of
inhibitory input from other cells. For example, in the anterior ventral cochlear nucleus
(AVCN), the most common cell types are the global and spherical bushy cell. These cells
receive very few axonal connections from auditory nerve fibers from a localized frequency
area of the cochlea and are the most likely contributors to the primary response pattern
seen in the cochlear nucleus. Their frequency specificity may also be enhanced by their
function as coincidence detectors, which reduce the random noise level from spontaneous
activity of the auditory nerve.18,19 Other cells may specialize in transmitting intensity of
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sound (multipolar cells) or temporal order of sound events (octopus cell). In the posterior
ventral cochlear nucleus (PVCN), the octopus cell is a common cell type, so-called
because these cells resemble an octopus with long tentacle-like dendrites. These dendrites
receive many more connections, across a broader frequency range of the cochlea,
compared with the AVCN bushy cells, and they are thus more broadly tuned. These cells
have been reported to respond well to amplitude modulated tones and clicks, but have a
reduced activity in response to steady state noise. In some species, the dorsal cochlear
nucleus (DCN) has been recorded to respond to spectral differences that may indicate they
provide some coding in response to monaural localization cues in a vertical plane.17,18
Figure 10. PST histograms illustrating different types of neuron firing patterns in the cochlear nucleus.
Source: Pfeiffer R. Classification of response patterns of spike discharges for units in the cochlear nucleus:
Tone-burst stimulation. Experimental Brain Research 1966, Volume 1, Number 3, 220-235.
Physiology of superior and inferior vestibular nerves1.3.2
The vestibular nerves as a sensory nerve conducts vestibular information from the inner ear
to the brain.1,3,7,11
The peripheral vestibular system includes the paired vestibular sensory end organs of the
semicircular canals (SCC) and the otolithic organs (Fig. 11). These receptors are found
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within the fluid-filled bony channels of the otic capsule and are responsible for perception
of both the sense of position and motion. 19 The vestibular nerves are the afferent
connection to the brainstem nuclei for the peripheral vestibular system.
Figure 11. Anatomic organization of the peripheral vestibular system (vestibular end-organs and the
vestibular nerve).
Source: http://otorrinos2do.wordpress.com/2009/12/08/physiology-of-the-vestibular-system/
The cells bodies of vestibular nerve afferents are located in the superior or inferior
divisions of Scarpa's ganglia, which lie within the internal auditory canal near the
emergence of the vestibular nerve into the cerebellopontine angle. 16
From the vestibular labyrinth, the afferent information travels ipsilateral in 1 of 2 branches
of the vestibular nerve. The superior vestibular nerve innervates the lateral and anterior
SCC as well as the utricle. The inferior vestibular nerve innervates the posterior SCC and
the saccule (e.g. see fig. 11).
Variation of nerve fiber counts among studies appears to be a function of age, although rate
of decline of the number of afferent fibers also appears to be variable. The branches of the
vestibular nerve travel together into the pontomedullary junction where they bifurcate.16
Primary vestibular afferents in the superior division of the vestibular nerve include axons
that synapse in the superior and medial vestibular nuclei or the uvula, nodulus, flocculus,
or fastigial nucleus of the cerebellum. 16-17
Primary vestibular afferents from the inferior branch synapse with neurons in either the
medial, lateral, or inferior vestibular nuclei, which, along with the superior vestibular
nuclei and other subnuclei, comprise the vestibular nuclear complex.16
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Perception of angular accelerations is chiefly the responsibility of the three paired SCCs
(superior, posterior, and lateral). Within the ampullated portion of the membranous
labyrinth are the end-organs of the cristae, containing specialized hair cells that transduce
mechanical shearing forces into neural impulses. Histologically the hair cells of the
ampulla are located on its surface. Their cilia extend into a gelatinous matrix better known
as the cupula, which acts like a hinged gate between the vestibule and the canal itself (e.g.
see fig. 12). The otolithic organs of the utricle and the saccule are found within the
vestibule. Chiefly responsible for the perception of linear accelerations (eg, gravity,
deceleration in a car), their end-organs consist of a flattened area, rich in hair cells, in the
macular area whose cilia project into a similar gelatinous matrix. The matrix, however,
differs from the matrix associated with the SCCs in its support of a blanket of calcium
carbonate crystals better known as otoliths, which have a mean thickness of approximately
50 μm Information from the vestibular end-organs is transmitted along the superior (which
receives information from the superior, horizontal SCCs and utricle) and inferior (which
receives information from the posterior SCC and saccule) divisions of the vestibular nerve.
Although its role is primarily afferent in the transmission of electrical activity to the central
vestibular nuclei of the brainstem, an efferent system does exist that probably serves to
modify end-organ activity. Each vestibular nerve consists of approximately 25,000 bipolar
neurons whose cell bodies are located in a structure known as Scarpa’s ganglion, which is
typically found within the IAC.17, 20
Figure 12. A stylized representation of the crista with the angular acceleration receptor
Source: http://otorrinos2do.wordpress.com/2009/12/08/physiology-of-the-vestibular-system/
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Type I neurons of the vestibular nerve derive information from corresponding type 1 hair
cells, whereas type II neurons derive information from corresponding type 2 hair cells at its
simplest. The cristae ampullares convey information approximately angular in acceleration
of the head to the central nervous system. The maculae convey information about linear
acceleration and head position relative to gravity. 18
The utricular macula is oriented horizontally and the saccular macula is oriented vertically.
Tilting the head to the side stimulates the saccular macula and titling the head forward or to
the back stimulates the utricular macula.15 All these sensory organs contain hair cells with
their stereocillia responding to the head motion analogous to the way the inner hair cells in
the cochlea respond to the acoustic signal. Depending on the head position and the
direction of the head movement, the endolymph flow in the semicircular canals and the
vestibule stimulates the hair cells of the organs which control balance.18 For example, the
cilia of the maculae are embedded in the gelatinous membrane containing a relatively
heavy amount of calcium carbonate (otoconia); movements of the head cause the otoliths
to bend the cilia, causing depolarization/hyperpolarization of the hair cells, depending on
the direction of movement.14,18 The signals from the organs which control balance are
transmitted through the vestibular portion of the vestibulocochlear nerve to four vestibular
nuclei within the brainstem and further to the brain.18
The fibers from the vestibular nuclei also crossover to the contralateral nuclei from which
they project, among others, to oculomotor nuclei that drive eye muscle activity, resulting in
a vestibule-ocular reflex that helps maintain fixation of the eyes on the object moving, in
relation to the head position. In this way, the fibers are responsible for a complex
coordination between the vestibular system, visual system, proprioceptors, and structures
within the cerebellum, brainstem, and the whole cortex.18
Primary vestibular afferents enter the brainstem dividing into ascending and descending
branches. Within the brainstem there appears to exist a nuclear region with four distinct
anatomic types of second-order neurons that have been traditionally considered to
constitute the vestibular nuclei. It appears, however, that not all these neurons receive input
from the peripheral vestibular system. The main nuclei are generally recognized as the
superior (Bechterew’s nucleus), lateral (Deiters’nucleus), medial (Schwalbe’s nucleus),
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and descending (spinal vestibular nucleus). Functionally, in primate models, the superior
vestibular nucleus appears to be a major relay station for conjugate ocular reflexes
mediated by the SCCs. 14, 15, 18
The lateral vestibular nucleus appears to be important for control of ipsilateral
vestibulospinal (the so-called “righting”) reflexes. The medial vestibular nucleus, because
of its other connections with the medial longitudinal fasciculus, appears to be responsible
for coordinating eye, head, and neck movements. The descending vestibular nucleus
appears to have an integrative function with respect to signals from the vestibular nuclei,
the cerebellum, and an amorphous area in the reticular formation postulated to be a region
of neural integration. Commonly referred to as the “neural integrator” among
neurophysiologists, the nucleus is responsible for the ultimate velocity and position
command for the final common pathway for conjugate versional eye movements and
position.16
The vestibular nerve in part also projects directly to the phylogenetically oldest parts of the
cerebellum namely, the flocculus, nodulus, ventral uvula, and the ventral paraflocculus on
its way directly through the vestibular nucleus. Better known as the vestibulocerebellum,
this area also receives input from other neuronal pathways in the central nervous system
(CNS) responsible for conjugate eye movements, especially smooth-pursuit eye
movements, which, in addition to the VOR, are responsible for holding the image of a
moving target within a certain velocity range on the fovea of the retina. 13- 15
The Purkinje’s cells of the flocculus are the main recipients of this information, of which
some appears to be directed back toward the ipsilateral vestibular nucleus for the purposes
of modulating eye movements in relation to gaze (eye in space) velocity with the head still
or during combined eye–head (vestibular signal-derived) tracking. 15 Important for
cancelling the effects of the vestibule-ocular reflex (VOR) on eye movement when it is not
in the best interest of the individual (think of twirling ballet dancers or figure skaters and
how they can spin without getting dizzy), the vestibulocerebellum is also important in the
compensation process for a unilateral vestibular loss.
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The fundamental unit for vestibular activity on a microscopic basis inside the inner ear
consists of broadly classified type 1 and 2 hair cells (e.g. see fig. 13).
Figure 13. Schematic representation of type 1 and type 2 hair cells: Ct - cuticular plate; H - hairs; KC -
kinocillum; M - Mitochondria; NC - nerve chalice; NE - nerve ending; Nu –nucleus
Source: Rutka J. Ototoxicity 2004. Chapter 2, Physiology of the Vestibular System. p21.
Type 1 hair cells are flask-shaped and surrounded by the afferent nerve terminal at its base
in a chalice like fashion. One unique characteristic of the afferent nerve fibers that envelop
type 1 hair cells is that they are among the largest in the nervous system (up to 20 μm in
diameter). The high amount of both tonic (spontaneous) and dynamic (kinetic) electrical
activity at any time arising from type 1 hair cells has probably necessitated this feature for
the neurons that transfer this information to the CNS. Type 2 hair cells are more cylindrical
and at their base are typically surrounded by multiple nerve terminals in contradistinction.
Each hair cell contains on its top a bundle of 50 to 100 stereocilia and one long kinocilium
that project into the gelatinous matrix of the cupula or macula. It is thought that the
location of the kinocilium relative to the stereocilia gives each hair cell an intrinsic polarity
that can be influenced by angular or linear accelerations. It is important to realize that an
individual is born with a maximum number of type 1 and 2 hair cells that cannot be
replaced or regenerated if lost as a result of the effects of pathology or aging. Presumably
the same process holds for the type I and II neurons that comprise the vestibular nerve.17
Introduction
57
At the microscopic level, movements of the head or changes in linear accelerations deflect
the cupula or shift the gelatinous matrix of the otolithic organs with its load of otolithic
crystals that will either stimulate (depolarize) or inhibit (hyperpolarize) electrical
activity from type 1 and 2 hair cells. Displacement of the stereocilia either toward or away
from the kinocilium influences calcium influx mechanisms at the apex of the cell that
causes either the release or reduction of neurotransmitters from the cell to the
surrounding afferent neurons (e.g. see fig. 14).
Figure 14. The physiology of macular stimulation and inhibition from otolithic shift and its shearing effect
on stereocilia and kinocilium of the hair cells.
Source: Rutka J. Ototoxicity 2004. Chapter 2, Physiology of the Vestibular System. p23
The electrical activity generated is then transferred along the vestibular nerve to the
vestibular nuclei in the brainstem.
Information above the tonic (spontaneous) firing rate of the type 1 hair cells transmitted
along type I neurons is largely thought to have a stimulatory effect in contrast to a more
inhibitory effect attributable to type 2 hair cells and type II neurons. The SCCs largely
appear to be responsible for the equal but opposite corresponding eye-to-head
movements better known as the VOR. The otolithic organs are primarily responsible for
ocular counter-rolling with tilts of the head and for vestibulospinal reflexes that help in the
maintenance of body posture and muscle tone. 20
In order to ultimately produce conjugate versional VOR-mediated movements of the eyes,
each vestibular nucleus receives electrical information from both sides that is exchanged
via the vestibular commissure in the brainstem. The organization is generally believed to
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be specific across the commissure. Neurons in the right vestibular nucleus, for example,
that receive type I input from the right horizontal SCC project across the commissure to the
neurons found in the left vestibular nucleus that are driven by the left horizontal
SCC receiving contralateral type II input and vice versa.17, 19
Schwannoma of Vestibulocochlear nerve1.3.3
1.3.3.1 Background of Vestibular Schwannoma in the history of medicine
“De duro quodam corpusculo, nervio auditorio adherente” –were the first postmortem
descriptions made for Acoustic Neuroma (Vestibular Schwannoma) in 1777, by Eduard
Sandiford - Professor of Pahology in Leiden, in his book called “Anatome infantis cerebro
destitute”.22, 26
He described the appearance of small growth, externally hard like cartilage but internally
quite soft. At that time he thought that this cause of deafness clearly beyond the reach of
medication or surgery and must be declared incurable. 26
From 1777, the knowledge about Vestibular Schwannoma (VS) has been accumulating
more and more as well as the clinical symptoms in patients with VS which were correlated
to the intracranial autopsy findings of several authors.20
During the early nineteenth century number of case reports appeared in which antemortem
symptoms and clinical signs were correlated with postmortem findings. Early findings
have probably been described by the French scientist Leveque-Lasore in 1810. By the mid-
1800s, the two neurologists, Toynbee and Stevens, describe a patient, who manifested
unilateral deafness, facial numbness and progressive blindness, which was affected by a
tumour in the CPA. The first definitively accurate postmortem description of this tumour
was not made until Sir Charles Bell carefully presented his autopsy findings in 1830.21, 23
Jean Cruveilhier,21, 25 known for his atlas Anatomie pathologique du corps humain, which
included the first ever color illustrations of brain pathology,34 published an
unprecedentedly detailed account of the progression of symptoms and autopsy findings in a
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26yearold woman with a VS. She became deaf at the age of 19 years and presented seven
years later with headaches, progressive blindness, and facial weakness. Although
Cruveilhier was unable to correctly localize the tumour until autopsy, he initially believed
that the tumour was at the skull base.21 But no one would correctly diagnose and localize
VS prior to an autopsy until almost fifty years later, when Oppenheim in Germany became
the first to accomplish this feat.21,23 In 1900, Sternberg was the first to describe the
histopathology of a VS, whereas leading physicians such as Oppenheim, von Monakow,
Jackson, Gowers, Babinski, and Starr were refining their knowledge of functional brain
anatomy, especially in the cerebellar region.19,23
The physician's developments in diagnosis and localization facilitated an earlier diagnosis
of VS while the patient was still alive and set the stage for surgical intervention. The
concurrent evolution of anesthetic and aseptic techniques during this period fueled the era
of surgical exploration in the posterior fossa. Nonetheless, further refinement of the
surgical methods available for the supratentorial space and intraoperative control of
intracranial tension was necessary to approach the infratentorial space relatively safely.
In 1890, von Bergmann made the first surgical attempt at removing a tumor, which at
autopsy was discovered to be a VS; he was unable to intraoperatively localize the tumour
before the patient died.24 The first successful VS surgery was most probably performed by
Annandale in 1895. Although a year earlier Ballance resected a tumour that may have been
either a meningioma or VS.26
Until the 1900s the most physicians has been considering the intracranial surgery to be
unwise and irresponsible. 26 But in the early 1900s earlier tumour diagnosis and
localization was possible and surgical intervention for intracranial pathology gained some
popularity. Prominent surgeons such as von Monakow published optimistic papers
encouraging doctors to be less reluctant in attempting intracranial surgery.23
As more surgeons independently attempted surgical intervention for VS, a variety of
techniques and approaches developed, some of which were early versions of the pro-
cedures used today.19 Woolsey, Fraenkel, and Krause used a unilateral suboccipital
approach with some success. Borchardt performed the first “transsigmoid”VS surgery in
1905 and the same year, Horsley first resected a VS.25 The patient in Horsley’s case
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survived the operation but became severely disabled, most likely due to a brainstem
infarct. In 1903, Garreé was the first to attempt surgery for a bilateral VS and had dismal
results, as did Biggs a few years later in 1909.21
Four years later in 1913, at the International Congress of Medicine in London, the three
well known European surgeons, Horsley (London), Eiselsberg (Vienna), and Krause
(Berlin) reported mortality rates for the VS surgeries they performed, with the following
resuts: 67% in 15 cases, 77% in 17 cases, and 84% in 31 cases, respectively. 26, 27 They are
stated that all of them used a unilateral suboccipital approach and an index finger or
spatula to quickly dislodge the tumour, which usually caused injury to the cerebellum and
brainstem. Eiselsberg and Horsley further attempted the operation in 2 stages without
better success.26
The first translabyrinthine approach was described in 1904 by Panse and was similar to the
one used today. But the translabyrinthine approach was abandoned because of its high risk
of cerebrospinal fluid leakage, destruction of the middle ear, and limited exposure of large
tumours.21, 27 Due to the high mortality rates after the above-stated approaches, some
surgeons combined petrosal and suboccipital approaches with little success.23 But the first
successful result towards reducing mortality was obtained by Cushing. In 1904, Cushing
began working with Amory Codman to record a patient’s pulse, temperature, respiration,
and ether dosage during surgery in an attempt to discover the changes indicative of
imminent death.23 This novel idea led to further progress in neuroanesthesia and more
specifically in posterior fossa surgery. Cushing also introduced the silver clip in 1911 and
electrocautery in 1925 for controlling intraoperative hemorrhage.26
Using the new tools as well as his initial experience with intracranial supratentorial
surgery, Cushing surgically treated VSs with remarkably lower mortality rates than those
of his predecessors. In 1917 he published the results of 30 VS cases in his famous
monograph “Tumours of the Nervus Acusticus and the Syndrome of the Cerebellopontine
Angle”, in which he reported a vastly superior mortality rate of 10–15%.24 Unlike to earlier
approaches, Cushing proposed a bilateral suboccipital craniectomy for subtotal
intracapsular tumour decompression. He believed that this method was safer than complete
resection, allowed decompression of the brainstem, and avoided medullary compression
during surgical manipulation of the tumour. Although this was not the first time a bilateral
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suboccipital approach had been proposed, Cushing was one of the first surgeons to
emphasize the importance of controlling intracranial pressure by using a ventricular tap
and therefore avoiding medullary compression and cerebellar herniation.
The bilateral approach allowed surgeons to explore both CPAs, as findings on radiographic
images were not always reliable. Cushing’s gentle and meticulous methods, combined with
his conservative philosophy of performing only intracapsular decompression, proved the
safety but not necessarily the efficacy of VS surgery using the now-obsolete technologies
of his day. 21After a few years of partial resection for VS, despite his significantly lower
mortality, unfortunately, this method become associated with a higher tumour recurrence
rate and the five year mortality rate was 54%.23 Cushing accepted that another approach for
total resection would be far superior if neuroanesthesia, operative, and diagnostic
technologies could be improved. After a couple of years Dandy’s introduction of air ven-
triculography (1918) allowed neurosurgeons to localize and operate on smaller tumours
partly through the early detection of hydrocephalus. Dandy was very technically skilled,
and he believed in his ability to improve on Cushing’s results. By this time the syndrome
of the CPA was more widely recognized, and surgical intervention was no longer reserved
only for patients at the terminal stage of the disease. The above factors assisted Dandy in
achieving a gross total resection (GTR) of VSs which were relatively smaller.
Despite the benefits of ventriculography, however, Cushing was extremely reluctant to
embrace its clinical use, claiming that it would undermine the importance of a detailed
neurological examination.24 He did not consider Dandy’s innovation a next step in the
advancement of intracranial surgery.27 Dandy believed that the 54% 5-year mortality rate
Cushing had reported was unacceptable, and he searched for a safe way to perform a GTR
of VS despite Cushing’s doubts about its feasibility. In his early experience with
intracapsular decompression, Dandy was convinced that the residual “shell of tumour”was
responsible for delayed neurological deterioration after surgery. He thought he found the
answer when in 1922 he published a preliminary report on a successful total VS resection
performed 5 years earlier. 23, 24 In this report, he described how he had made a bilateral
suboccipital flap, first removing the interior portion of the growth as described by Cushing,
then meticulously clipping the veins and arteries surrounding the capsule, and finally
pulling the capsule carefully away from the brainstem. Dandy wrote, “As the capsule is
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cautiously retracted, several small blood vessels crossing from the brainstem or cerebellum
are brought into view and doubly ‘clipped’and the vessel divided.”28
Previously, Horsley had advocated blunt finger removal of an intact large tumour, and
Cushing had favored subtotal enucleation of VS as an adjunct to osseous suboccipital
decompression. Dandy took the next step in the history of VS surgery by performing
extensive intracapsular decompression followed by meticulous tumour capsule excision
and careful management of surrounding vasculature to respect important vessels and avoid
postoperative hemorrhage. 24 In this 1922 report, however, Dandy failed to mention any of
Cushing’s 1917 monograph, and so Cushing promptly wrote a letter attacking his manners
and professional ethics and dismissed Dandy’s success.26 Rather than considering Dandy’s
new approach, Cushing rigidly maintained his belief that the high mortality rates of total
VS resection would make it irresponsible even to attempt such an approach. He considered
Dandy’s method to be inconsistent with the standard of care. Some neurosurgeons that had
been trained by Cushing followed his recommendations. 21
In Europe the modern viewpoints of VS has been dominated by the efforts of House,
Yasargil and Fisch (1969), Glasscock (1973), Sterkers (1979), King and Morrison (1980),
Samii and Wigand (1992).26 Particularly, surgeons from England, France, Germany and
Denmark have made great contribution to the development of knowledge of VS and
management of patients with VS.
In Denmark, two CPA tumours were operated on via the translabyrinthine approach by the
otologist, EC Schmiegelow, who operated on two patients at the National Hospital,
Rigshospitalet, in 1914. 21 It was a huge step forward in VS surgery When William House
developed the translabyrinthine approach in 1960. Nevertheless, it resulted in a 20%
cerebrospinal fluid leak. But after microsurgical techniques were introduced by M Tos in
1976, who removed a medium size VS via the translabyrinthine approach in the
Department of Otolaryngology, Gentofte University Hospital. 23 Even this approach later
termed as a Danish VS model, where Tos and Thomsen in close cooperation with the
neurosurgeons J Riishede, G Thornval and A Harmsen established one team to manage VS
in Denmark.23
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The invention of the Gamma Knife Machine for the management of patients with VS has
revolutionized tumor control. The Gamma Knife Surgery for VS was first conducted by
professor Leksell in Sweden in 1969. In 1986, the Leksell Gamma Knife type “B”was
introduced. But the worldwide interest in GKS roused only after 1991, when results of
GKS for VS were reported at the first international conference on VS held in
Copenhagen.26 GKS was spotlighted as an ideal treatment for patients with a high risk for
surgery, old patients, and patients who refused to undergo an operation. Since then, many
medical centers have reported good results of GKS for a VS.28
Over the years, starting from 2000, the Leksell Gamma Knife type “C”with a robotic
automatic positioning system and an automatic helmet changer was introduced, which
allowed for more convenient and rapid treatment, and this is still being used today. 28, 30
In 2004, the Leksell Gamma Knife type “4C”was introduced. It features new Leksell
Gamma Plan software, provides the ability to co-register non-stereotactic images, allows
planning from various image sources such as computed tomography, magnetic resonance
image, and positron emission tomography (PET), and sharing the remote images from the
center where a gamma knife is not available.29
1.3.3.2 Histopathology of Vestibular Schwannoma
In a majority of literature, different markers in an SV have been revealed such as Luse
bodies, fibrous collagen bundles, myelin sheath irregularities, and subepithelial nerve fiber
losses and all were observed in the vestibule. But histopathological examinations of VS
always detects two tissue types, Antoni “A”and Antoni “B”. The Antoni A and Antoni B
types are termed after the the Swedish pathologist Antoni.20
It is the distal part of the eighth nerve, with Schwann cells enclosing the axons, where an
overproliferation of Schwann cells leads to the formation of VS. As a result, acoustic
schwannoma cells can survive and proliferate in the absence of axon-derived growth
factors, in a similar manner to mature, denervated Schwann cells. 32 The tumours have a
remarkably diffuse yellow appearance and as described by Sandiford with it a firm
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consistency. When compared to other benign intracranial tumours, VS have the least
proliferative status. 30, 31
Antoni type “A” tissue is type usually described as densely packed cells with small
spindle-shaped densely staining nuclei and Antoni “B” refers to a looser cellular
aggregation of vacuolated pleomorphic cells. 20 In any particular VS, one tissue type may
predominate (e.g. see fig. 15).
The cells are dispersed randomly around blood vessels, microcysts, collections of
xanthomatous cells and sites of previous hemorrhage. Lymphocytes attest to antecedent
degenerative events within Antoni B tissue. The degree of nuclear pleomorphism varies
considerably among acoustic neurinomas as well as between different areas within the
same tumor. This pleomorphism often contributes to a random population of large and
bizarre nuclei that taunt the pathologist with thoughts of anaplasia; however, fortunately,
malignant transformation is of a rarity that permits individual case reports. Mitotic figures
are most infrequent. Necrosis is commonly present but most often testifies to the
meagerness of native blood vessels and their compression by tumor expansion within a
restricted compartment.20, 21
Figure 15. Atoni type A (On the left) is a VS with a thick concentration of cells and the Antoni type B (On
the right) is schwannoma. The pattern is a loose texture of cells with a honeycomb appearance. The
accumulation of lipids within the cells gives it its characteristic look.
Source: http://www.otopathology.com/acoustic.htm
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Schwann cells possess a basement membrane that lies external to the plasma membrane.
This feature distinguishes Schwann cells from fibroblasts. In addition, the presence of
widely spaced collagen validates this identification. The histological features of a
vestibular schwannoma are generally diagnostic, and the assessment of anaplasia or
malignancy has already been resolved in favor of benignity by the natural history of this
neoplasm.
Russell & Rubinstein (1989) described that mucinous and microcystic changes are
especially prone to occur in Antoni B tissue. When confluent, the changes presumably
result in the production of large cysts. 20
In some literature the cystic elements in VS have been reported as a degenerative “A”
tissue especially it refers to large and old tumours. But in other literatures this theory has
been neglected and criticized along with stating that the distinctive types of Schwann cells
could be cultured from “A”and “B”types of human schwannomas. 20Tumors derived from
type “B”tissue had a more pronounced liquificative action upon the culture media than
those composed of “A”tissue.
VSs can reach sizes of up to several centimeters in diameter and thus, most of the cells
comprising a tumor are not adjacent to the axon. As a result, vestibular schwannoma cells
can survive and proliferate in the absence of axon-derived growth factors, and in a similar
manner will mature into denervated Schwann cells.32 A VS receives its arterial blood
supply primarily from the branches of the basilar arteries, as well as from branches of the
vertebral arteries.29
Of course, as the tumor grows, it follows the direction of least resistance, often medially
into the CPA, at which stage it may be of considerable size. As a result, a tumor often
consists of two parts, the stalk within the IAC and the main portion occupying the CPA.
Schwann cells are multivalent neuro-ectodermal cells, which are considered homologous
to oligodendroglia of the central nervous system, both of which form and maintain the
myelin sheath.33 The immunohistochemical identification of nuclear antigen associated
with cellular proliferation offered a very promising approach to the measurement of growth
fraction in a VS.20 The occurrence of both sporadic VSs and those associated with
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Neurofibromatosis NF appears to be associated with an aberration of a tumor suppressor
gene on chromosome 22q12. The biological background and reason for the diverse growth
patterns of a VS is, however, largely unknown and the natural history of the VS remains
enigmatic.
Growth of any solid tumor with a volume of more than 2 or 3mm requires angiogenesis in
demand of sufficient tissue supply of oxygen and nutrients through diffusion. Angiogenesis
is defined as a process of new blood vessel formation from preexisting vasculature and is
characterized by a cascade of processes, during which the vessel basal membrane and the
surrounding tissue stroma is degraded by endothelial cell proliferation and migration.
Established hypoxia induces paracrine secretion of proangiogenetic factors from the tumor
cells, thus activating adjacent endothelial cells, which proliferate and migrate.34
The most potent proangiogenetic factor among the several is Vascular Endothelial Growth
factor-A (VEGF). VEGF causes vasodilatation, increases vascular permeability, induces
angiogenesis through endothelial cell proliferation and migration, and thus plays an
important role in regulating angiogenesis. It promotes extravasation of plasma proteins
from tumour vessels to form a new and provisory extravascular matrix favoring inward
migration and the proliferation of endothelial cells.34
1.3.3.3 Clinical manifestations of Vestibular Schwannoma
The clinical presentations of a VS is highly variable and includes unilateral high frequency
sensoneural hearing loss, tinnitus, disequilibrium, pressure in the ear, otalgia, and
occasionally vertigo, which result from pressure exerted by the tumor upon the cochlear
and vestibular portions of the eighth cranial nerve. But hearing loss is the most common
finding, occurring in more than 95% of patients over the course of this disease.35
While hearing loss is common in a VS there are plenty of other causes of hearing loss.
Approximately 10% of cases of unilateral progressive hearing loss are caused by a VS33
and one out of 100 patients with otologic symptoms will actually have a VS.1
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The sudden hearing loss occurs in about 25% of patients with a VS. However, because a
VS is a rare condition, sudden hearing loss attributable to an acoustic tumor occurs in only
1-5 percent of patients with sudden hearing loss, as there are many more common
causes.38 Even a sudden hearing loss with complete recovery can be caused by a VS.35 The
mechanism of hearing loss is related to the direct compression of the cochlear nerve.
Hearing loss occurs in VS patients as a symptom may be of several years’duration prior to
diagnosis.33, 36, 37
The average time from onset of symptoms to clinical diagnosis has been shown to range
from approximately 4 to 7.3 years.33 But in some occasions, this time could last much
longer.36 Nevertheless, as many as 5 to 12 percent of patients with a newly diagnosed VS
have normal hearing, in part as a result of the detection of smaller tumors by means of an
MRI. In most cases, the onset of hearing loss is gradual, but in 15 percent of cases, it may
be sudden if compression of the internal auditory artery occurs.33
The subjective tinnitus is another very common consequence of vestibular schwannoma or
cochlear nerve dysfunction, it usually presents with concomitant hearing loss which is
unilateral and confined to the affected ear. Tinnitus may even be the first symptom of a
VS, without the person experiencing hearing loss. Like hearing loss, tinnitus is also present
mostly in the high-frequency range. Most of those affected with tinnitus are usually
severely impacted.
According to Kim et al.,48 tinnitus is associated with 71% of a VS at presentation. Unlike
hearing loss, tinnitus has a low impact on patient functioning; therefore, it rarely serves as
the impetus to seek medical attention.48 Nonetheless, unilateral tinnitus without obvious
cause warrants investigation of the auditory brainstem response (ABR) or MR imaging.
Tinnitus in the absence of hearing loss is extremely rare.10 The pathophysiology of tinnitus
associated with a VS is thought to be similar to that of hearing loss, that is, neural or
vascular compression. Unlike the asymmetric hearing loss, the tinnitus has low specificity
in the diagnosis of a VS.
Approximately 50 percent of all patients with a VS have vestibular symptoms like vertigo
and disequilibrium.49
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Frequency of Symptoms at Presentation of VS.
Symptoms Percent
Sensorineural hearing loss 96
Unsteadiness 77
Tinnitus 71
Headache 29
Mastoid pain/otalgia 28
Facial numbness 7
Diplopia 7
Table 1. An analysis of 100 translabyrinthine operations.
Source: Kim Louis, Klopfenstein Jeffrey, Porter Randall, Syms Mark. Acoustic neuroma: Symptoms and
diagnosis. Barrow quarterly. Vol 20 No.4.2004. 7-13.
Although, the usual origin of a VS is the inferior vestibular nerve50 vertigo prior to surgery
is not common, occurring in only about 20 percent of persons with a VS.42 Vertigo may be
related to the available compensation of vestibular functions or nerve resistance to the
compression. However, it occurs in later stages of the diseases. According to Timothy et al,
the hyperventilation induced nystagmus (HVIN) may be far more specific for a VS.42,43,50
Evaluation of HVIN requires more sophisticated equipment than is available in most
offices. It also requires the examiner to be familiar with this condition, and it is somewhat
obscure.50
Furthermore, the above mentioned signs, in a VS course, may present any symptoms
related to any intracranial mass such as sensory changes on the face or tongue, decreased
corneal reflex, direction-changing nystagmus, ipsilateral numbness of the face, facial nerve
motor dysfunction, a slurring of speech, ataxia, gait disturbance, an incoordination of one
or both upper extremities, numbness or tingling of the malar eminence, and occasionally
long tract signs.48 Dysfunction of a facial nerve also can be counted as a symptom
presenting in later stages of a VS and/or large VS. For example the facial nerve numbness
occurs in 50 percent of cases with the tumor size > 2 cm.42 Facial twitching, also known as
facial synkinesis or hemifacial spasm, occurs in about 10 percent of the patients with a
VS.50 Decreased or absent corneal reflex is a consequence of trigeminal nerve dysfunction,
although this deficit is rarely noticed by patients.33
Trigeminal nerve dysfunction is, however, responsible for the more common complaint of
numbness or tingling of the malar eminence. Brainstem compressive symptoms include
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ipsilateral upper or lower extremity dysfunction, and cerebellar symptoms include ataxia
and gait disturbance.33 Usually these symptoms occur in late stages of a VS course and are
observed in large-sized tumors. Symptoms from hydrocephalus related to tumor
obstruction of the fourth ventricle include headache, nausea, vomiting, diplopia,
papilledema, and changes in mental status. The incidence of hydrocephalus in VS patients
is low, occurring in 4% of cases according to a University of California-San Francisco
series. Significant tumor growth is usually required to produce obstructive
hydrocephalus.49
Symptoms, like raised intracranial pressure, headaches, nausea, vomiting, and dullness of
mental faculties are gradual and persistent symptoms. The symptoms are also characteristic
of the later stage of the disease. These symptoms appear gradually and are persistent. An
onset of headaches as a symptom of a VS is typically a sequela of hydrocephalus. It occurs
prior to surgery in roughly 40 percent of those with large tumors.39 Therefore, the
symptoms of a VS are highly dependent upon the size of the tumor. Patients with small
tumors present with unilateral hearing loss and symptoms of vestibular nerve
compression.39 Patients with larger tumors present with symptoms of trigeminal nerve
dysfunction, facial nerve dysfunction, and increased intracranial pressure. Finally,
continued growth of the tumor are evident in symptoms related to brainstem and cerebellar
compression.33
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Explorations of hearing impairments in Vestibular Schwannoma1.3.4
1.3.4.1 Conventional Audiometry
The hearing loss is a most frequent initial sign and most common symptom of VS. Over
the years the Audiometry became a time-tested useful tool in diagnosis vestibular
schwannoma as 95% of all VS patients at early or late stages of the disease would have a
hearing loss. 48
It usually develops over month to year and it associated with impairment of speech
disproportionate to the pure tome. In 10% of cases, sudden hearing loss occurs and it
attributable to the vascular interruption of the internal auditory artery. 49,50
A complete audiologic test includes pure-tone audiometry, acoustic reflex testing with a
measurement of reflex decay and speech reception audiometry. Figure 16.
Figure 16. Audiometry room and audiometry equippment “Audiotest 340”(Our photo)
Introduction
71
The most frequent hearing impairment in patients with VS has been found to be
asymmetrical high-frequency sensorineural hearing loss (SNHL). Although, it should be
taken into account that no more than 1 out of 20 patients with large tumours have
symmetry within 15 dB at 4000 hz, but only about 1 in 1000 patients with hearing
asymmetry have VS.42 (Figure 17.).
In general, it has been estimated that 5 percent of persons with sensorineural hearing loss
have a VS.48 But in reality, perhaps this number is much higher with a prevalence of VS
than is commonly accepted. Usually, the speech reception (SRT) is normal in many
patients with small tumors. According to some trials, there are many cases of a VS being
registered with symmetrical hearing but with a large VS on one side. Approximately 50%
of all VS patients with small tumors normally have excellent speech discrimination, and
one third of patients with large tumors still have near-normal (> 80%) speech
discrimination.42 Although a small percentage of patients with asymmetric hearing
impairment end up having a VS, a missed early diagnosis of VS may jeopardize hearing
and may have legal implications.51,52
Figure 17. A simple audiogram and tympanogram of a patient with a left-sided vestibular
schwannoma (Our photo)
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Figure 18. Ipsilateral SNHL in patient with right sided VS (Our photo)
The criteria have not yet been established for identifying the configuration of the pure tone
audiogram constituting abnormal results that warrant further investigation using methods
such as MRI. Several studies have classified the configurations of the pure tone audiogram
among patients with a VS,1 but few reports have described the prevalence of a VS
associated with each of these configurations. The purpose of this study was to retrospec-
tively determine the prevalence of a VS for each configuration of the pure tone audiogram
in patients with asymmetric sensorineural hearing loss. By varying the sound intensity,
thresholds can be obtained at octave intervals from 250 to 8000 Hz. This test requires the
cooperation of the patient, who must indicate every time he is able to hear the pulsed tone,
no matter how faint or short it may be. The incidence of normal audiograms in several
cases has been reported elsewhere to be 3 to 6 percent.49 Isolated low-frequency pure tone
loss is a rare occurrence in patients with a VS. Audiometry seems to be a poor predictor of
tumor size. In a study of 300 patients with vestibular schwannomas, Thomsen and Tos
found no significant difference between the degree of pure tone loss and the size of tumors
less than 4 cm. A strong correlation was found, however, between the extent of hearing
loss and a tumor size greater than 4 cm.48
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There were a few studies conducted to reveal VS related deafness. In some studies (Masaaki
Suzuki at all, 2010) the prevalence of a VS in patients with idiopathic sudden deafness
(ISD) was 2.8%52.
Prior to the availability of ABR testing, several additional tests were used to distinguish
between cochlear and retrocochlear lesions. These tests included tone decay testing, the
suprathreshold adaptation test, the performance intensity function for phonetically
balanced words test, the short-increment sensitivity index and the alternate binaural
loudness balance test. For the most part, these audiologic tests have been replaced by ABR
testing. In one series, an extensive audiologic test battery without ABR testing detected a
mixed retrocochlear loss in 69 percent of the cases and pure retrocochlear findings in only
27 percent of patients with vestibular schwannomas. 50,37
1.3.4.2 Word recognition test (WRT).
WRT (speech discrimination tests) are also useful in the diagnosis of a VS, which assesses
the patient’s ability to understand speech when presented at a loudness level that is well
above the patient's threshold. This test is administered by using single syllable words. The
result is presented as a percentage score.54
The WRT can be helpful in predicting the usefulness of a hearing aid. An increase in the
word recognition score (WRS) with amplification, suggests that a hearing aid might be
useful. WRT has some limitations because many patients don't communicate with
monosyllabic speech, so a good score on the WRS may not necessarily correlate with
good, functional performance.53 Scores are also weighted towards the perception of high
frequency consonants. Poor performance overestimates everyday communication
impairment for patients with high frequency hearing loss. The WRT also underestimates
hearing problems in noise.45
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1.3.4.3 Auditory brainstem response (ABR) audiometry
The ABR is the most useful audiometric test in the diagnosis of a VS, and the use of Brain
Stem Auditory Evoked Potential (BSAEP) in the VS diagnosis has been established for
years. First described by Jewett and Williston in 1971, ABR audiometry is the most
common application of auditory evoked responses.100, 105
As technology continues to evolve, the ABR will likely provide more qualitative and
quantitative information regarding the function of the auditory nerve and brainstem
pathways involved in hearing (e.g. see fig. 19).
In the 1980s and 1990s, the ABR became popular as a cost-effective initial screen for
patients considered at risk of an VS, with it's performance being judged in light of the size
of tumors then being detected radiologically (typically over 1 cm). However, with the
advent of gadolinium-enhanced MR imaging in the late 1980s and the subsequent
development of noncontrast MR imaging, these tests have allowed much smaller tumors to
be detected, leading to improved surgical outcomes and hearing preservation.129
Figure 19. ABR audiometry with the software currently used in CHUS (Our photo)
ABR audiometry refers to an evoked potential generated by a brief click or tone pip
transmitted from an acoustic transducer in the form of an insert earphone or headphone.
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The elicited waveform response is measured by surface electrodes typically placed at the
vertex of the scalp and ear lobes. The microvoltage of the signal is averaged and charted
against the time (millisecond), much like an EEG. The waveform peaks are labeled I-VII.
These waveforms normally occur within a 10-millisecond time period after a click stimulus
presented at high intensities (70-90 dB) of the normal hearing level (e.g. see fig. 20).
Figure 20. Normal adult auditory brainstem response audiometry waveform response I-V absolute latencies
and interpeak intervals (I-III, III-V, I-V) are within normal limits bilaterally (Our photo)
Although the ABR provides information regarding auditory function and hearing
sensitivity, it is not a substitute for a formal hearing evaluation, and results should be used
in conjunction with behavioral audiometry whenever possible. 106,110, 112.
ABR audiometry typically uses a click stimulus that generates a response from the basilar
region of the cochlea. The signal travels along the auditory pathway from the cochlear
nuclear complex proximally to the inferior colliculus. 100, 106, 108
ABR waves I and II correspond to true action potentials. Later waves may reflect
postsynaptic activity in major brainstem auditory centers that concomitantly contribute to
waveform peaks and troughs. The positive peaks of the waveforms reflect combined
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afferent (and likely efferent) activity from axonal pathways in the auditory brain
stem. 100, 102
Wave I: The ABR wave I response is the far-field representation of the compound
auditory nerve action potential in the distal portion of cranial nerve (CN) VIII. The
response is believed to originate from afferent activity of the CN VIII fibers (first-order
neurons) as they leave the cochlea and enter the internal auditory canal. 105, 100 Wave II:
The ABR wave II is generated by the proximal VIII nerve as it enters the brain stem. 100
Wave III: The ABR wave III arises from second-order neuron activity (beyond CN VIII) in
or near the cochlear nucleus. Literature suggests wave III is generated in the caudal portion
of the auditory pons. The cochlear nucleus contains approximately 100,000 neurons, most
of which are innervated by eighth nerve fibers. 102, 103 Wave IV: The ABR wave IV, which
often shares the same peak with wave V, is thought to arise from pontine third-order
neurons mostly located in the superior olivary complex, but additional contributions may
come from the cochlear nucleus and nucleus of lateral lemniscus. 109, 110
Wave V: Generation of wave V likely reflects activity of multiple anatomic auditory
structures. The ABR wave V is the component analyzed most often in clinical applications
of the ABR. Although some debate exists regarding the precise generation of wave V, it is
believed to originate from the vicinity of the inferior colliculus. 100 The second-order
neuron activity may additionally contribute in some way to wave V. The inferior colliculus
is a complex structure, with more than 99% of the axons from lower auditory brainstem
regions going through the lateral lemniscus to the inferior colliculus.
Wave VI and VII: Thalamic (medial geniculate body) origin is suggested for generation
of waves VI and VII, but the actual site of generation is uncertain.
ABR audiometry is considered an effective screening tool in the evaluation of suspected
retrocochlear pathology such as vestibular schwannoma (Figure 21). 100, 101, 105 However,
an abnormal ABR finding suggestive of retrocochlear pathology indicates the need for
MRI of the cerebellopontine angle. 104, 105
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Figure 21. Abnormal ABR (Our photo)
In addition to retrocochlear pathologies, many factors may influence ABR results,
including the degree of sensorineural hearing loss, asymmetry of hearing loss, test
parameters, and other patient factors. These influences must be factored in when
performing and analyzing an ABR result. 100, 102,110.
In general, ABR exhibits a sensitivity of over 90% and a specificity of
approximately 70-90%. 106, 107
Sensitivity for small tumours is not as high. For this reason, a symptomatic patient with a
normal ABR result should receive a follow-up audiogram in 6 months to monitor for any
changes in hearing sensitivity or tinnitus. The ABR may be repeated if indicated.
Alternatively, MRI with gadolinium enhancement, which has become the new criterion
standard, can be used to identify very small (3-mm) VS.
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The ABR sensitivity in the diagnosis of CN VIII tumours by size according to several
studies is as follows:
In a 1994 study by Dornhoffer, Helms, and Hoehmann, the sensitivity was 93% for
tumours smaller than 1 cm. 100
In 1997, Zappia, O'Connor, Wiet, and Dinces reported a sensitivity of 89% for small
tumours smaller than 1 cm, 98% for medium tumours 1.1-2 cm, and 100% for tumours
larger than 2 cm. The overall sensitivity was 95%.102 In a 1995 study, Chandrasekhar,
Brackmann, and Devgan reported a sensitivity of 83.1% for tumours smaller than 1 cm and
a sensitivity of 100% for tumours larger than 3 cm. Overall sensitivity was 92%.103 In
1995, Gordon and Cohen reported the following sensitivities: 69% for tumours smaller
than 9 mm, 89% for tumours 1-1.5 cm, 86% for tumours 1.6-2 cm, and 100% for tumours
larger than 2 cm.103, 104
In a 2001 report by Schmidt, Sataloff, Newman, Spiegel, and Myers, the sensitivity was
58% for tumours smaller than 1 cm, 94% for tumours 1.1-1.5 cm, and 100% for tumours
larger than 1.5 cm. The overall sensitivity was 90%.105, 106 In a large prospective study that
compared ABR with contrast-enhanced MRI (the criterion standard) in 312 patients with
asymmetric sensorineural hearing loss, Cueva found that ABR yielded a sensitivity and
specificity of 71% and 74%, respectively, in revealing the cause of lesions for asymmetric
sense and oral hearing loss (including, but not limited to, vestibular schwannoma). The
ABR-positive predictive value was only 23%, whereas its negative predictive value was
96%. Seven of 31 positive cases had other lesions that ABR could not identify as a cause
of the hearing loss. 106
Although traditional ABR measures decrease in sensitivity as a factor of tumour size,
recent studies have shown that by using a new stacked derived-band ABR that measures
amplitude, very small tumours may be detected more accurately. 100, 108
This new technique, combined with traditional ABR audiometry, may soon make possible
the detection of very small tumours with accuracy approaching 100% using ABR
audiometry.
Other applications of ABR continue to evolve as some reviewed literatures suggests that
although the overall ABR wave latencies are within normal limits in patients with tinnitus,
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those patients have longer latencies than control patients without tinnitus.107 It almost
means that ABR may be useful in monitoring and understanding tinnitus.
They are variety of scientific viewpoints and opinions regarding diagnostic value of ABR.
The results of individual trials are also controversial.
Several investigators have reported the sensitivity of ABRs testing as 93% or greater. 119,
120, 121 However some other authors stated that in their trial 85% of VS patients had
abnormal ABRs. 122
Of course the tumour size and nerve of origin is important factors affecting the ABR
sensitivity. Wilson DF at all, states that in their group of patients one of 25 patients with
extracanalicular tumours had normal ABRs for a false-negative rate of 4%; however, 5 of
15 patients with intracanalicular tumours had normal ABRs for a false-negative rate of
33%. 118 Figure 22.
Figure 22. Sensitivity of ABR testing by tumour size
Source: Wilson DF. Talbot JM, Mills L. The sensitivity of auditory brainstem response testing in small VSs.
Laryngoscope. 1992 Sep; 102(9):961-964
The ABR was less sensitive in detecting intracanalicular VS than in detecting
extracanalicular VS. 118
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1.3.4.4 Otoacoustic emissions (OAE) testing
An otoacoustic emission is a low-level sound emitted by the cochlea either spontaneously
or evoked by an auditory stimulus. Specifically, OAEs provide information related to the
function of the outer hair cells. 62, 66
Over the past 20 years, their use in routine audiological assessments has increased
significantly. Today, OAEs are used commonly in the audiological assessment of difficult
to test patients, such as persons who cannot or will not volunteer reliable behavioral
responses.
Otoacoustic emissions were first reported by Kemp in 1978. The primary purpose of OAE
tests is to determine cochlear status, specifically hair cell function. 57, 58
Present OAEs in an ear indicate many things about the auditory system. First, a present
OAE tells us that the conductive mechanism of the ear is functioning properly. This
includes proper forward and reverse transmission, no blockage of the external auditory
canal, normal tympanic membrane movement, and a functioning impedance matching
system. Present OAEs also indicate that outer hair cells (OHC) function is normal, which,
in most cases, correlates with normal hearing sensitivity. OAE testing does have some
limitations. OAE testing does not evaluate the inner hair cells, CN VIII, ascending central
auditory pathway, or auditory processing function. 67,80
Understanding the cochlear anatomy and physiology must exist to understand OAEs.
Generally speaking, OAEs are waves generated by movement of the basilar membrane and
are measured in the external auditory canal.80 However, with an in-depth understanding of
cochlear anatomy and physiology, OAEs can be directly related to OHC function. There
are many events leading up to this. First, there is a stimulus delivered to the ear. This
stimulus invokes movement of the basilar membrane, which in turn causes the OHCs to
move, or be deflected. 80, 83
When the OHCs move, their stereocilia bend in one direction or the other. Ions rush in and
rush out, changing the membrane potential within the hair cell. The changes in voltage
across the plasma membrane lead to OHC length changes, which are called electromotility.
The electromotility of the OHCs has a feedback effect on the basilar membrane, causing it
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to vibrate. Therefore, the electromotility of the OHCs is thought to be the mechanism
which underlies OAEs. Furthermore, research studies over the past 25 years have
demonstrated that when the OHC electromotility is blocked, OAEs are absent, which
solidifies the relationship between OHC motility and OAEs. 80, 83
This information can be used to screen hearing, partially estimate hearing sensitivity within
a limited range, differentiate between the sensory and neural components of sensorineural
hearing loss, and test for functional hearing loss. 62,63 The information can be obtained
from patients who are sleeping or even comatose because no behavioral response is
required. 61-63
The normal cochlea does not just receive sound and produces low-intensity OAEs. These
emissions are produced most probably, by the cochlear outer hair cells as they expand and
contract. 61 The presence of cochlear an emission was hypothesized in the 1940s on the
basis of mathematical models of cochlear nonlinearity. 63 However, OAEs could not be
measured until the late 1970s, when technology created the extremely sensitive low-noise
microphones needed to record these responses (e.g. see figure 23).
Figure 23. TEOAE software “ILO 292”; Contents: Ear probe, Small speaker, Microphon and
Response Analyzer connected to computer (Our photo)
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The 4 types of otoacoustic emissions are as follows:
- Spontaneous otoacoustic emissions (SOAEs) - Sounds emitted without an
acoustic stimulus (ie, spontaneously)
- Transient otoacoustic emissions (TOAEs) or transient evoked otoacoustic
emissions (TEOAEs) - Sounds emitted in response to an acoustic stimuli of very
short duration; usually clicks but can be tone-bursts
- Distortion product otoacoustic emissions (DPOAEs) - Sounds emitted in response
to 2 simultaneous tones of different frequencies
- Sustained-frequency otoacoustic emissions (SFOAEs) - Sounds emitted in
response to a continuous tone. 62, 67
The PTA measures throughout the outer ear, middle ear, cochlea, cranial nerve (CN) VIII,
and central auditory system. However, OAEs measure only the peripheral auditory system,
which includes the outer ear, middle ear, and cochlea. The response only emanates from
the cochlea, but the outer and middle ear must be able to transmit the emitted sound back
to the recording microphone. 66, 68
OAE testing often is used as a screening tool to determine the presence or absence of
cochlear function, although analysis can be performed for individual cochlear frequency
regions. 61 OAEs cannot be used to fully describe an individual's auditory thresholds, but
they can help question or validate other threshold measures or they can provide
information about the site of the lesion. 65,66
Using current technology, most researchers and clinicians find a correlation between
frequency-specific analysis of TOAEs/DPOAEs and cochlear hearing loss. However, at
this juncture, the correlation cannot fully describe auditory threshold. Naturally, a
correlation would not be expected for noncochlear hearing loss. 65, 67, 68
Multiple responses are averaged. All OAEs are analyzed relative to the noise floor;
therefore, reduction of physiologic and acoustic ambient noise is critical for good
recordings. Because no behavioral response is required, OAEs can be obtained even from
patients who are comatose. For a quiet and cooperative patient, recordings usually require
less a few minutes per ear. 78, 80 For uncooperative or noisy patient, recordings may take
significantly longer or may be impossible to obtain on a given visit.
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In spontaneous otoacoustic emissions (SOAE) This nonevoked response is usually
measured in narrow bands (< 30 Hz bandwidth) of frequencies recorded in the external ear
canal. No stimulus is required. Obtain multiple recordings to ensure replicability and to
distinguish the response from the noise floor. SOAE recordings usually span the 500-Hz to
7000-Hz frequency range. 82,84
In transient otoacoustic emissions cicks are the most commonly used stimuli, although
tone-burst stimuli may be used. Most commonly, 80- to 85-dB sound pressure level (SPL)
stimuli are used clinically. The stimulation rate is less than 60 stimuli per second. TOAEs
are generally recorded in the time domain over approximately 20 milliseconds. Alternating
responses are stored in alternating computer memory banks, A and B. Data that correlate
between the 2 memory banks are considered a response. 80 Data that do not correlate are
considered noise. When present, TOAEs generally occur at frequencies of 500-4000 Hz.
Data in the time domain then are converted to the frequency domain, usually in octave
band analysis.82
In Distortion product otoacoustic emissions the stimuli consist of 2 pure tones at 2
frequencies (ie, f1, f2 [f2>f1]) and 2 intensity levels (ie, L1, L2). The relationship between
L1-L2 and f1-f2 dictates the frequency response. An f1/f2 ratio yields the greatest
DPOAEs at 1.2 for low and high frequencies and at 1.3 for medium frequencies. To yield
an optimal response, set intensities so that L1 equals or exceeds L2. Lowering the absolute
intensity of the stimulus renders the DPOAEs more sensitive to abnormality. A setting of
65/55 dB SPL L1/L2 is frequently used 88, 89 (e.g. figure 24).
Figure 24. An example of DPOAEs recorded from 80 year old female patient with left sided VS (Our photo)
Introduction
84
Responses are usually most robust and recorded at the emitted frequency of 2 f1–f2;
however, they generally are charted according to f2 because that region approximates the
cochlear frequency region generating the response. 80, 90
But anyway, most investigators believe that otoacoustic emissions whether they be
spontaneous, product distortion, or evoked are present in healthy cochleae. 96, 97
Studies have shown that TEOAEs are lost on the lesioned side in a variable number of
patients with VS, probably because of cochlear vascular damage 90, 95 According to Singh
et al 94 the presence of TEOAEs on the lesioned side in 63 patients with VS who were
surgically treated with the aim of saving hearing function was a favorable prognostic factor
for hearing preservation, probably as a result of better cochlear vascularization.
An Otoacoustic emission testing is regarded as the only test capable of demonstrating the
function of the organ of Corti, especially in the outer hair cells, in an objective,
noninvasive, and reproducible way. There is also a consensus that different noxious factors
that can affect the cochlea such as ototoxics and acoustic disorders diminish or eliminate
otoacoustic emissions. 94, 96
It is accepted that otoacoustic emissions are modified by stimulation of the efferent
auditory system, as contralateral acoustic stimuli reduce distortion product and evoked
emissions.98 For these reasons, the use of otoacoustic emissions testing is widely
acknowledged as useful for making auditory assessments of newborns and patients who
have been exposed to ototoxics or environmental noise, and for controlling cortipathy that
is, damage to or a lesion in the organ of Corti.98
In cases of a VS and other central auditory system disorders, the OAEs presents but ABR
altered. Interestingly, a number of reviewed literatures have indicated that OAEs
(TEOAES or DPOAEs) can be both affected and unaffected by the presence of a VS.54,57
An explanation for such data can be derived from information of how the growth of the
tumor affects the vascular supply of the cochlea or how the growth of the tumors induces
mechanical pressure alterations on the vascular supply and the cochlea itself. The OAE-
based measures can provide information on the sensory component of any hearing
disorder; thus, they can provide precise indexes of evaluating sensorineural hearing
impairment cases which can play an important role in the detection of a VS.57
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Explorations of balance dysfunctions in Vestibular Schwannoma1.4
Posturography.1.4.1
Posturography is a general term that covers all the techniques used to quantify postural
control in an upright stance, in either static or dynamic conditions. Among those
techniques is computerized dynamic posturography (CDP), also called test of balance
(TOB). 200-201
CDP is a non-invasive specialized clinical assessment technique used to quantify the
central nervous system adaptive mechanisms involved in the control of posture and
balance, both in normal and abnormal conditions (e.g. see fig. 25)
Figure 25. Assessment of VS patient with Computerized Dynamic Posturography equipment from “Smart
Balance Master Neurocom®”(Our photo)
Due to the complex interactions among the sensory, motor, and central processes involved
in posture and balance, CDP requires different protocols to differentiate among the many
defects and impairments, which may affect a subject's postural control system.
CDP challenges that system by using several different combinations of visual and support
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surface stimuli and parameters. It has been proven effective in assessing vestibular as well
as some neuromuscular disorders affecting balance. 202
Computerized Dynamic Posturography is an integral component in the diagnostic workup
of imbalance or dizziness when used to identify the underlying sensory (vestibular, visual,
somatosensory) and motor control impairments. CDP is not considered to be a site-of-
lesion test nor is it pathonomonic for vestibular disease.24
Balance and dizziness disorders often have multiple causes that cannot be isolated to a
single localized pathology. Clinical evidence indicates that an impairment reduction
strategy is the most effective way to reduce the symptoms associated with imbalance and
dizziness with multiple causes.23. 27
Whereas traditional site-of-lesion tests are designed to confirm the presence and
anatomical location of pathology, CDP, in contrast, documents the physiological
impairments that are the functional manifestations of pathology. Because the balance
system is highly adaptive, patients with similar pathology can present with different
impairments, depending on the stage (progression) of the disease or disorder. 123
In many patients with chronic balance disorders, no anatomical pathology can be identified
that accounts for the patient's symptoms and impairments. Because of the "disconnect"
between pathology and impairments, CDP and traditional site-of-lesion tests provide
complementary rather than redundant information in the diagnostic workup of the dizzy
and/or unsteady patient.128
The Sensory Organization Test (SOT) objectively identifies problems with postural control
by assessing the patient's ability to make effective use of (or suppress inappropriate) visual,
vestibular, and proprioceptive information. 200 During the SOT, useful information
delivered to the patient's eyes, feet and joints is effectively eliminated through calibrated
"sway referencing" of the support surface and/or visual surround. The support surface
and/or visual surround tilt to directly follow the patient's anteroposterior body sway,
eliminating orientation information. By controlling the usefulness of the sensory (visual
and proprioceptive) information through sway referencing and/or eyes open/closed
conditions, the SOT protocol systematically eliminates useful visual and/or support surface
information and creates sensory conflict situations. These conditions isolate vestibular
balance control, as well as stress the adaptive responses of the central nervous system. In
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short, patients may display either an inability to make effective use of individual sensory
systems, or inappropriate adaptive responses, resulting in the use of inaccurate sense. 202
The CDP has become an increasingly popular modality for evaluating balance function.
Most clinicians and researchers use the equipment, protocol, and normative values
developed by NeuroCom International of Clackamas, Ore., as the standard for testing and
comparison. 200
A central aspect of the CDP protocol is SOT and it helps the physician evaluate how
visual, somatosensory, and vestibular inputs affect a patient's ability to maintain functional
balance. This objective test measures the extent of a patient's sway while standing on a
force platform during six conditions (e.g. see fig. 26-27).
Figure 26. Test conditions SOT 1 to 6 (Our photo)
Condition 1 is a simulation of a common, normal state. With eyes open, and the platform
and visual surround are stable; In condition 2, the platform and visual surround are both
still fixed, but the patient's eyes are shut; In condition 3, the eyes are open and the
platform is fixed, but the visual surround tilts in the direction of the patient's sway, thereby
delivering inaccurate visual information about orientation in space; Conditions 4, 5, and 6
are the same as conditions 1, 2, and 3, respectively, except that the platform moves. The
sway-referenced platform tilts with the patient's sway, thereby altering somatosensory
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input. As a result, conditions 5 and 6 effectively force a patient to rely on vestibular inputs
alone to maintain balance.
Figure 27. Normal SOT in a patient with left sided Antoni type “B”Vestibular Schwannoma (Our photo)
Some authors indicate that in their studies 83% of all patients with VS before the surgical
removal of tumour shows abnormalities during CDP conditions 5 and 6. But postoperative
follow-up of this patients shows that three month after the operation only 21% of patients
shows abnormal CDP. 123
In case of VS patients undergoing to surgical removal of tumour the CPD performs usually
only once for diagnostic purposes. However, after the surgical removal of VS the patients
periodically follows up with CDP, where CDP in the one hand rehabilitates the patients but
in the other hand patients will physically adapts to the movements of CDP platform, thus it
doesn’t mean that the vestibular function of patients getting to be improved. These patients
most probable will have problems with daily gait. 200
CDP Information is critical to planning treatment focused on impairment reduction, and is
therefore indicated whenever an impairment reduction strategy is appropriate. Based on a
retrospective study of the treatment planning process in more than 4000 chronic dizzy
patients, the following guidelines were developed for the use of CDP in treatment
planning.126,200
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Craniocorpography1.4.2
The Craneocorpography (CCG) is an objective and quantitative testing method of
vestibulospinal function and balance.
The GCC consists of photo-optical recording of movements of the head and body during
standing and stepping tests. 198 The stepping test was first described by Unterberger and
colleagues in 1963. In 1978, Claussen described the photographic technique for recording
results of the stepping test, which he called the craniocorpography test 216 (e.g.see fig 28).
The CCG uses light markers placed on the forehead, the occiput, and both shoulders of a
patient. Such lights are reflected through a mirror system on the ceiling into a recording
video camera and on to a computer that receives, analyzes, and prints the signal.198, 216
While testing process the patient is blindfolded by means of a sleeping mask, cutting off
visual stimuli, and the patient loses contact with the ground while stepping; hence the
proprioceptive stimuli are also gradual 217, 218 (e.g. see fig 28-29).
Figure 28. In craniocorpography, the patient is blindfolded by means of a sleeping mask, cutting off visual
stimuli, and the patient loses contact with the ground while stepping; hence the proprioceptive stimuli are
also gradual (Our photo)
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The patient will maintain balance only through the stimuli received from both vestibular
systems. Any deviation, rotation, or sway beyond the normal range will indicate the
involvement of the peripheral or central systems. 198
The GCC can record easily, quickly and inexpensively vestibulospinal reactions, both
qualitatively and quantitatively analyze, archive and compare them subsequently can be
obtained at the same or other patients.
The Unterberger-Fukuda test requires a patient to step at least 80 steps on the spot. The test
evaluates longitudinal displacement from the starting point to the end point; lateral sway,
which is the width of the head movement curves; angular deviation, which is the angle
between the directions at the starting point and at the end point; and body spin, which is the
rotation around the body axis. 217, 218
For the evaluation of the stepping test, mainly uses two parameters: lateral sway, which is
the lateral displacement of the shoulders and head between steps and is measured in
centimeters, and angular deviation, which is the angle between the initial and final position
of the patient and is measured in degrees. Lateral sway is assumed to be related to central
disorders and angular deviation to peripheral lesions. 198, 217-219
With these two parameters, we define, basically, four types of CCG assumed to be related
to a specific site of lesion. This provides a very important clue for the topographical
diagnosis, as follows:
- type I, normal;
- type II, peripheral lesion or an enhanced angular deviation with normal lateral
sway;
- type III, central lesion or an enhanced lateral sway and normal angular deviation;
- type IV, combined, central plus peripheral lesion or an enhancement of the lateral
deviation and the lateral sway 218-219 Figure 30.
Claussen et al. 198, 217, 218 reported that the parameters obtained through the CCG and the
TOB (test of balance) are significant for the final diagnosis. CCG and the TOB are useful
techniques for assessment of vestibular function in cases of vestibular disorders caused by
VS. CCG and the TOB are significant tests for scrutinizing peripheral, central, and
combined lesions in cases of vertigo. Vestibular functions can be tested simultaneously on
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both sides.These tests can be easily performed in the outpatient department and are not
time-consuming or expensive even for the long term follow up of VS patients.
Figure 29. On the left: CCG type I normal, with shematic interpretation of normal CCG. Bottom - an
example of CCG in healthy subject. On the right: CCG typy II corresponding unilateral vestibular weakness
(Our photo)
Caloric testing1.4.3
Caloric testing assesses and records the function of each labyrinth separately, making it
possible to define which side is compromised. 203, 204
The caloric response is connected with the central nervous system, which is important in
differentiating between central and peripheral vestibular diseases. It is a part of Electro or
Videonystagmography (ENG/VNG) reflecting an attempt to discover the degree to which
the vestibular system is responsive and also how symmetric the responses are, between left
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and right. It is a test of the lateral semicircular canals alone it does not assess vertical canal
function or otolithic function. 205
VNG testing is used to determine if a vestibular disease may be causing a balance or
dizziness problem, and is one of the only tests available today that can decipher between a
unilateral and bilateral vestibular loss. VNG testing is a series of tests designed to
document a patient’s ability to follow visual objects with their eyes and how well the eyes
respond to information from the vestibular system.
It is based on the principle of generating thermal variation within the external auditory
canal; by changing the temperature of the middle ear, this thermal variation changes the
density of endolymph within the lateral semicircular canal, producing convection currents
that stimulate the sensorial cells located in the ampullary crest. 203
The patient is placed in dorsal decubitus at 30º relative to the horizontal plane. This
position places the lateral canal vertically, as a liquid column, and places the ampullary
crest superiorly.203-204, 206 By having the patient more comfortable and relaxed, consistent
and accurate test results are more easily achieved (e.g. see fig 30).
Figure 30. Caloric test - patient is lying on the table while water is being squirted into her ear, and drains into
a basin. The goggles on the patient are being used to record her eye movements (Our photo)
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The bithermal caloric test is performed using 50 ml of water at 44°C and 30°C to irrigate
the tympanic membrane over a period of 30 seconds. The irrigation is done through a 3
mm diameter catheter introduced into the external auditory canal with its tip lying just a
millimeter away from the tympanic membrane. The caloric test results are evaluated using
culmination frequency as the parameter and are plotted on the butterfly
chart (e.g. see fig 31). 207
Figure 31. The Results of Standard VNG testing shows 71% right/unilateral weakness in a patient with right
sided VS (Our photo)
From the peak slow-phase velocity of nystagmus following numbers are obtained - cold
right, cold left, warm right, and warm left. Spontaneous nystagmus (SN) should be
subtracted from these, and then the absolute value taken. From these responses, Left cool
(LC), Left warm (LW), right cool (RC), right warm (RW) three additional numbers are
derived:
Total response - absolute sum of all appropriately directed responses which is usually
should be 20 or greater. TR= (RC+LC+RW+LW). The goal is to detect bilateral weakness.
When responses are corrected for spontaneous nystagmus, the procedure here is to sum the
absolute value of responses that go in the right direction, left cold and right warm should
be right-beating, right cold and left warm should be left beating.
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Directional preponderance (right beating - left-beating/total) should be 35% or less. There
is little if any clinical value in DP.
Unilateral paresis or RVR, RVR = (RC+RW-LC+LW)/TR. This is called "Jongkee's
formula". It should be 25% or less. If all responses are appropriately directed (see
commentary on TR above), one can simply take the sum of the absolute values of
responses due to the right ear, subtract the sum of the absolute responses due to the left,
and normalize to the sum of the absolute values of all responses.
An upward change in the middle ear temperature above the body temperature causes the
endolymph to move upwards, generating an endolymphatic current within the canal
towards the ampulla. If the stimulus temperature is lower than the bodily temperature,
there is the opposite movement, which generates an ampullary current towards the canal,
away from the ampulla.
The action of these convection currents on the ampullary crest alters the action potential of
this sensory receptor, stimulating or inhibiting these currents. Stimulation initiates the
VOR, a simple reflex arc from the vestibular nucleus to the oculomotor nuclei, which
generates the vestibular nystagmus. The nystagmographic response is evaluated and
compared with a normal standard. Caloric testing does not assess the function of the
sacculus or the utricle of the vertical canals. 203-204
In the literature there are almost no work has been done regarding the results of VNG in a
group of patients with VS, except ENG.
Kirtane et al 207, studied 30 cases, 16 were found to have large schwannomas compressing
the cerebellum or brainstem as proved on surgical exploration or at autopsy. The ENG
showed evidence of a central lesion in these patients in the form of an abnormal pendular
eye tracking test, an abnormal gaze test, failure of visual fixation suppression or
hyperactive contralateral caloric response. 206
The pendular eye tracking test, if abnormal, indicates a central lesion. They observed to
occur in 10 patients, each of whom had large VS compressing the cerebellum and/or the
brain stem. Significant spontaneous nystagmus was recorded in only 12 patients (40%).
Linthicum et al 209, reported recordable SN in only 10% of their cases. However in series
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of patients studied by Kirtane et al 207, the direction of the spontaneous nystagmus beat
was nonlocalising, beating towards the side of the tumour in 5 cases and away from the
tumour in 6 cases.
The results of bithermal caloric test seem to be most important and valuable test of the
entire ENG test battery. 207 Kirtane and his colleagues twenty seven patients (90%) had the
anticipated ipsilateral, hypoactive, warm and cold, caloric responses. Attention, however,
must be paid to the caloric responses elicited from the normal ear. Normal contralateral
caloric responses are to be expected. They were seen in 11 cases (36.7%), all of whom had
small or moderate-sized schwannomas. 207,208 Interestingly, in their group of patients, 10
cases (33.3%) demonstrated hyperactivity of both warm and cold caloric responses on the
contralateral side. These patients were found to have fairly large neuromas compressing
the brain stem which probably caused compression of the cerebello-vestibular fibers to the
contralateral vestibular nuclei. These cerebello-vestibular fibers passing through the
inferior cerebellar peduncle cross in the midline close to the restiform body and are mainly
inhibitory. A lesion in these fibers as is caused by a large VS leads to a release of the
contralateral vestibular nuclei from the inhibitory influences of the cerebellum, thus
explaining the noninhibition of the contralateral caloric responses. 207,209
Nowadays the VNG testing is considered the new standard for testing inner ear functions
over ENG, because VNG measures the movements of the eyes directly through infrared
cameras, instead of measuring the mastoid muscles around the eyes with electrodes like the
previous ENG version. VNG testing is more accurate, more consistent, and more
comfortable for the patient.
Bilateral hypoactivity in their series was found in 9 patients (30%). Of these, only 2
patients had bilateral VSs. A schwannoma situated medial to the porus acousticus and
arising from the inferior vestibular or cochlear nerve may give a normal caloric response
since the impulses resulting from lateral semicircular canal stimulation pass in the superior
vestibular nerve which may yet be free from compression. This occurred in 3 of their
patients (10%).209
Thus, in conjunction with audiological and radiological findings, ENG is a valuable aid in
establishing a definitive diagnosis of a VS and in evaluating its probable size and extent.
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Hence the complete ENG test battery should be performed in every case suspected to have
VS. 207, 210
Vestibular Evoked Myogenic Potentials1.4.4
The Vestibular Evoked Myogenic Potentials (VEMPs) is a diagnostic tool in the process of
which investigated patients with specific vestibular disorders.
Basically, the VEMP is a biphasic response elicited by loud clicks or tone bursts recorded
from the tonically contracted sternocleidomastoid muscle, being the only resource
available to assess the function of the saccule and the lower portion of the vestibular nerve.
It is known to be inhibitory electrical potentials generated after a sound stimulus (clicks or
pure tones), originated in the saccule and conducted by the lower portion of the vestibular
nerve all the way to the CNS, generating inhibitory electrical responses picked up by
electrodes placed on the sternocleidomastoid muscle (SCM). 211
The patients are put in a chair, seated and instructed to turn their heads to the opposite side
of the sound stimulus, in order to contract the contralateral SCM muscle. VEMPs are read
by electrodes placed on the patient’s SCM (ipsilateral to the sound stimulus), the positive
electrode is placed on the upper third of the muscle, while the negative electrode is placed
on the muscle tendon, just above the clavicle. 212 (e.g. see fig. 32).
Figure 32. VEMPS software and electrode placement (Our photo)
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The electrical responses from these potentials are made up of two biphasic waves, the first
is positive, with a latency around 13ms, known as p13; followed by another wave, this time
negative, with a latency around 23ms, known as n23 (e.g. see fig. 33-34).
Figure 33. Parameters of Evaluation of VEMPs (Our photo)
Figure 34. VEMPs showing 87% asymmetry rate in patient with right sided VS (Our photo)
These responses are present in most of the normal individuals studied, differently from a
second biphasic complex known as n34-p44, which according to Colebatch would be
absent in 40% of the normal individuals studied, while Robertson described that this
second complex would be present in 68% of normal individuals. 211,212
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In spite of several conducted studies there are still exist some controversial points
regarding the VEMPs. One of those controversies is the relationship observed between the
electrical response amplitudes and the level of contraction of the muscles tested (usually
the SCM).
Because it becomes very hard to be able to compare the test of an elderly patient with that
from a young athlete, who very likely has a much higher level of muscle contraction.
Following important controversy regarding VEMPs could be the index of sound stimulus
generated through clicks or tone bursts.212
As we know that VEMPs neural pathways involve lower portion of the vestibular nerve, so
it can be used in diagnosis of vestibular schwannomas. Some studies in the literature
already show this important contribution of VEMPs, such as the one developed by
Murofushi et al. in 1998, who observed 80% of altered VEMPs in 17 patients with
established diagnosis of vestibular schwannoma. In 2001, Takeichi et al. performed a
similar study in which he observed altered VEMPs in 13 of 18 patients diagnosed with
vestibular schwannoma confirmed by MRI. In a general way, VEMPs can contribute to the
diagnosis of vestibular tumors, but must not be used as the sole diagnostic method, because
it only assesses the function of the inferior vestibular nerve. Nonetheless, when performed
together with MRI, the ABR, audiometry and caloric test, they may help in the exact
location of the tumor in the vestibular pathways.212
Neurologic examinations in Vestibular Schwannoma1.5
Neurological examination plays an important role in diagnosing acoustic tumours. Because
it assesses motor and sensory skills, the functioning of one or more cranial nerves, hearing
and speech, vision, coordination and balance, mental status, and changes in mood or
behavior, among other abilities. Items including a tuning fork, flashlight, reflex hammer,
ophthalmoscope, and needles are used to help diagnose brain tumours.133
Otoneurologic testing includes otoscopy, exploration of muscular strength, sensibility,
cranial nerves, cerebellar testing, and exploration of spontaneous or induced nystagmus
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with head shaking, absence of saccadic movements by Halmagy testing, Romberg and
Unterberger Testing.
Usually the VS is a cause of positive otoneurological findings such as pathologic
nystagmus, positive pastpointing and postural instability, a conclusion regarding the
involvement of the vestibular system can usually be reached on bedside examination.
Moreover, the presence or absence of signs of brainstem or cerebellar dysfunction, are
sometimes sufficient to determine the nature of the disturbance without any need to
conduct laboratory tests.124,138
Examinations of patients in otoneurology room can be performed in following order. First
of all the examiner will check the eye movements of patient via asking the patient to keep
their head perfectly still directly in front of examiner. The patient will follow the finger of
examiner without head movements. It is important to ask patient if the patient experiences
any double vision and if so when is it worse. This is to check the oculomotor nerve
function.133 Following the trigeminal nerve function can be assisted. It has sory supply to
the face and motor supply to the muscles of mastication.
Initially test the sensory branches by lightly touching the face with a piece of cotton wool
and then with a blunt pin in three places on each side –around the jawline, on the cheek
and on the forehead.11
The corneal reflex would also be examined as the sensory supply to the cornea is from this
nerve. This is done by lightly touching the cornea with the cotton wool. This should cause
the patient to shut their eyelids. So we will ask the patient to look in the other direction, so
we will not be testing the blink reflex. Then gently but firmly will touch the cornea at its
junction with the sclera. Sensitivity to pain increases medially from this point and
decreases laterally. The junction of the cornea and sclera is a good compromise between
causing pain to the patient and obtaining the reflex.133
There is a rapid blink of the eye being tested and a consensual blink of the other eye. If
there is seventh nerve weakness on the side being tested, then observe the consensual
reflex.The patient will close his/her eyes tightly and the examiner will look for
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completeness of eye closure. Also the nasolabial folds and mouth will be observed while
the patient is concentrating on the eyes.134
As the orbicularis oculi contract tightly, there are milder associated contractions of muscles
about the mouth and nose; these milder contractions are better suited to displaying slight
weakness than when these muscles are tested directly.124
Additionally it can be asked a patient to smile, show you teeth, or pull back the corners of
the mouth. Look for asymmetry about the mouth. The most subtle signs of mild facial
weakness are the blink reflex and incomplete lid closure. More often we in otoneurology
practice will ask to patient to get out the tongue and move to right and left side.
To test the sensory fibers of the facial nerve, we can apply sugar, salt, or lemon juice on a
cotton swab to the lateral aspect of each side of the tongue and have the patient identify the
taste. Taste is often tested only when specific pathology of the facial nerve is suspected.4
The eighth cranial nerve carries two special sensory afferent fibers, one for audition and
one for vestibular function. The cochlear division of CN 8 is tested by screening for
auditory acuity. This can be done by the examiner lightly rubbing his fingers together next
to each of the patient's ears and comparing the left and right side responses. 124
In addition, the Rinne and Weber tests are easy to perform and can help differentiate
conductive deficits from neurosensory lesions. The Weber test consists of placing a
vibrating tuning fork on the middle of the forehead and asking if the patient feels or hears
it best on one side or the other. The normal patient will say that it is the same on both sides.
The Rinne test consists of comparing bone conduction, assessed by placing the tuning fork
on the mastoid process behind the ear, versus air conduction, assessed by holding the
tuning fork in air near the front of the ear.
Normally, air conduction volume is greater than bone conduction sound volume. For
neurosensory hearing loss, air conduction volume is still greater than bone conduction, but
for conduction hearing loss, bone conduction sound volume will be greater than air
conduction volume.133
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Diagnostic Imaging in Vestibular Schwannoma1.6
Imaging has become a sensitive method of evaluating patients with possible VS.130 MRI
continues to evolve but is already considered the preferred imaging study for the
evaluation of a patient with suspected VS. Other imaging techniques remain as useful tools
in certain clinical settings, but many techniques, considered state of the art less than a
decade ago, have faded into almost complete obsolescence. 29. 131
Because of the increasing acceptance of MRI as the imaging procedure of choice, much of
discussions deal with MRI. Other modalities, such as CT, are discussed where appropriate.
It should be remembered that either gadolinium enhanced MRI or contrast-enhanced CT
can demonstrate almost any VS.132 The usual clinical situation, however, is that the
clinician is trying to ensure that the patient does not have an VS, and so the most desirable
test is the one that is the most sensitive.
Magnetic Resonance Imaging (MRI)1.6.1
MRI has largely replaced other radiological and clinical investigations in the screening of
patients with audio-vestibular symptoms for the presence of vestibular schwannoma.
Smaller tumours can now be detected, leading to earlier surgical intervention with
improved rates of hearing preservation. 132
Since the introduction of MR imaging technology, the number of patients with relatively
small, incidentally found, asymptomatic VS has increased. A recent study estimates the
incidence of VS at 0.2% of all scans done in asymptomatic patients. 137
There has been a significant increase in the incidence of VS over the past 30 years,
from 5 tumours per million per year in 1976 to just under 20 per million per year in 2001.52,
53 Much of this increase in incidence is due to the advent of better noninvasive diagnostic
techniques, especially MRI. 53
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Noncontrast high-resolution MRI, the recommended method for diagnosis of VS, enables
accurate evaluation of the cranial nerves within the cochlea, labyrinth, internal auditory
canal, and cerebellopontine angle. Furthermore, the incidence of giant tumours has
recently dropped, whereas that of small and medium-sized tumours has increased.52
Thus, in some occasions the CT may not visualize the intracanalicular region well, and it is
here that MRI establishes its advantage 130 (e.g. see fig 35).
Figure 35. MRI scanner MAGNETOM Symphony Maestro Class (CHUS) (Our photo)
Thin section fast spin echo T2 weighted sequences are capable of clearly demonstrating
the auditory nerves and, on the basis of small studies, this unenhanced MRI sequence has
been advocated as a screening technique for detecting vestibular schwannoma 133
(e.g. see fig 36).
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Figure 36. Axial fast spin echo T2 weighted (top) and gadolinium enhanced T1 weighted (bottom) images
from one patient. On the left the fast spin echo images clearly demonstrate a 3 mm intracanalicular
intracanalicular VS
Source: O'Rourke B, Wallace R. Imaging of VSs. Barrow Quarterly 2004,Vol 20, (4)
However, the presence of audiovestibular symptoms and studies with large numbers of
patients are required for the proper assessment of alternatives to gadolinium enhanced
imaging for VS screening.
The vestibular schwannoma is a soft tissue tumour. Although the lesion can certainly come
into contact with the brain, the role of imaging is usually to try to contrast the lesion
against the CSF. It may be difficult to appreciate VS on CT done without contrast
administration because the density differences are insufficient for consistent visualization
of a tumour. 22
MRI, on the other hand, gives excellent soft tissue visualization but does not show the
bony detail nearly as well as CT. Cortical bone gives a lack of signal or signal void on
MRI. Air also is seen as a lack of signal on the MRI scan. In a normal situation, therefore,
the observer is not able to differentiate the otic capsule from the air filled middle ear. Both
appear black. The petrous apex often contains fat, which is seen as bright signal on the T1-
weighted (short TR/TE) image. 130
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Fluid does give some signal on the T1-weighted image. Fluid is not nearly as bright as fat
but still can be seen quite easily, especially when contrasted against the signal void of the
dense bone of the inner ear. Thus the perilymph/endolymph in the labyrinth and the CSF in
the IAC can be seen on the image. On the T1-weighted image, the soft tissue and the CSF
have different signal intensities. 132
Soft tissues such as the nerves or brain have somewhat greater signal than the CSF. Often
the nerves can be seen crossing the CPA cistern and occasionally can be followed into the
IAC. 132
The appearance of VS depends on the internal architecture of the tumour, its site of origin
along the neural pathway, and the size of the lesion as well as the specifics of the imaging
procedure being performed. The tumour can have a somewhat variable internal
architecture. The tumour is made up of various concentrations of Antoni A and Antoni B
type histological patterns. Both types can often be identified within the same tumour. This
variability of histology along with the presence of cystic areas and even small hemorrhages
is thought to account for the wide spectrum of appearance of the VS. 133
MRI is sensitive enough to define intracanalicular nerves for clinical purposes. Although
contrast-enhanced T1-weighted imaging remains the most commonly employed method
for evaluation, high-resolution T2-weighted imaging allows delineation of the individual
nerves and evaluation of their relative sizes.134
When combined with knowledge of normal anatomy, this information can also be used to
detect tumour. Sagittal oblique imaging in a plane perpendicular to the long axis of the
internal auditory canal provides a cross-sectional view of the canal and allows individual
nerves to be depicted (e.g. see fig.35). The high T2-weighted signal of the surrounding
cerebrospinal fluid (CSF) provides excellent contrast between the relatively T2- weighted
hypointensity of nerves. T2-weighted fast spin-echo (FSE) MR imaging acquired on a 1.5
Tesla-strength magnet with thin-section thickness, a small field of view, and a large matrix
(512 x 512) provides excellent anatomic detail. Direct two-dimensional (2D) acquisition in
the axial, coronal, and sagittal oblique planes through the internal auditory canal is typical.
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The three dimensional volume acquisitions can be obtained as a single axial acquisition,
and that data set can then be used for multiplanar reconstructed images. The high-
resolution anatomic detail of these T2-weighted images not only detects nerve sheath
tumours but also allows tumour volume and the degree of nerve involvement to be
evaluated. The ability of high-resolution T2-weighted imaging to depict tumour
involvement of individual nerves may provide prognostic information that can help
preserve hearing in selected patients.
Figure 37. High-resolution T2-weighted images of the left internal auditory canal showing the localization of
facial and vestibulocochlear nerves within the IAC
Source: O'Rourke B, Wallace R. Imaging of VSs. Barrow Quarterly 2004,Vol 20, (4)
In terms of cisternal vestibular schwannomas, meningiomas within the cerebellopontine
angle cistern are probably the most common differential consideration. Both can appear as
large, round, densely enhancing, extraaxial masses causing significant local mass effect.
Meningiomas typically arise adjacent to the porus acousticus but sometimes extend into the
internal auditory meatus itself. The presence of a 'dural tail' or an obtuse angle with respect
to the petrous bone can also help differentiate a meningioma from a schwannoma (e.g. see
fig.).149
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Figure 38. An extraaxial, enhancing tumour is shown in the right cerebellopontine angle with typical
characteristics of a meningioma. *While this lesion does extend into the internal auditory canal, the cisternal
component is hemispherical and forms obtuse angles with the petrous bone. A thin 'dural tail' (arrow) extends
along the ventral aspect of the prepontine cistern.
Source: Curtin DH, Hirsch W. Imaging of VSs. Neurosurg Clin N Am 19, 2008. 175–205
Other common cerebellopontine angle masses such as epidermoids and arachnoid cysts are
easily distinguished by their hyperintense T2-weighted signal characteristics and lack of
enhancement (e.g. see fig.). On postcontrast T1-weighted imaging, an intracanalicular
lipoma can appear as an ovoid hyperintense mass that can be differentiated from a
schwannoma on precontrast T1-weighted images. (e.g. see fig.39).
Figure 39. (A) T1- and (B) T2-weighted images of a cerebellopontine angle arachnoid cyst.
The cyst matches the signal of cerebrospinal fluid on all sequences and is not enhance. Note the mass effect
and distortion of the left vestibulocochlear nerve complex
Source: Curtin DH, Hirsch W. Imaging of VSs. Neurosurg Clin N Am 19, 2008. 175–205
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Performing contrast enhanced imaging alone will pick up all detectable VSs 135, 136 as well
as some other causes of abnormal enhancement. Some disease processes that may present
with similar audiovestibular symptoms are more readily identifiable on gadolinium enhanced
MRI than on non-contrast images 135. However, this strategy may overlook some other
disease processes for example, localized ischemic changes or demyelination in the brain
stem and cerebellum which may be relevant to a patient's clinical presentation and which
may only be evident on T2 weighted images. Many radiologists and referring clinicians
appreciate the additional information that the rapid, inexpensive, fast spin echo sequence
provides.
Satisfactory fast spin echo images, where two normal nerves are seen within the internal
auditory canal on the symptomatic side, appear to exclude the presence of VS. We would
expect to identify all detectable tumours if contrast enhanced images were only acquired in
patients whose initial fast spin echo images did not fulfill this criterion. This strategy would
yield a sensitivity of 100% for detection, and a negative predictive value of 100% for
exclusion, of VS.135
The prevalence of vestibular schwannoma in patients undergoing contrast enhanced
imaging, that is the positive predictive value of a fast spin echo scan that has not excluded
VS, would be 6.5%. 134, 136
The MRI imaging strategy intended to identify small intracanalicular VSs cannot rely on
fast spin echo T2 weighted imaging alone. Gadolinium enhanced T1 weighted imaging
could be restricted to patients where fast spin echo images do not exclude VS but this
strategy requires continuous supervision by an experienced radiologist. 132
In most practices the screening examination should continue to include a gadolinium
enhanced sequence in order to optimize the detection of small VSs. 134-136
Computed Tomography imaging (CT)1.6.2
Although the MRI considered as a gold standard testing which gives excellent soft tissue
visualization but does not show the bony detail nearly as well as CT.132
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The bony anatomy is demonstrated in excellent detail by high-resolution CT when
performed with a bone algorithm. The cortical edges of the IAC are sharply deﬁned, and 
intricate internal anatomy of the labyrinth is routinely visualized. 136
The bone algorithm allows limited visualization of the soft tissues, however, and the
contents of the IAC are not seen.
Air contrast high resolution CT is the most accurate method available for detecting small
VSs. Indications for this technique are discussed along with general approaches to these
patients. 136
The tumour shows as a bright white lesion protruding from the IAC on CT. On the MRI,
the bright white of the high signal from the enhancing tumour is seen on the T1-weighted
image (Figure 38).There have been scattered reports of nonenhancing VSs, but if they
exist, they are too rare. 133
Calciﬁcations are occasionally mentioned as rarely being present in VSs. They are
extremely uncommon. In fact, if anything more than minimal calciﬁcation is present, an 
alternative diagnosis, such as meningioma, should be considered. Calciﬁcations, when 
present, are expected to be tiny, and they are unlikely to be seen on MRI, where small
calciﬁcations are averaged together with contiguous soft tissue and become virtually 
invisible. CT is much more likely to show small ﬂecks of calcium if they are present.
Figure 40. (A) A VS with high resolution computed tomography showing contrast. Soft tissue algorithms
show the tumor (T) protruding into the internal auditory canal (IAC). (B) A Bone algorithm shows the
enlargement of the IAC
Source: Curtin DH, Hirsch W. Imaging of VSs. Neurosurg Clin N Am 19, 2008. 175–205
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Lesions arising in the temporal bone such as a cholesterol cyst, cholesteatoma, or one of a
variety of bone tumours are usually easily distinguished from VS. The origin outside the
IAC is usually obvious. Occasionally a tumour, such as a paraganglioma, can have a
substantial component protruding into the CPA cistern, but once again the ﬁnding of the 
characteristic erosion of the jugular fossa on CT or the characteristic black dots on MRI
representing rapid ﬂow inlarge tumour vessels indicate the true identity of the tumour.
Following a piece of Teflon made polytef incerts in place to separate a vessel from a nerve
can sometimes resemble a schwannoma (e.g. see fig. 41). It can be dense on CT. There can
be some enhancement of the contiguous tissues on CT or MRI. The site of the previous
craniotomy is obvious, and the patient gives the appropriate clinical history.
Figure 41. A Polytef in the CPA cistern. Increased radiodensity represents a piece of Teﬂon used to separate
the nerve from the vessel. Source: Curtin HD, Hirsch WL Jr. Imaging of acoustic neuromas. 1992. Neurosurg
Clin N Am. 2008 Apr;19(2):p202
On some occasions, some patients cannot undergo an MRI. When a patient cannot undergo
an MRI, a contrast enhanced, high resolution CT scan is still a highly reliable
examination.136 When the primary question is whether the patient has a VS, a gadolinium
enhanced MRI scan is the preferred imaging modality. In the past, one could not be
completely sure that there was no VS unless the nerves could be visualized all the way
through the IAC and no enlargement was present (e.g. see fig. 42).
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Figure 42. The Air cisternogram shows the inﬁlling of the internal auditory canal (IAC), with air outlining 
the nerves. Note that the air passes all the way to the extreme lateral portion of the IAC
Source: Curtin HD, Hirsch WL Jr. Imaging of acoustic neuromas. 1992. Neurosurg Clin N Am. 2008
Apr;19(2):p202
Almost all VSs will be found by high quality modern CT scanning. Some clinicians prefer
CT scanning, especially when the clinical picture is not as clear cut and high quality
images of the otic labyrinth are desirable at the same time that the IAC is evaluated. 132, 133
Also CT remains more available in some locations and so becomes the initial study, with
MRI reserved for the few cases in which the CT scan is considered equivocal.123
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The natural Evolution of Vestibular Schwannoma1.7
Follow up management is an important part of any pretreatment discussion with patients
who have VS, because excision or radiosurgical treatment can potentially compromise
function.138, 139, 140
Despite the availability of published data highlighting clinical, radiographic, and biological
parameters of significance when managing VS conservatively, deciding between early
treatment and expectant management remains a significant challenge for practitioners. 138
Observation management with serial MR images has provided useful information about the
variability in natural history of untreated VSs. 141
Increasing utilization of MRI has revealed that the growth rate of VS can vary
unpredictably from case to case, and observation of early stage patients in whom no
increase in volume was detected over the years (or even decades) has permitted surgical
treatment to be deferred and in some cases avoided altogether.
According to some authors the difference incidence between its postmortem and clinical
diagnosis suggests that in a significant number of cases the tumour’s growth rate can be
extremely limited, if not absent. 144
However, the practical implications of this finding have been a cause of controversy:
although it has facilitated the planning of increasingly conservative surgical treatment, the
specific indications for immediate surgery remain a matter of debate. 143
In order to search for a possible predictive factor of growth rate Modugno 155 et al.
performed analysis using 6 clinical variables (tumour size, sex, age, initial symptoms, ABR
pattern and duration of the symptoms). According to their results in 30/47(63.8%) cases,
no growth was detected during the entire period of follow-up, while in the remaining 17/47
(36.2%) patients, a volumetric increase was recorded. Growth was observed within the first
year in 10/17 (58.8%) cases, at 2, 3 and 4 years from diagnosis in 1/17 (5.8%), 3/17
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(17.6%) and 1/17 (5.8%) cases respectively, after 6 years in 2/17 (11.7%) cases (e.g. see
fig. 43).
Figure 43. A chart showing the rate of growth of a VS during the follow-up years
Source: Modugno GC et al. Small VSs: Monitoring the Growth Rate by MRI. Acta Neurochir (Vienna) 1999.
14.141: 1063-1067
The growth rate, according to Modugno155 et.al., expressed in absolute millimetric increase
of the greatest axis of the neoplasm, ranged from 1 to 12mm/year with a mean value of
4.0mm/year. In 5/17 (29.4%) cases the growth was < 2mm/year; in 10/17 (58.8%) cases it
was between 3 and 6mm/year; in the remaining 2/17(11.7%) cases it was > 9mm/year. In
this case the relative increase ranged from a minimum of 11.1% to a maximum of 150%,
with a mean value of 55.9%. When growth was recorded, the therapeutic choice varied
considering different parameters. The results of comparative analysis of literature, between
different works are quite interesting (e.g. see table 2).
Author Case
(n)
Age
(Years)
F.U
years
RM No
Growth (%)
Valvassori (144) 35 16-81 1-2 - 43
Thomsen (145) 21 37-79 4,2 - 85
Ogawa (148) 36 15-73 4,5 - 19
Bederson (146) 70 2,2 - + 47
Sterkers (147) 21 49-79 3,5 - + 47
Nedzelski (149) 50 50-83 3,4 - + 52
Woods (151) 27 55-80 2,1 - + 40
Noren (152) 98 16-82 2,5 - + 30
Rosenberg (153) 16 65-86 4,3 - 44
Strasnick (154) 50 40-90 2,6 - + + 32
Charabi (150) 97 <81 3,4 - + 26
Table 2. Percentage of cases with a VS growth and a review of literature.
Source: Modugno GC et al. Small VSs: Monitoring the Growth Rate by MRI. Acta Neurochir (Vienna) 1999.
14.141: 1063-1067
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By contrast, Thomsen, et.al.,145 reported no growth in as many as 85% of cases submitted
in a longitudinal follow-up study for a mean period of observation of 4.2 years. However,
it is noteworthy that in a 5-year multicenter study, which included Thomsen's group, a
much lower overall percentage (26%) of cases without growth was reported.2
It is possible to conclude from the literature that in about 45% of the patients with a
diagnosis of a VS, the MRI did not reveal any growth for an average period of 2±4 years of
follow-up. 155
Several investigators have published their institutional results, but to date, there have been
few efforts to combine these experiences to achieve the statistical power needed to
determine the suitability of follow-up management for these tumors.
Sughrue, et.al.,138 performed a comprehensive review of the literature on the hearing
preservation and intervention rates, with special emphasis on tumor growth rates, in a large
population of patients with a VS who were treated conservatively. Their results suggest
that the patients with tumors that grew < 2.5mm/year had better hearing outcomes than
patients with tumors that grew > 2.5mm/year. They did not find a similar relationship
between initial tumor size and rate of hearing preservation.139
In fact, patients with preserved hearing had statistically larger tumors on average at
presentation, but the 2mm difference in average size must be interpreted within the context
of limitations associated with imaging resolution and observer reliability. This suggests
that for patients with tumors < 2.5 cm, the tumor growth rate is a more important indicator
of who is at risk for progressive hearing loss than tumor size at presentation. The
mechanism behind this observation is unclear;138 however, it has been hypothesized that
faster growing tumors represent a biologically more aggressive subset of lesions, which are
more likely to infiltrate and disable the cochlear nerve, regardless of the initial size of the
tumor.
Facial nerve outcomes in patients with a VS in whom the disease is managed
conservatively, have consistently excellent outcomes throughout the series reports. The
patients with faster growing tumors had a nearly identical reported rate of subsequent
intervention to that of patients with slow growing tumors, despite poorer hearing
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outcomes.138 In literature, some authors performed studies analyzing predictor factors
where the mean age of the patients in whom growth was recorded was slightly higher, but the
difference did not appear significant. As for the initial symptoms, tinnitus was more frequent
in cases with growth, but even this difference was not significant.140 ABR also showed a
greater frequency of electrophysiological patterns correlated with a block of the central
pathways in the cases with growth, although this difference was not significant.
As regards the relation between tumor growth and duration of the symptoms, variance
analysis showed only a tendency towards an inverse correlation: the average duration of
the symptoms was shorter in patients who presented with tumor growth.150
Regarding growth patterns, in a recent multicenter study, Charabi, et.al.,23,150 recognized
the following five different types of behavior: 1) continuous growth (40%), 2) non-visible
growth (18%), 3) continuous growth after a variable period of quiescence (18%), 4) a
regressive tendency (8%), and 5) irregular growth (16%). The fact that the third subgroup
had the longest mean period of observation led Charabi, et.al.,23,150 to argue that, in a per-
centage of cases with apparently no growth, a volumetric increase could be revealed at a
later date (a finding which could be in keeping with the observations of Thomsen, et.al..145
However, the fact that the mean age of the patients with no growth was significantly higher
than that of the patients with linear growth, after a period of quiescence, could also suggest
the following opposite hypothesis: that patients who do not present any growth could
belong to a separate, independent population. A larger series of experiments with longer
follow-up periods must therefore be accomplished before any clear conclusions can be
drawn.
Tumour size, age and sex have been particularly considered in the literature. However, no
significant correlation has been found between any of these parameters and tumour growth.
Ogawa et al.148 maintain that older age, female sex and bigger tumour size are likely to
predict a volumetric increases of the neoplasm, but their data do not reach statistical
significance. A different predictive factor was proposed by Charabi et al.23, 150, who found
a significant inverse correlation between tumour growth and the reported duration of
symptoms before diagnosis.
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Treatment modalities of Vestibular Schwannoma1.8
Present day there are 3 treatment modalities or options exists for patients with VS.
 Watch and Wait;
 Conventional neurosurgery;
 Radiosurgery with Gamma Knife.
Follow up or observation with serial MRI1.8.1
In recent years, the wide diffusion of the Internet has meant that many patients come to
consultation with prior knowledge about the various treatment options, which far from
making matters clearer, often mislead patients due to incomplete and biased information. It
is very important for all patients to be informed of the 3 treatment modalities. 156
In majority of cases above listed treatment options would be informed or presented to
patient to choose the treatment option.145
With the exception of some situations where the choice of treatment is clear, for example
observation for a 90-yearold patient with a 3 mm tumour or surgery for a 30-yearold
patient with a 5 cm tumour, the decision on the best therapeutic option for patients with VS
is very difficult to take. In this case otoneurologist would recommend the best option and
the patient would accept ether will look for the second opinion. The ideal situation for such
patients could be to consult the ideal situation is for a patient to consult a multidisciplinary
team in a center with experience. It is important to take into account that the majority of
patients with VS present only hearing loss and/or tinnitus at the time of diagnosis, and
disabling symptoms are rare. 23, 150, 156 Thus, the vast majority of preoperative patients
have very good quality of life despite having a tumour. 156 After the chosen treatment
regardless the type of it, even if there are no serious or unforeseen complications, this
quality of life worsens.153 Obviously, this situation is exacerbated if severe complications
or sequelae appear.143
That is why it is very important that the patient understands - the goal of VS treatment is to
avoid problems derived from the growth of the tumour, which by its nature and location
can lead to intracranial hypertension and death. 23, 155, 150, 156 But these problems can appear
after many years, so the treatment involves, at the present time, a reduction in the quality
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of life to avoid serious complications in an uncertain future.156 Exceptions to this rule are
patients with large and symptomatic tumours, in which treatment is imperative, and
patients with severe vertigo. In these cases, quality of life may improve after treatment.
Follow up or observation/ wait-and-scan treatment approach consists in performing serial
MRI, the first one generally 6 months after diagnosis and, if there are no significant
changes, every year.156, 155, 149
Along with serial MRI, it is important to perform audiometric test in each review.
Even some clinical hospital’s ORL dept. includes otoneurology divisions which equipped
with other machines and of course they afford to perform some other tests like
Craneocorpography, posturography, Videonystagmography/caloric test etc.
In older patients with small tumours where the expected growth of the tumour is not life-
threatening in the years they presumably have left to live, this attitude would be the
treatment indicated. 156 In these cases, as long as no significant changes are observed in the
symptoms, an annual MRI is carried out (e.g. see fig 44).
Figure 44. Image shows the growth of a VS after one and a half years of observation
Source: Lassaletta L et al. An update on the treatment of vestibular schwannoma. Acta Otorrinolaringol Esp.
2009;60(2): pp131-140
Advanced age, deterioration of general condition, absence of relevant symptoms,
longstanding clinical condition indicating slow growth, are all factors in favor of this wait-
and-scan treatment.
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Age factor and the size of the tumour, hearing level could be predict the exact type of the
treatment. If the combination of advanced age and small tumour size is hardly questioned
as an indicator for observation, there are other situations which may also indicate the same
treatment. But the most case could be a case of young patient with a small tumour and
good hearing. In this case, all 3 therapeutic options could be considered: microsurgery to
resect the tumour and preserve hearing while the tumour is still small; radiosurgery to
control the growth of the tumour, thus avoiding the potential morbidity of surgery, relying
on preserving hearing; and observation, as the rate of tumour growth is not initially known
and the possibility exists that it may not grow or it does so at a normal rate, in which case
the injury will not become life-threatening for many years. And lastly, the slow rate of
growth of most tumours makes observation a valid option as an initial approach in almost
all tumours, except in very large ones which may become life threatening in the short or
medium term. 156
The main advantage of observation is that it avoids the complications of surgery or
radiation. A theoretical disadvantage of this wait-and-scan approach is the delay in
providing definitive treatment if the growth of the tumour is established, although it has
not shown that this delay has a negative impact on the quality of life. Other drawbacks are
the need for lifelong imaging tests and the psychological factor, due to knowing that there
is an untreated intracranial tumour. 156 Along the recommendation or just when the
observation is chosen as a therapeutic option, it is important to inform the patient that it is
likely that the hearing loss will increase, even if the tumour does not grow.158
According to several authors the decision of conservative management is not
straightforward, although some treatment guidelines have been proposed. An algorithm
designed by Smouha et al. (2005) recommends observation in elderly patients, with small
tumours, and no symptoms other than hearing loss. 196-197 They define elderly patients as
over 45 years and small tumours as less than 25 mm in diameter. Upon observing growth
beyond 2 mm/year or changes in symptoms, intervention is indicated. Unfortunately there
is little correlation between symptoms and tumour size, and patient quality of life may
diminish even without growth. 189 Therefore, treatment may also be indicated when
symptoms progress but the tumour size remains static. Concerns about patient compliance
have also been voiced, and high attrition rates were noticed in some conservative
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management studies.197 Nonetheless, observation remains a practical choice for many
patients. 196-197
Conventional neurosurgery1.8.2
The introduction of the microscope, microsurgical techniques, monitoring of the facial
nerve, the refinement of anesthesia and the experience acquired at some centers have
helped to generate new targets in VS surgery. Present day, the goal is not just excision of
the tumour with minimal mortality, but also the preservation of facial function and, where
possible, hearing. While mortality has fallen to values below 1%-2% at experienced
centers, and preservation of facial function is achieved in most cases, the preservation of
hearing is achieved in only a select few. As in other areas of otolaryngology falling
between different specialities, there is controversy about which specialist should carry out
VS surgery. The answer is usually neurosurgeon, but whether the neurosurgeon or not it
should be performed by the person with most experience in it.149
In theory, any otoneurology surgeon or neurology surgeon with enough experience can
carry out the complete surgery, although it is rare for a neurosurgeon to have experience in
the milling of the IAC. In some medical centers that’s why VS surgery performs by the
otolaryngologist and some others it performs in cooperation between otolaryngology
specialists and neurosurgeons which has been enriching and brought several advantages:
each specialist provides their expertise in different fields, allowing for shifts to be set up so
that, in patients with large tumours, dissection of the cranial pairs can be performed more
restfully, and all approaches can be used, some of which are not accessible to certain
specialist. 156
In conventional neurosurgery there are three different surgical approaches could be
applied: Retrosigmoid (RS), translabyrinthine (TL) and the middle cranial fossa (MCF). 156
In many occasions the surgical removal is only treatment for large VSs because
stereotactic radiosurgery is not applicable. The translabyrinthine,161-162 retrosigmoid
suboccipital, 163-164 and middle fossa approaches165 are the three basic approaches for the
removal of these tumours. Recent papers recommend the translabyrinthine approach for the
removal of large tumours and have reported good results with this technique. 160
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The selection of surgical approach is based on multiple factors, including pure tone
thresholds, speech discrimination score, auditory-evoked responses, tumour size, hearing
status of both ears, and patient age and preference. Surgery practices vary in degree of
experience and preferred techniques.166 Despite these differences, however, imaging
directs preoperative management by addressing tumour size, extent of IAC penetration,
cerebellopontine angle involvement, relationship of the tumour to cranial nerves, and
relevant anatomic variants. 167 Preoperative MR imaging is generally considered the
standard procedure unless contraindications exist. (e.g. see fig 45).
Figure 45. Selection criteria for the surgical approach
Source: Whittaker CK, Luetje CM Vestibular schwannomas. J Neurosurg 1992;76:897–900
1.8.2.1 The retrosigmoid (suboccipital) approach (RS)
The retrosigmoid or suboccipital approach used to attempt hearing preservation. Success
rates vary from 30-65% in CPA tumours smaller than 1.5 cm with good hearing and
limited involvement of the IAC. However a tumour extending to the fundus is a
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contraindication to the RS approach for hearing preservation. The tumour removal is
accomplished with mirrors. 144, 157.
All the patients in the authors series have, however, been operated through the
retrosigmoid route as this is the only route that is not only adequate for all sizes of tumour
but also suitable for preservation of facial function and hearing. No doubt enough literature
is available now to document TL and MCF approaches as good means of tackling selected
tumours (e.g. see fig 46).
Figure 46. The suboccipital approach
Source: http://www.mayfieldclinic.com/PE-AcousticSurgery.htm
1.8.2.2 The translabyrinthine approach (TL).
The translabyrinthine approach is oldest surgical approach applied to VSs. William House
developed the translabyrinthine approach for excision of VSs in 1964. 160 This approach is
familiar to most neurosurgeons and otoneurologists and is frequently used to remove VSs.
This procedure provides the best line of sight of the facial nerve and consequently offers
the highest success rate of facial nerve preservation for a patient. 158
The translabyrinthine approach (Fig 42) eliminates hearing but generally results in the
lowest tumour recurrence rate.168 Cerebellopontine angle exposure is adequate even for
very large tumours, but an anterior sigmoid sinus or high-riding jugular bulb can make
dissection of the cerebellopontine angle component more difficult compared with the
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suboccipital approach. Differences in retraction, resection, and wound closure unique to
the translabyrinthine approach are described later and are readily apparent at MR imaging.
Translabyrinthine approach is the preferred surgical choice by most doctors when the
hearing level is no longer useable. It is also a good choice when a tumour is above 20 mm
as, statistically, facial nerve damage increases with large tumours. 160
This approach also makes use of a postauricular incision. 159-160 A complete mastoidectomy
is performed, and bone over the sigmoid sinus and tegmen is skeletonized. Ossicles may or
may not be removed, depending on the surgeon, to facilitate packing the middle ear to
lessen the risk of CSF leak. Bone is removed from the adjacent middle and posterior fossa
and from around the sigmoid sinus. The sigmoid sinus can then be retracted, unlike with a
suboccipital resection. A labyrinthectomy is performed by removing the three semicircular
canals and opening the vestibule after identifying the jugular bulb, which marks the
inferior extent of dissection. Bone around the superior, posterior, and inferior portions of
the IAC is removed, the IAC fundus lying just medial to the vestibule. After tumour
removal, surgeons use a number of techniques to limit the risk of CSF leak. 160
Figure 47. Drawing illustrates the translabyrinthine approach
Source: Silk PS, Lane JI, Driscoll CL. Surgical Approaches to Vestibular Schwannomas: What the
Radiologist Needs to Know. November 2009 RadioGraphics, 29, p1962
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The main disadvantage of this approach is that this procedure sacrifices an individual's
hearing and other complications associated with this surgery is CSF leaks, meningitis, and
rarely fat graft prolapsed.160 In addition, the dural based blood supply to tumours in this
region is encountered and may be interrupted early in the course of dissection. That’s why
it should only be selected when a person has severe hearing loss or the tumour is too large
for hearing preservation surgery. 159
1.8.2.3 Middle Cranial Fossa approach
The MCF approach is generally reserved for small tumours, which are mainly
intracanalicular and have less than 1 cm of cerebellopontine angle extension, and for
patients with good hearing. This is the only technique that allows complete access to the
IAC without violating inner ear structures. 167, 169 However, exposure of the
cerebellopontine angle cistern is limited, and tumours with a large cerebellopontine angle
component cannot be easily and safely addressed with this method. 169
This procedure begins with a preauricular skin incision and temporal craniotomy. The
middle meningeal artery may require division. The dura mater over the petrous ridge and
adjacent MCF floor is dissected to allow placement of a retractor over the petrous ridge. 169
The temporal lobe is then elevated. Exposure is limited due to the risk of temporal lobe
injury if retraction is too aggressive. 170
Radiosurgery with Gamma Knife1.8.3
Stereotactic radiosurgery (SRS) is an accepted alternative to microsurgery for smaller
tumours and non-surgical candidates, offering similar tumour control rates. 182-185
Ideal active management for small-to-medium-sized vestibular schwannomas is still
disputed and unclear, as some recent studies favored the radiosurgical over microsurgical
approach, while others showed no difference between groups of patients that were treated
microsurgically, radiosurgically, or untreated with observation (Figure 48). 179-181.
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Source: http://www.yalemedicalgroup.org/stw/Page.asp?PageID=STW029077 (12.11.2013)
Meta analysis including studies from the 1990's identified an average tumour control rate
of 91% with Gamma Knife radiosurgery (GKRS).186 A more recent review identified a
range of control rates, from 89-100% reported in various studies. Complicating the
interpretation of such results, many of which report on patients first treated over a decade
ago, is that Gamma Knife technology and treatment planning continues to undergo
significant evolution. Improvements in imaging resolution and computer planning
software, have allowed physicians to better spare adjacent brainstem and nerve
structures.187,188 Furthermore, the therapeutic dose used for treating VS has decreased over
the past two decades, with marginal doses of 12 Gy and maximum doses of 20-25 Gy
identified as current standards.189 Therefore, controlling vestibular schwannomas with
fewer risks may be accomplished with contemporary SRS.
The effect of irradiation on tumour tissue is shrinkage of tumour cell by DNA damage and
intratumoural vascular obliteration. Ionized irradiation causes DNA damage to cells, and
the apoptosis of cells promotes early tumour shrinkage.
In the case of late responding tissues, a long cell cycle time causes delayed tumour
shrinkage. Meanwhile, the irradiations of the blood vessels of the tumour interrupt the
blood flow through hyalinization of arterioles, myointimal cell injury, and endothelial
Figure 48. Schematic of stereotactic Radiosurgery with the Gamma Knife®
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proliferation, which slowly reached to ischemia, hypoxia of the tumour cells, and damage
to the cells.190
Regarding the natural course or conservative management for VS, Yamakami et al.183
reported on the natural course of 903 patients who underwent conservative treatment; in
the average observation period of 3.1 years, 51% of the tumours had grown and the mean
growth rate was 1.87 mm /year. In the end, 20% of the patients needed surgical treatment.
The tumour size may not grow within a certain time, but surgical treatment becomes
necessary at some point in a long-term follow-up observation for VS in a young patient.
Considering this fact, treating the tumour when it is still small will help the patient and
provide a better prognosis.191
The outcome for patients managed conservatively has been the subject of several reviews.
Yamakami et al. reported that over a mean follow-up of 3.1 years, 51% of tumours grew,
20% eventually required intervention, and 37% of patients ultimately lost useful hearing
(N = 903 patients). 183 In a meta-analysis by Smouha et al (2005)., 43% showed growth,
20% required treatment, and 51% of patients experienced hearing loss over a mean follow-
up of 3.2 years (N = 1345 patients). 183, 196-197
Myrseth et al (2007)., reviewed the literature and determined that over a 3 year period 30-
50% of patients undergoing conservative management will lose useful hearing and 15-50%
will ultimately require active treatment. 189, 196 Patients must be aware that a significant
fraction managed conservatively will eventually require intervention or experience
progression of symptoms.196
Complications of Vestibular Schwannoma treatment1.9
Complications conventional microsurgery1.9.1
Postoperative Hearing Loss and Delayed Complications include headache, CSF leak,
meningitis, facial nerve weakness, and, occasionally, vascular injury. Headaches of
varying severity occur in approximately 46% of postoperated patients and resolve within 1
year in one-half of cases.171
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CSF rhinorrhea remains a significant cause of morbidity after resection of VS, with rates of
rhinorrhea after this procedure reported to range between 0 and 27%.221
According to Brennan et al. 226, the CSF leak and its association with the risk of
meningitis remain as important issues in the surgical treatment of VS. An incidence
between 0 and 30%, with an approximate rate of 12% is reported. 226 The CSF leak often
manifests as otorhinorrhea and can originate from inadequate sealing of exposed mastoid
or petrous air cells, poor wound closure, or hydrocephalus. CSF otorhinorrhea is more
common with the RS approach, with a prevalence of approximately 2.2% in a recent large
series. CSF wound leak was seen in 6% of cases in the same series (Figure 49-50).
A larger series by Falcioni et al 173 published in 2008 reported an overall CSF leak rate of
8.3%. Diaz Abadon et al 224 studied 170 postsurgical patients operated due to VS (163
cases) and other (7cases) CPA tumours. In their series 27 patients (15,9%) presented CSF
leake as complication VS surgery. Also they are performed comparative study of current
complication depending on applied surgical approach with literature review. (Table 3).
Author/year Case
(n)
CSF
fistulae,
%
TL,
%
CSF
fistulae,
TL%
RS, % CSF
fistulae
RS, %
MCF,
%
CSF
fistulae
MCF,
%
Shea MC, 1979 80 15 37,5 30 62,5 0 0
Jacob A, 2007 359 64,3 14,2 13,9 13,2 19,5 11,4
Selesnick SH, 2004 5964 - 9,5 - 10,6 - 10,6
Sanna M, 2004 707 2,8 84,9 1,8 5,4 18,4 7,6 3,8
Darrouzet V, 2004 400 6,9 57,2 - 32 - -
Fishman AI, 2004 215 6,6 52 5 36 8,5 12 8.3
17 *
Becker SS, 2003 300 11 33,3 13 33,3 10 33,3 10
Kalamarides M,
2004 14
220 12 63 - 27 10 -
Cueva RA, 2005 343 0,8 51,6 - 47,1 1,23 -
1,2 *
Coca A, 2007 120 12,5 36,6 - 62,5 0,8
Leonetti J, 2001 589 0,5 35,5 3,8 32,4 0,51 0
0 *
6,9 *
Lee SH, 2002 160 10,5 0 100 0
Wu H, 1999 277 3 100 0 0
28,2 *
Díaz Anadon, 2008 170 15,9 24 17,1 66 17 5 0
Table 3. Incidence of CSF fistulae as a postsurgical complication depending on applied surgical approaches
to CPA. *FM: fosa media aproach; RS: retro sigmoid aproach; TL: translaberintine aproach.* Prevous series.
Source: Diaz Anadon A et al. Fístulas de LCR tras la cirugía de tumoures del ángulo pontocerebeloso y su
relación con el índice de masa corporal; Published in Acta Otorrinolaringol Esp.2009; Vol.60.N 05. p321
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Figure 49. Image of a CSF leak following suboccipital resection of a VS. *A craniotomy defect is seen
traversing mastoid air cells (arrow), allowing an egress of CSF into the middle ear cavity.
Source: Silk PS, Lane JI, Driscoll CL. Surgical Approaches to Vestibular Schwannomas: What the
Radiologist Needs to Know. November 2009 RadioGraphics, 29, p1965
Following severe facial nerve injury is uncommon with microscopic techniques, and most
tumours are now being removed by experienced teams of neurosurgeons and
neurotologists.223
Transient facial nerve palsy is more common with the MCF approach as mentioned earlier.
Vascular injury occurs infrequently, but the sigmoid sinus and jugular bulb can be directly
compromised or may potentially thromboses after retraction, possibly with devastating
consequences.225
It is important to assess for an intact torcula and the potential for adequate contralateral
venous flow should there be injury to the sigmoid sinus or jugular bulb. In the rare case of
absent flow on the contralateral side, the translabyrinthine approach would be
contraindicated. Parenchymal venous injury can also occur as a result of large adherent
tumours with complicated dissection. Arterial injuries occur rarely, with the anteroinferior
cerebellar artery being most at risk. 169,223,225
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Figure 50. CSF wound leak. Axial nonenhanced CT scan shows changes from suboccipital resection, with a
CSF wound leak that resulted in a pseudomeningocele
Tinnitus is a most frequent also remaining most challenging issue among postoperative
complications of VS.
Kameda and colleagues (2010) 174 report their single-institution, retrospective study of
tinnitus outcomes after resection of VS via the retrosigmoid approach.
Of their 242 patients with VSs, 171 (70.7%) complained of tinnitus before surgery. This
symptom disappeared in 25.2%, improved in 33.3%, remained unchanged in 31.6%, and
worsened in 9.9% after tumour removal.174
Another study conducted by Levo et al. 227 observed 251 cases of postsurgical VS and
according to their results: Preoperatively, 62.6% of the patients had experienced tinnitus.
Of those with preoperative tinnitus, 47.4% also had it postoperatively, but of those 93
patients without preoperative tinnitus, 39.8% had tinnitus postoperatively. Tinnitus is one
of the primary symptoms of VS, together with hearing impairment and disequilibrium.
The risk of postoperative tinnitus is almost 40%, and with preoperative tinnitus, the risk is
7.6% higher. Even though the cochlear nerve was resected in 45 cases, tinnitus later was
noted in 3 patients. The status of postoperative tinnitus was not associated with useful
hearing preservation (p = 0.153) or tumour size.
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Kameda and colleagues 174 conclude that retrosigmoid tumour resection may provide some
chance (~ 60%) for improvement of and some risk (10%) of worsening tinnitus.
Outcomes of VS surgery depend on the size and adherence of the tumour, the use of
cranial nerve monitoring, and of course the skill of the surgical team.
According to Acoustic Neuroma Association reports 60% of members have acceptable
facial function after surgery. The medical literature reports vary, but overall, facial
movement is preserved in 75% and useful hearing is preserved in 20% of patients228, 229.
Delayed hearing loss may occur after surgery in 30 to 50% of patients who had useful
hearing immediately after surgery. Partial-removal techniques have higher rates of hearing
and facial function preservation; however, the long-term results of these techniques are still
being investigated.227-229
Complications of Gamma Knife Radiosurgery1.9.2
Complications that are associated with stereotactic radiosurgery for vestibular
schwannoma include hearing deficits, facial palsy, hydrocephalus, and brain stem damage,
although the incidence of some of these conditions is much lower than with microscopic
open surgery.231
In the literature there are many reports on postradiosurgical complications such as cranial
neuropathy, cerebellar infarction and edema, cyst enlargement, malignant transformations,
intratumoral hemorrhage, and hemifacial spasm in relatively large VS. 139,190, 196
Bush and colleagues looked specifically at Gamma Knife patients who had "useful
audition" pretreatment and found that, at a tumor marginal dose of 13.8 Gy mean at the
50% isodose line, 42% maintained useful hearing posttreatment.60
Regarding trigeminal and facial nerve dysfunctions after radiosurgery for VS, Kondziolka
et al.160) reported in 1998 that the application of 16.6 Gy marginal dose on average
resulted in facial dysfunction 15% and trigeminal dysfunction 16%.
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However, many authors reported lower incidence of complication (<4%) with low dose
radiosurgery (Table 4).
Author, year Number
of
patients
Mean
tumor
volume,
size
Mean
maximal
/marginal
dose
Mean
follow
up
period
Tumor
control
rate
(%)
Hearing
preserva
tion rate
(%)
Facial
palsy
(%)
Trigemi
nal
neuropa
thy (%)
Kandziolka190
1998
162 Diameter
22 mm
(8-39)
32,7 (24-
50)/16,6
(12-20)
5-10
years
97 47 (G-R*
I-III)
15 16
Moller
2000
111 - 40-12 0.25-10
years
96 80 14 4
Prasad
2000
200 0.02-
18.3cc
34 (17-
53)/13(9-
20)
4,3years 92 58 2 4
Regis
2004
1000 12.7
mm3
-/- - 97 77.8 (G-
R I) 47.6
(G-R II)
1.3 0.6
Flickinger
2004
313 1.1 ml
(0.04-
21.4)
26 (20-
26) 13
(12-13)
24
months
93.5 78.6 (G-
R I,II)
0 4.3
Hasegawa
2005
73 6.3 cm3 28.4 (16-
36) / 14.6
(10-18)
135
months
87 37 (G-R
I,II)
- -
Chung
2005
195 4.1 cm3 21.9(17.1-
34.0)/ 13
(11-18.2)
36 (1-
110)
93.6 60 (G-R
I,II)
1.4 1.1
Lunsford
2005
829 - -/13 (10-
20)
6 years 98.6 78.60 <1 <3.1
Table 4. Published results of gamma knife radiosurgery for VS. *G-R Gardner Robertson grade
Source: Lim YJ, Choi SK. Gamma Knife Radiosurgery for Vestibular Schwannomas. J Korean Neurosurg
Soc 2007 (42), p164
In cases of residual or recurred mass after microsurgery, the repeated operation was
recommended generally, however, recently radiosurgery is considered as a secondary
treatment instead of reoperation. On the other side, in case of increased tumor size due to
failed radiosurgery, microsurgery is indispensable. However, many authors reported that it
may be difficult to remove the tumor due to fibrosis after radiosurgery.230
Hearing preservation is another important issue to consider in the treatment of vestibular
schwannoma with either microsurgery or radiosurgery. The hearing preservation rate
following microsurgery was reported to be 40-70% in patients with serviceable hearing
(Betchen et al., 2005)231
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Hearing preservation is an important issue in gamma knife radiosurgery as well. As the
experience with gamma knife radiosurgery has grown, the radiation dose has decreased.
Currently, a marginal dose of 12 or 13 Gy is the standard dose for treating vestibular
schwannoma. Regis et al. (Regis et al., 2008) reported a 60% hearing preservation rate in
patients in a large study with a mean follow-up of 7 (minimum 3) years. These authors also
mentioned that patients who were not treated using gamma knife radiosurgery lost an
average of 9-39 dB compared with an average loss of 2 dB at 3 years following
radiosurgery, which corresponds with a preservation of hearing functionality of 60-75%.
The probability of preserving functional hearing was higher in patients who had initial
symptoms that were other than a decrease in hearing, in patients who were younger than 50
years, and in those patients whose cochlea received a dose of less than 4 Gy during
treatment. (Tamura, et al., 2009).
The mechanism that underlies hearing deterioration following gamma knife radiosurgery is
not fully understood. Some of the mechanisms that have been proposed include a
temporary expansion of the tumour in the canal, vascular insufficiency of the auditory
system, the toxic dispersion of free radicals, among others (Wackym et al., 2010).
Hayhurst et al. (Hayhurst, et al., 2011) reviewed the non-auditory complications that were
associated with gamma knife radiosurgery in 80 patients who were followed for more than
2 years. Twenty-seven (33.8%) of their patients developed non-auditory adverse radiation
effects, and patients with a target volume that exceeded a threshold of 5 cc were more
likely to develop complications.
Other complication of GKRS can be Hydrocephalus occurring in approximately 14% of
cases and in 4% to 6% of cases after gamma knife treatment.232, 233
Although it has been reported that gamma knife radiosurgery may contribute to the
development of hydrocephalus, a causal relationship has not been established and remains
controversial. 232
Elevated CSF protein levels are thought to then obstruct CSF resorption at the level of the
arachnoid granulations.These events are reported to occur in acoustic schwannomas
without radiosurgical treatment, though Radiosurgery may exacerbate these events in some
patients. 234
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The condition of patients with significant dysequilibrium or recurrent vertigo is not
improved and may actually worsen by stereotactic radiation. Patients who are poor
candidates for stereotactic radiation should still be informed of the availability of the
therapy and be told why they are poor candidates, in the context of the relative risks and
benefits of radiotherapy as opposed to microsurgery.235
Tumour Recurrence1.10
After VS surgery, the rate of tumour recurrence is generally very low, ranging from <1%
to 9%. 175-177
According to reviewed literature, the most common cause of VS recurrence after surgery is
from incomplete tumour removal, when some of the tumour had to be left behind. This
usually happens unplanned, and depends on what happens during surgery.177
An increased risk of residual or recurrent tumour is seen with the suboccipital approach
due to relatively blind dissection of the IAC fundus. Residual tumour is deliberately left in
approximately 1%–2% of patients if dissection is complicated or vital structures such as
the facial nerve are at risk for injury. 178
In 2007 Balasubramaniam and colleagues reviewed 20 cases and revealed 10 de novo
secondary tumors, of which eight were malignant, with six being malignant gliomas. The
majority of thier cases (14 of 20) involved AN, with most being in patients with
neurofibromatosis-2 (8 of 14), reflecting the large numbers and long-term use of
radiotherapy for AN. Accelerated growth of primary benign VS and subsequent resection
with histopathological confirmation of malignant transformation was found in 6 patients,
all of whom had NF-2.235
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2 Objectives
1. To conduct an epidemiologic analysis of patients with Vestibular Schwannoma
diagnosed in our Department.
2. To evaluate the utility of different tests for audiologic and vestibular explorations in
the diagnosis of Vestibular Schwannoma.
3. To analyze the natural history of Vestibular Schwannomas, both morphologically
and in terms of their functional repercussions.
4. To compare the efficacy of two different therapeutic strategies (the wait-and-watch
policy and Radiosurgery) in the management of small Vestibular Schwannomas.
5. To establish a therapeutic protocol for small Vestibular Schwannomas.
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3 Materials and Methods
Materials3.1
Patients3.1.1
One hundred seven (107) patients with Vestibular Schwannoma (VS) underwent a
retrospective study which has been implemented in the Galicia population which attended
Santiago de Compostela University Hospital from the period between February 21, 1992
and May 05, 2011.
In this study, we have included only cases of VS and most of which were diagnosed by the
means of gadolinium-enhanced MRI. As criterions of exclusion we have used the tumors
apart from a VS or cases of CPA/IAC tumors of unknown origin.
Among the studied cases, there was 1 (0, 92%) young male, at the age of 36, who was
diagnosed with a bilateral VS due to Neurofibromatosis Type II (NF2). In spite of knowing
the clear distinct origin of the NF2, we have included this patient as a clinical presentation
and the nature of the tumor was absolutely the same.
Technical support3.1.2
3.1.2.1 Audiometer
The Audiometric testing was performed mainly by the clinical audiometer labeled
“Audiotest 340”(Interacoustic Incidencia, Barcelona) with the background noise less than
5dB (Figure 17). The results of audiometric testing were found from the patient’s case
records folder in paper form. In the event that some of the patients were diagnosed
primarily at the other provincial hospitals, the testing results have been found in the
Hospital Electronic Medical History (IANUS) of Galicia which connects 14 hospitals and
440 health centers.
3.1.2.2 The Craniocorpography
For the analyzing the craneocorpographic (CCG) tests, we used the results of the CCG
model Eymasa CCG600SE® consisting of lights and a Polaroid® (Polacolor® PRO 100)
camera with the size of objective 127mm, angle of coverage 41º and the convex mirror
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with the angle of coverage 93° (e.g. see fig. 48). The results were found in patient case
reports and as well as at IANUS in e-versions.
3.1.2.3 Computerized Dynamic Posturography software
For the estimation of balance or equilibrium, we have used the posturography testing
results realized by the means of the Posturography machine labeled Smart Balance Master
Neurocom® (e.g. see fig. 26). The CDP in our case was first recognized at the time of
diagnosis and then through the follow-up years.
3.1.2.4 Caloric testing tool and software
In order to assist and analyze the vestibular functions since 1992, the following
computerized caloric analyzers were used: “Nystar plus” manufactured by Nicolet
Instrumental®, “Veonus”from Biodigital® and later more modern VNG software from
“Intracoustics®”(e.g. see fig. 31). The VNG consists of infrared goggles (video Frenzel
goggles) for the recording of eye movement during the irrigation and cables transmitting
the information into the PC.
3.1.2.5 Otoacoustic emissions
The OAE has been applied for a VS patient at the prediagnostic stage, especially when the
patient presented severe hearing loss. So, the purpose of this testing was to reveal whether
the patient was definitely deaf or hard of hearing. Because the OAE has four different
types, in our case we have used the results of the Distortion product otoacoustic emissions
(DPOAEs) realized by the means of TEOAE software “ILO 292”(e.g. see fig. 23-24).
3.1.2.6 Auditory Brainstem Response audiometer and software
Usually, before getting an MRI, the ABR audiometry was administered for the patients
suspect for a VS. The results were realized by “Nicolet Viking IV P System”from Nicolet
Biomedical, Inc., (e.g. see fig. 20) in the Neurophysiology department of CHUS.
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3.1.2.7 Vestibular Evoked Myogenic Potential tool and software
In addition to above mentioned tests, we have analyzed the results of VEMP testing
implemented by the SmartEP system from “Intelligent Hearing Systems”(e.g. see fig. 51).
Figure 51. VEMP software with the SmartEP system from “Intelligent Hearing Systems”used for current
study (Our photo)
3.1.2.8 Magnetic Resonance Imaging
We have used MRI testing reports performed by Gadolinium contrast. Almost in all cases,
MRI testing has been realized in the Radiology division of CHUS (e.g. see fig. 32). We
obtained the results from patient's case records as well as e-versions from IANUS.
Materials ans Methods
142
Methods3.2
The study included 107 (100, 0%) patients which clinically followed up from July 21.1992
to May 05, 2011, with the mean follow up period 56.52 ±10.79 (range 25.02-71.74)
months.
This work consists of both retrospective and prospective clinical observations. The
retrospective study based on the investigation of patients having undergone treatment for
VS. Data were collected from patient records, outpatient consultations, telephone
interviews and re-evaluations of MR scans series.
Audiometric testing3.2.1
The audiometric testing has been realized for all VS patients at the outpatient department
of the Otolaryngology division of Santiago de Compostela University Hospital Clinic from
the period between February 21, 1992 and May 05, 2011.
The measurement of PTA implemented was done by the adding up the following threshold
levels: 500Hz, 1000Hz, 2000Hz and 3000 Hz and dividing the sum of the values by the
four and further revealing the mean. The found number expresses the pure tone average in
decibels (dB). It can be explained with following simple formula:
Threshold value at 500Hz + threshold value at 1000Hz + threshold value at 2000Hz +
threshold value at 3000Hz= x / 4 = Pure Tone Average
Apart from the calculation of PTA, in each follow up revision, starting from 6 months, one
year, two years, until ten years, depending on the remoteness of VS diagnosis of each VS
case, we have calculated the Difference of PTA (DPTA) in order to know how the hearing
will be changed over time. For example, if the primary PTA of the patient equals 68,75dB
and after 5 years it equals 80dB, in this case we will find DPTA by the means of
subtraction of primary PTA from the PTA value after 5 years. It can be illustrated with the
following expression:
PTA at the time of diagnosis (68, 75)-PTA after x (5) years (80dB) =DPTA (-11, 25).
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Testing of balance with Dynamic Craneocorpography3.2.2
The CCG testing has been realized in the CCG room of the outpatient department of
CHUS. The CCG equipment uses light markers placed on the forehead, the occiput, and
both shoulders of a patient, which reflects through a mirror system on the ceiling into a
motion recording video camera and on to a computer that receives, analyzes, and prints the
result (e.g. see fig. 52).
Figure 52. The Craneocorpography device (Our photo)
During the realization of the Unterberger stepping test, the camera records the movements
of light markers placed on the forehead, the occiput, and both shoulders of a patient.
In order to cut off the visual stimuli of the patient, we have used the sleeping mask. In this
way, the patient loses contact with the ground while stepping and will maintain balance
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only through the stimuli received from both vestibular systems. The records of the CCG
testing have been analyzed according to Claussen which described 4 different
types (page 85).
Computerized Dynamic Posturography (CDP)3.2.3
In our group of patients the CDP, like other vestibular tests, were initially realized for
prediagnostic VS patients and then checked up during each follow up revision. In all cases,
the center of gravity was determined under six sensory conditions, the analysis of which
makes up the Sensory Organization Test (SOT):
1. Immobile surface, immobile visual surround, eyes open.
2. Immobile surface, eyes closed.
3. Immobile surface, mobile visual surround, eyes open.
4. Mobile surface, immobile visual surround, eyes open.
5. Mobile surface, eyes closed.
6. Mobile surface, mobile visual surround, eyes open.
Each of the six conditions was performed in triplicate, giving a total of 18 tests per session
and each test lasts 20 seconds. The following parameters were considered in the data
analysis:
 Balance score (0–100%) obtained in each condition, calculated as the arithmetic
mean of the three individual test scores.
 Mean overall balance score (0–100%), calculated as the arithmetic mean of the 18
individual test scores.
 Somatosensory ratio, SOM= [condition-2 score]/ [condition-1 score]·100; a
measure of the patient´s ability to use somatosensory information for maintenance
of balance.
 Visual ratio, VIS= [condition-4 score]/ [condition-1 score] ·100; a measure of the
patient´s ability to use visual information for maintenance of balance.
 Vestibular ratio, VEST= [condition-5 score]/ [condition -1 score] ·100; a measure
of the patient´s ability to use vestibular information for maintenance of balance.
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 Preference ratio, PREF= [condition-2+condition-5 score]/ [condition-3+condition-6
score] ·100; a measure of the patient´s reliance of visual information, even when
that information is incorrect.
Caloric testing with Videonystagmography (VNG)3.2.4
We realized the VNG for the diagnostic purposes at the time of diagnosis and also for the
estimation of vestibular functions of VS patients over the follow-up years.
We have revealed the functionality of each ear and if a VS may be the cause of a dizziness
or balance problems. To monitor the movements of the eyes, VNG goggles are placed
around the eyes to record eye movements during testing.
1. Ocular Mobility;
2. Optokinetic Nystagmus;
3. Positional Nystagmus;
4. Caloric Testing.
For the caloric testing, we used 50 cc of water in 44 ºC to 30 ºC with the period of stimuli
being 40 seconds following the indications of Bartual;112. first, right ear with 44 ºC of
water; second, left ear with 44 ºC of water; third, left ear with 30 ºC of water; fourth, right
ear with 30 ºC of water. The interval between the each irrigation was 5 minutes and the
patient was placed in the Hallpike position. The evaluation is both qualitative and
quantitative, being most useful at slow phase of nystagmus.
For the interpretation, we used Jongkee´s213 formula:
% Caloric paresis = 100 x [(LC + LW) - (RC + RW)/(LC + LW + RC + RW)].
The strength of left-beating nystagmus to right-beat calculated:
% Directional preponderance (DP) = 100 x [(LC + RW) - (RC + LW)/ (LC +
LW+RC+RW.
Greater than 30% of directional preponderance is considered to be abnormal, although this
is a rather nonspecific finding in isolation. The result is said to be normal when this index
is lower than 25%. In turn, the vestibular areflexia (100% canalicular paralysis) is
considered if there is no response to cold water.
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Otoacoustic emissions3.2.5
As a screening tool to determine the presence or absence of cochlear function in VS
patients with different sizes of the VS tumour, we have investigated the results of DPOAEs
by the sounds emitted in response to two simultaneous tones of different frequencies.
Each test has been performed by the audiologist in a special cabin designed for OAE.
The technique of performing of DPOAE starts from inserting a properly sized probe,
according to ear canal volume, with a soft flexible tip to obtain a seal. Stimuli consisted of
two pure tones at two frequencies (i.e., f1, f2 [f2>f1]) and two intensity levels (i.e., L1,
L2). The relationship between L1-L2 and f1-f2 dictates the frequency response. An f1/f2
ratio yields the greatest DPOAEs at 1.2 for low and high frequencies and at 1.3 for medium
frequencies.
In order to obtain or yield an optimal response, intensities are tuned up so that L1 equals or
exceeds L2. Lowering the absolute intensity of the stimulus renders the DPOAEs more
sensitive to abnormality. A setting of 65/55 dB SPL L1/L2 is frequently used.
Responses are usually most robust and recorded at the emitted frequency of 2 f1–f2;
however, they generally are charted according to f2 because that region approximates the
cochlear frequency region generating the response. The result we have registered to our
database is simple “present”or “absent”of response to stimuli.
Auditory Brainstem Response (ABR) audiometry3.2.6
Auditory brainstem response was performed with the Nicolet Viking IV (Nicolet
Biomedical Instrument Inc). Active electrodes were attached to the ipsilateral mastoid
region and were referenced to a vertex electrode. A ground electrode was placed on the
forehead. The latencies of wave I and wave V, the I-V interpeak interval, the interaural
latency difference of waves V (ILD V) and I-III, III-V the interaural differences between I-
V interpeak intervals (ID I-V) were evaluated. The interaural differences were determined
by subtracting the value of the left side from the value of the right side (Table 5).
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Table 5. The normal value of waves in ABR (CHUS)
Results were considered normal if the interaural difference was 0,2 milliseconds (ms) or
less for the wave I-V IPLs. Results were considered borderline if the interaural difference
for the wave I-V IPLs was between 0.2 and 0.3 ms. If the interaural difference was 0.3 ms
or greater for the wave I-V IPLs, ABR results were considered abnormal. Also the absence
of wave III-V or the absence of ABR was considered suggestive of retrocochlear
pathology.
Vestibular Evoked Myogenic Potentials (VEMP) testing3.2.7
The VEMPS has been performed like other tests have been performed in the
otolaryngology outpatient department of CHUS. The test records information using an
evoked response laptop, a sound generator, and surface electrodes to pick up neck muscle
activation or other muscles, if this is of interest.
There are different methods of obtaining the VEMP. Our method of obtaining activation is
to have patients sit upright with their chin turned over the contralateral shoulder to tense
the SCM muscle.
Electrode montage for VEMPs records information in the following places:
 The ground electrode placed on the forehead;
 The reference electrode placed on the sternum;
 Active electrodes to the medial third of SCM muscle.
We explained to the patient to sit in an upright position and to rotate the chin to the
opposite side while trying to tighten the neck muscles. The device has visual feedback that
Wave Media DS (±) Wave Media DS (±)
I 1.7 0.15 I-II 2.1 0.15
II 2.8 0.17 I-V 4 0.23
III 3.9 0.19 III-IV 1.2 0.16
IV 5.1 0.24 III-V 1.9 0.18
V 5.7 0.25 IV-V 0.7 0.19
VI 7.3 0.24 V-VI 1.5 0.21
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indicates whether the intensity of muscle contraction is satisfactory (50 - 200μV). An
average we have realized is150 stimuli in each ear with clicks at 99 with the duration of 0.1
ms. In interpretation, we have focused primarily on P1/N1 (P13/N23) amplitude
measurements or threshold asymmetries between the right and left sides. Side-to-side
differences in VEMP amplitude as an asymmetry ratio we have calculated with the
following formulas:
Asymmetry Ratio = 100 (AL –AR)/(AL + AR)
Where AL equals the peak-to-peak amplitude (P1/N1) on the left side and AR equals the
peak-to-peak amplitude on the right side.
We have considered normal AR to be less than 35% 211.
Magnetic Resonance Imaging3.2.8
Our group of patients were being followed up over the years, therefore in each revision in
the ENT department, they were directed to the Radiology Department to perform an MRI
scan for comparing the size of the VS with the previous MRI. All MRI scans of the VS
patients were performed with gadolinium contrast.
According to the radiologists of CHUS, to enable an accurate and consistent comparison of
findings on MRI images, tumour size is defined by calculating the mean intracranial
diameter according to the measurements along three easily defined axes on Gd-enhanced
T1-weighted images.
Thus, the maximum anteroposterior and mediolateral distances were measured on axial
images, parallel and perpendicular to the sagittal plane. The maximum craniocaudal
diameter was determined by assessing coronal images.
The mean diameter as well as the greatest intracranial dimension was noted for each tumor.
A decrease or increase in size was regarded as significant if the change of mean diameter
was at least 2mm. This cutoff was chosen based on limitations in spatial resolution of the
standard 1.5-tesla MR imaging used for most follow-up studies. Intracanalicular tumors,
without intracranial extension, were measured in all three dimensions, with a change in
size being defined as significant if the transverse diameter had decreased or increased 2mm
or more.
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From the radiologist's report, we always picked up the maximal size of the VS. For
example, according to above measurement methods, if they reported the following
dimensions: 22x17x14mm in this case as the maximum size of the tumor, in the follow-up
revision we registered it to be 22mm.
Moreover, by using the previous reports of the radiologists, we compared the size of the
VS tumor with current and primary scan. In this way, we had a size difference for each
follow-up year.
All the information in numbers from the radiologist's reports were downloaded to the
Microsoft Excel 2007 file.
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4 Results
Demographic and Epidemiological characteristics of patients with VS4.1.1
Gender4.1.2
A current study included 107 (100.0%) patients who attended to the Santiago de
Compostela University Hospital for the period between February 21, 1992 and February
26, 2013 with the overall average observation period of 56.52 ±10.79 (range 25.02-71.74)
months. Among the 107 (100.0%) patients, there were 57 (53.8%) females and 50 (46.2%)
males, (e.g. see fig. 53) including 1 (0.9%) male patient with a bilateral VS due to NF2.
Because of its genetic origin, we analyzed the bilateral VS separately and we will describe
it at the end of the results.
Figure 53. Chart showing the distribution of patients by gender
Age4.1.3
Among investigated unilateral VS patients there were 57 (53,8%) females with the median
age of 57,45 ±14,24 (range, 24-86) and 49 (46, 2%) males with median age of 56,16
±15,14 (range 24-85). Although the number of females was slightly higher than the
number of males, but this difference was statistically not significant (Table 6).
Table 6. Distribution of VS patients by gender
Gender Number of cases &
percentage
Age at the time of diagnosis
Median age/± Age range IQR
Female 57 (53, 8%) 57,51 ±14,20 24-86 48-69,0
Male 49 (46, 2%) 56,21 ±14,97 24-85 43,5-69,5
Total 106 (100,0%) 57,0 ±14,50 24-86 46,7-69,0
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Clinic Characteristics of patients with VS4.2
Primary symptom4.2.1
First of all, we have revealed the primary symptoms of a VS which brought the patient to
the physician (Table 7). In the majority of cases, 68 (64.1%), the primary symptom of a VS
was hearing loss in the affected ear. The second major presenting symptom of a VS was
tinnitus. The first sign of a VS in 24 (22.1%) of the patients was the complaint of having
tinnitus (Table 7).
Primary sign of VS Number of patients Percentage
Hearing loss 68 64,1%
Tinnitus 24 22, 1%
Vertigo 9 8, 3%
Unsteadiness 4 3, 7%
Dizziness 1 0,9%
Total 106 100,0%
Table 7. Distribution of patients regarding the type of presenting symptoms of a VS
Symptoms at the time of diagnosis4.2.2
Apart from the symptoms of presentation reported by patients, there were additional
symptoms found at the oto-neurologic examination which immediately brought about their
diagnosis.
In 11 (16.1%) out of 68 (63.2%) patients, the hearing loss was the only presenting
symptom of a VS and there were no any other symptoms at the time of diagnosis. But in
54 (59.0%) of the patients with hearing loss, the tinnitus and vestibular symptoms
presented were associated with hearing loss.
Only in one case (0.94%) out of 106 patients, did the tinnitus purely present a VS at the
pretreatment stage. In contrast, in 23 (21.6%) cases of hearing loss, vestibular and other
symptoms, were associated secondly to tinnitus. The cases of vertigo and unsteadiness
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never presented as an only sign of a VS and the patients were always associated with either
symptom. But in the case of one (0.94%) patient, the dizziness was purely presented as a
VS. The detailed clinical symptoms and their association can be seen in Table 8.
Presenting
symptom
Additional symptoms found at the time of diagnosis
Hearing loss (68) Only hearing loss (11)
Tinnitus (40) Only tinnitus (26)
Instability and/or vertigo (10)
Hypoesthesia in Ramsay-Hunt area (2)
Instability and hypoesthesia in R-H area (1)
Vertigo and facial palsy (1)
Vertigo, dizziness and/or
instability (14)
Only vertigo, dizziness and/o instability (13)
Dysphony (1)
Other: earache (1), pain in hemifacial area (1) and lack of speech indelibility (1).
Tinnitus (24) Only tinnitus (1)
Hearing loss (19) Only hearing loss (18)
Headache (1)
Other: vertigo (1), instability (1), plugged ear (1) and dizziness, nausea and
vomiting (1)
Dizziness (1) Only dizziness (1)
Instability (4) Hearing loss (1)
Hearing loss, dizziness and loss of consciousness (1)
Tinnitus (1)
Clumsiness of right hemisphere and facial paresis (1)
Vertigo (9) Hearing loss (6) Only hearing loss (3)
Instability (1), tinnitus (1) and hypoesthesia in
Ramsay-Hunt area (1)
Tinnitus (2)
Instability (1)
Table 8. Distribution of presenting symptoms (which brought the patient to a physician) and symptoms
found at the time of diagnosis of a VS
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4.1.1. Side of the lesion.
According to the gadolinium contrast and the enhanced MRI, a total of 55 (51.9%) patients
presented with a right-sided VS and 51 (48.1%) patients presented with a left-sided VS.
Among the patients with a right VS, there were 30 females (52.6%) and 25 males (50%).
In a group of patients who presented with a left-sided VS, there were 27 females (47.4%)
and 24 males (51.0%). We did not find an association between the side of affection and
gender (p value =0.87 (Chi- squared test)).
Localization of VS4.2.3
Regarding the localization of a tumor, there were, in general, 25 (23.6%) patients who
presented with an extracanalicular VS, 41 (38.7%) who presented with a pintracanalicular
VS, and 40 (37.7%) patients who presented with an intra-extracanalicular VS. Among the
patients with an intracanalicular VS, there were 27 (65.8%) females and 14 (34.1%) males.
In a group of patients with an intra-extracanalicular VS, there were 19 (47.5%) females and
21 (52.5%) males. In Table 10, is the presentation of distribution of patients regarding the
localization of a VS.
Patients Localization of VS Total
Extracanalicular Intracanalicu
lar
Intra-
extracanalicular
G
en
de
r Female
Number of gender 11(19,3%) 27(44,4%) 19(33,3%) 57
% of affected side 44,0% 65,9% 47,5% 53,8%
Male
Number of gender 14 (28,6%) 14(28,6%) 21(42,9%) 49
% of affected side 56,0% 34,1% 52,5% 46,2%
Total
Number of gender 25(23,6%) 41(38,7%) 40(37,7%) 106
% of affected side 100% 100% 100% 100%
Table 9. Distribution of VS patients regarding gender and localization of a VS
In order to know if there is any correlation between the localization of a VS and the gender
of the patients, we have applied the Chi-squared test which didn’t show statistical
significance (p-value 0.09).
The following graph 2 illustrates the frequency of VS related symptoms and information
regarding the localization of a VS.
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Figure 54. Distribution of presenting symptoms regarding the localization of the tumor
The plotted graph above shows a visual relationship between localization and primary
symptoms of a VS and the applied two tailed Pearson and Spearman test equally showing
the significant relationship between localization and initial symptoms (p=0.01).
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Exploration4.3
Audiologic Testing4.3.1
4.3.1.1 Pure Tone Audiometry
4.3.1.1.1 Pure Tone Thresholds
We found that in the cases of the 68 (63.5%) patients, the early symptom of a VS noticed
by the patients was hearing loss. But the loss of hearing was not always the patient's reason
for coming to the hospital; therefore, in diagnostics testing, we have revealed 96 (90.56%)
patients with hearing loss. Among the patients with hearing loss, there were 51 (53.1%)
females with the mean PTA of 64.93dB and 45 (46.8%) males with a mean PTA of
60.96dB. Ten (8.4%) patients presented with a normal PTA (e.g. see table 10).
Table 1. The results of early conventional audiometry of patients with a VS
As we see from the above table, at the time of diagnosis, a total of 96 (90.56%) patients
presented with hearing loss, including 89 (83.9%) SNHL. Seven patients (6.6%) with
deafness had a PTA of 58.80dB. The overall average PTA was lower in patients under 40
years (49.94 ±32.69 (Range12.50-120)) than patients aged above 40 years (60.54 ±28.07
(Range 13-120)). Due to the small sample size (15 (14.1%)), for the group of patients
under 40, the T-test did not show a significant difference p= 0.10907.
4.3.1.2 Audiometric Configuration
During the data collection, we also registered the shape of audiometric configuration of VS
patients with hearing loss and the shapes were significantly varied. The audiometric
configurations that comprised the average thresholds used to define each category were
described as sloping, rising or flat. The audiometric configuration was considered sloping
Hearing level at diagnostic stage Number of patients Percentage
SNHL 89 83,9%
Deafness 7 6,6%
Normal hearing 10 8,4%
Total 106 100%
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when the thresholds occurred at equal or successively higher levels from 250 and 8000 Hz
>20dB. We determined that the configurations were rising when thresholds occurred at
equal or successively lower levels from 250 to 8000 Hz. The difference between thresholds
at 250 and 8000 Hz was always >20 dB and the configurations were flat when thresholds
across the frequencies did not vary more than 20 dB from each other (e.g. see table 11).
The data plotted above shows that the majority of VS patients (63.5%) in the baseline stage
showed NSHL with a slopping configuration, and 5.0% of the patients presented with a
rising audiometric configuration. The flat or pantonal hearing loss was observed in 25% of
the cases of VS. The frequency of other audiometric configurations, like the U-
shaped/Basin-shaped, mountain-shaped, etc., registered in 6.3% of the VS patients.
Patients with sloping hearing loss included 25 (41%) with an intracanalicular VS, 24
(39.3%) with an intra-extracanalicular VS and 12 (19.6%) of the patients with an
extracanalicular VS series. Patients with pantonal hearing loss included 11 (45.8%) of
those with an intracanalicular VS, 4 (16%) with an extracanalicular VS and 9 (37.5%) with
an intra-extracanalicular VS. Of the patients (5(5.2%)) with a rising audiometric
configuration, 3 (4.9%) presented with an intracanalicular VS and 2 (3.2%) had an intra-
extracanalicular VS.
Audiometric configuration n % Size of VS mm
Average/± Range
Sloping or hearing loss mostly in higher
frequencies
61 63,5% 14.48 ±7.1 2-34
Rising or hearing loss in low
frequencies
5 5,2% 17,4 ±18.2 7-50
Flat or pantonal hearing loss 24 25% 14,3 ±8.68 4-35
Other 6 6,3% 15.1 ±17.4 10-30
Total 96 100%
Table 2. Type of audiometric configuration in a group of VS patients
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4.3.1.2.1 The association between demographic and clinical data
In order to reveal the prevalence of hearing loss by age group and gender among the
patients with a VS, we have conducted a comparative analysis between female and male
patients as seen in Table 12.
Gender Total number
of patients
PTA/dB
Mean Median Minimum Maximum Std. Dev
Female 57 60,26 55,0 16,25 120,00 29,52
Male 49 57,10 52,50 3,75 120,00 28,50
Total 106 58,68 53,12 3,75 120,00 28,96
Table 3. Comparative data of hearing loss at diagnosis and gender of the patients
As we see from Table 13, the mean values of a PTA in both groups do not differ
significantly. Moreover, applied statistical tests (t-Student) did not show a statistically
significant difference between the two groups in terms of gender and hearing loss (p =
0.47).
In order to reveal if the value of PTA depends on the localization of a VS, we have
compared the PTA in each type of localization. Graph 5 illustrates the mean and median
values of a PTA in three different kinds of a localization where we can observe the
difference in PTA between types of VS localizations.
The overall difference between the three types of localization groups were found using the
ANOVA test, and the results were significantly different (p=0.014). According to
Bonferroni, with multiple comparisons, there were statistical significant differences
between intracanalicular and intra-extracanalicular types of localization (p=0.016).
Between the extracanalicular and intra-extracanalicular (p=0.750) and between the
intracanalicular and extracanalicular (p=0.200) group of localization, there was no
statistical significant difference (e.g. see table 13).
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Localization of VS N/% PTA/dB
Mean Median St. Dev
Extracanalicular 25 (23,5) 61,7400 55,50 25,58
Intracanalicular 41 (38,67) 48,87 43,75 25,47
Intra-Extracanalicular 40 (37,73) 67,13 58,75 31,77
Table 4. The value of PTA regarding the localization of a VS
As we see from Table 13, the overall average PTA of an intracanalicular VS ≤50dB, while
the overall average PTA of an extracanalicular and an intra-extracanalicular VS is ≥60dB.
4.3.1.3 Auditory Brainstem Responses (ABR)
Although the ABR is not considered as a gold standard diagnostic test for a VS, the test is
usually performed before the MRI, especially when the patient presents with asymmetric
hearing loss and tinnitus along with vestibular symptoms.
In our series, we found 43 (40.5%) VS cases with the ABR testing which was performed at
the diagnostic stage. Among those tested, there were 25 (58.1%) females at the mean age
of 51.17 (Range 69.73-24.75) with a mean PTA of 54.43 ±26.27 (Range 16.25-111.25)dB
and a mean sized VS of 1.50 ±8.62 (Range 2-34mm). There were 18 (41.9%) males at the
mean age of 58.33, the mean PTA of 60.60 ±31.63 (Range 12.50-120dB) and with a mean
sized VS of 17.44 ±8.47 (Range 2-35mm).
The overall averages for both groups were 56.71 ±28.5 (Range 3.75-120dB) and the initial
size of the VSs was 14.56 ±8.46 (2-35mm). In the group, 21 (48.8%) patients presented
with an intracanalicular VS, 7 (16.2%) presented with an extracanalicular VS and 16
(37.2%) patients presented with an intra-extracanalicluar VS.
In ABR testing, the morphology and latency of waves, including the interaural latency of
wave V (IA5), were under our main focus.
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4.3.1.3.1 Morphology
Among the 43 results, there were 20 (46.9%) patients who presented with waveform
morphology, in 8 (18.5%) cases of patients, the waveform morphology was abnormal and
in 17 (39.5%) patients, the waveform morphology was absent. Patients who were absent
of waveform morphology had more profound hearing loss, their average overall PTA was
70.1 ± 25.20 (Range 30-120)dB, and the size of their VS averaged 15.1 ±7.8 (4-35mm).
4.3.1.3.2 Waveform latencies
The average latency of waveforms I-V, I-III, III-V and the interaural difference of latency
wave V are all presented in Table 14.
ABR waves Latency (ms)
Average Minimal Maximal Std. Dev
I-V 4,81 3,5 6,48 0,90
I-III 2,74 2,1 4,1 0,89
III-V 2,05 1,64 2,72 0,30
V - interaural 0,70 0,08 4,0 0,73
Table 5. The results of ABR waveform latencies
In the cases of 35 (81.3%) patients, the waveform I-V, I-III, III-V were all delayed, and in
36 (83.7%) patients, the interaural latency difference of wave V was pathologic. Seven
(16.2%) patients (out of 43 VS patients) presented with completely normal ABRs while
having a tumor with the average size of 10 ±8.99 (Range 2-32.5mm). We found abnormal
ABRs in cases of intracanalicular and intra-extracanalicular types of VSs, p=0.001 (One
Sample Kolmogorov-Smirnov Test).
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4.3.1.3.3 Association between demographic and clinical data
Among 43 available ABR testing results, there were 21 female and 22 male patients and
their average age was 55.6 years. We have compared the prevalence of females and males
in respect to ABR testing results. At first, we checked the absolute latencies of I-V, I-III,
III-V and we found that 83.7% of the patients have delayed latency. Among them 39.5%
were female (out of 43 patients) and 44.1% were male patients. The detailed difference can
be seen in Table 15.
As we see from Table 15, more than 80.0% of the patients showed a pathologic ABR in
latencies I-V and I-III (83.7%) but in the cases with III-V waves, less pathologic results
were found (58.1%). Apart from the latencies of I-V, I-III, III-V waves, we have separately
performed comparisons of male to female ratios regarding ABR interaural latency of wave
V (IT5), which can be seen in Table 16.
IT5 Total
Normal Pathologic
Gender Male 5 16 21
Female 2 20 22
Total 7 36
Table 7. Female and male proportion and results of IT5
Gender Latency I-V Latency I-III Latency III-V
Normal Pathologic Normal Pathologic Normal Pathologic
Female N 4/43 17/43 3/43 18/43 11/43 10/43
% 9,3% 39,5% 6,97% 41,8% 25,5% 23,2%
Male N 3 19 4 18 7 17
% 6,97% 44,1% 9,3% 41,8% 16,2% 39,5%
Total N 7 36 7/43 36 18 25
% 16,2% 83,7% 16,2% 83,7% 41,8% 58,1%
Table 6. The prevalence of abnormal ABR latencies regarding the gender of VS patients
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With the purpose of defining if there is any association, we have performed a comparative
analysis of ABR results among three different variables: the IT5, the localization and the
size of the tumor (e.g. see table 17).
Localization N (%) Size of the
tumor
N IT5
Normal Pathologic
Extracanalicular 8 (18,6) ≤ 10 1 0 1
11-20 3 0 3
21-30 1 0 1
> 30 3 0 3
Intracanalicular 17
(39,5%)
≤ 10 13 5 8
11-20 4 0 4
21-30 0
> 30 0
Intra-
extracanalicular
18 (41,9) ≤ 10 2 2 0
11-20 8 0 8
21-30 5 0 5
> 30 3 0 3
Total 43 43 7 36
Percentage 100% 100% 16,3% 83,7%
Table 8. Tumor size by ABR Interval Latency Difference for wave V (IT5)
From Table 17, we can see the results of the ABR test in respect to the localization of the
tumor, where we have found normal results in smaller tumors, both in intracanalicular and
intra-extracanalicular locations. Thus, there are strong correlations between the size of the
tumor and IT5 in the level of p < 0.001 (Chi- squared test).
4.3.1.4 Otoacoustic Emissions
We have found 28 (26.1%) available reports of DPOAE testing performed at the diagnostic
stage. Among them there were 16 (59.2%) females and 11 (40.7%) males. The average
overall age of this group was 56.30 (Range 24-81). The average size of PTA was 56.92
±34.6 (Range 3.72-120)dB and the average size of the VS tumor was 15.57 ±8.6 (Range 2-
35mm). In this group, there were 15 (14.1% out of 106) out of 28 patients who presented
with OAE. In 13 (12.1%) patient cases, the OAE was absent (e.g. see table 18).
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DPOAE n
Gender
Localization of tumor
Pure Tone
Average
(dB)
F(%) M(%) Intra-
canalicular
Extracanalicular or
Intr-
extracanalicular
Presents 15 8(53,6) 7(47%) 7 (47%) 8 (53,7%) 60,5
Absents 13 9(70%) 4(26,8%) 6 (46,1%) 7 (25%) 63,4
Total /% 28
(100%)
17
(61%)
11
(39,2%)
13 (46,5%) 15 (53,5%) 61,95
Table 9. Distribution of VS patients according to results of OAE
The 7 (6.5% out of 106) patients with the absence of an OAE presented with a VS more
than 20mm, located extracanalicular or intra-extracanalicular, and their overall average
PTA was 70.22 ±28.66 (Range 30-120)dB. In the cases which remained, 6 (5.6%) patients
presented with intracanalicular VSs more than 10mm in size (Table 19). Due to the small
sample size of patients, the statistical test regarding localization and size of VSs with OAE
was not significant.
Vestibular and Balance Testing4.3.2
4.3.2.1 Craneocorpography
In 68 (64.1%) cases, the patients were presented with a CCG test performed at the time of
diagnosis. Out of the 68 cases, there were 39 (57.3%) female patients and 29 (39.7%) male
patients. The average overall PTA of this group was 55.04 ±24.24 (Range 12.5-117.5) and
average overall size of the VSs was 16.98 ±10.18 (Range 2-50mm) (e.g. see table 19).
CCG Number of patients Size of VS (mm) Total
Female Male Mean/SD Range n (%)
Type I 9 (23%) 10 (34%) 16,55 ±11,24 4-50 19 (27)
Type II 20 (51,2%) 12 (41%) 16 ±9,58 3-50 32 (47)
Type III 3 (7,6%) 5 (17%) 14,08 ±8,2 2-26 8 (11,7)
Type IV 7 (17,9%) 2 (6,8%) 22 ±12,14 8-35 9 (13,2)
Total 39 (100%) 29 (100%) 16,98 ±10,18 2-50 68 (100%)
Table 19. Results of CCG testing regarding the gender of the patients
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As seen in Table 20 above, the average overall size of the VS in a Type IV CCG
(corresponding to VS) is higher than a Type I (corresponding to normal CCG). Students
who performed the t-test showed p=0.87183 due to a small sample size in a group of
patients who presented with CCG IV. Likewise in PTA, the average PTA in the Type I
group was 56.28 ±31.75 (Range 30-120). In Type IV 81.9 ±32.94 (Range 33.75-120), the
p-value was not significant (p=0.96) due to the small sample sizes in the CCG Type IV
group.
We also compared the clinical picture with the results of the CCG to determine whether
there is any association between them (e.g. see table 20).
Clinical
presentation
Number of patients in each type of CCG Total
Type I Type II Type III Type IV n (%)
Tinnitus 11 15 4 2 32 (47,0)
Vertigo 5 6 2 3 16 (23,5)
Imbalance 2 9 1 4 16 (23,5)
Dizziness 1 2 1 0 4 (5,8)
Total (n/%) 19 (27%) 32 (46%) 8 (11%) 9 (13%) 68 (100)
Table 10. Association of CCG with clinical picture of VS
As we see from the table above, the CCG Type IV corresponding to a VS was observed
only in 9 (13.2%) cases.
Apart from the above-mentioned demographic and clinical association of a VS with CCG,
we have analyzed the location of the tumor and its relationship with CCG. In the cases of
extracanalicular location of a VS, there were 5 (4.71%) patients with Type I, 8 (7.5%)
patients with Type II, 1 (0.94) patient with Type III and 4 (3.77%) patients with an
extracanalicular VS registered Type IV CCG. In the cases of intracanalicular location of a
VS, there were 8 (7.5%) patients with Type I, 13 (12.2%) patients with Type II, 2 (1.8%)
patients with Type III, and in 2 (1.8%) patients with Type IV were registered with CCG.
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The number of patients with a VS with an intra-extracanalicular location were 6 (5.6%)
with Type II, 11(10.3%) patients with Type II, 5 (4.71%) patients with Type III and in 3
(2.8%) cases, the patients were registered with a Type IV CCG.
We did not find any significant association between localizations, size of VS and the CCG.
Also there were no associations found between the CCG and the clinical presentations of a
vestibular schwannoma.
4.3.2.2 Computerized Dynamic Posturography
The 60 (56.6%) patients presented with paper-based CDP results performed at the time of
diagnosis. We have analyzed the data from the different conditions, and sensory analysis
by gender and age within these groups. Values obtained are presented in tables and graphs.
The overall results of CDP conditions can be seen in Table 21.
Overall
balance
Condition 5 Condition 6 VEST
Average 68,36 46,36 46,52 49,5
Median 70 46,6 48 48,5
Standard
deviation
10.94 12,72 14,14 16,26
Maximum 86 79 79 149
Minimum 27 0 0 1
Table 11. Descriptive statistics of SOT for all 60 (56,6%) patients
We have compared the number of normal CDP results with the pathologic balance in
different conditions of SOT. In the global balance cases, there are 38 (63.3%) patients
who have had normal overall balance and in the cases of 22 (36.6%) patients, the
overall balance was pathologic. In condition 5, there are 26 (43.3%) patients who
presented with normal results and 32 (53.3%) patients who presented with pathologic
results. In Condition 6, 32 (55.0%) patients are shown to have normal overall balance
and 27 (45%) patients are shown to be pathologic.
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Figure 55. Graphical view of the average balance reached in the different conditions of SOT
Table 22 shows the existence of significant difference for the condition 6 and chart 5
also showing that percentage of balance slightly higher for males among the
population.
The following Table 22 illustrates the comparative results of SOT in males and
females.
n Overall
balance/±
Condition 5 /± Condition 6 /± VEST /±
Female 31 66,53 ±10,43 44,81 ±19,47 39,84 ±21,39 51,52 ±29,1
Male 29 70,24 ±11,5 47,30 ±17,5 54,00 ±16,6 52,07 ±18,58
Table 12. Overall balance and CDP conditions regarding the gender of VS patients
By means of the t-Student, we have compared the female population with males and found
significant difference in condition 6 (p= 0.005).
4.3.2.3 Caloric Testing
We have found 67 (63.2%) cases of a VS with available caloric testing. Among the cases,
there were 36 (53.71%) females with the mean age of 56.91 (Range 24.16-58.55) years and
31 (46.2%) males with the mean age of 57.82 (Range 29.03-81.33) years.
Total
Female
Male
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The average overall PTA in the female group was 61.79 ±30.69 (Range16-120)dB and the
size of their VSs was 14.82 ±10.36 (Range 2-50mm). Along with this group, a group of
males presented with an average overall PTA of 58.64 ±28.39 (Range 3.75-120)dB and an
average overall VS size of 16.60 ±8.46 (Range 2-35mm).
In general, we found 37 (55.2%) pathologic responses and 30 (44.8%) normal bithermal
caloric responses. Among patients with pathologic responses, there were 4 (5.9%) patients
with vestibular arreflexia. In a group with pathologic responses there were 23 (63.8%)
females and 14 (46.4%) males. The overall percentage of normal results is the following:
pathologic ratio was 44.8:55.2 with females (63.8%) being predominate over males
(46.4%) . The results of the caloric tests for 67 patients can be seen in Table 23.
Vestibular testing
with WNG
Hypofunction Reflectivity Total
Normal Pathologic Normal Pathologic
Number of patients 30 37 29 34 67
Percentage 44,7 55,3 43,3 56,7 100
Table 23. Distribution of patients according to caloric testing results
In the female group, the average overall PTA (61.79 ±30.69) was slightly higher than those
in males (58.64 ±28.39), but on the other hand, the males presented with a little bit higher
overall size of VSs (16,60 ±8,46) than females (14,82 ±10,36).
The majority of patients (78.3%) who presented with abnormal caloric responses had
intracanalicular or intra-extracanalicular VSs and their overall average PTA was 67,24
±32.66 (Range 12.50-120)dB. The overall average size of the VSs was 16.82 ±10.02
(Range 4-50mm). Patients with normal caloric responses presented with a significantly
lower average PTA (49.13 ±21.78 (3.75-88.78)dB) and (13.77 ±7.96 (2-32.50)) size of VS.
4.3.2.4 VEMPs
In the cases of VEMPs testing, we have 21 (19.8%) reports of testing performed at the time
of diagnosis. Among the patients, there were 11 (52.38%) females and 10 (47.61%) males.
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The results of analysis showed that in the cases of 12 (57.14%) patients, the VEMPs was
presented in lesion side and in the cases of nine (42.8%) patients, the VEMPs test was
absent. Among the patients without VEMPs, one (4.7%) patient did not show a response
on the VS tumor side.
Among patients who presented with a VEMPs response, there were 5 (23.8%) females and
6 males (28.7%). Among the patients with an absence of a VEMPs response, there were 6
(28.5%) female patients and 4 (19.0%) male patients. Also, we registered the Asymmetry
Ratio (AR) between the two ears, which indicates the difference between right or left
VEMPs. The average asymmetry for all 12 (57.1%) patients who presented with a response
to the VEMPs stimuli was 33.94% (±24.0) with the maximum being 87.0% and the
minimum being 6.2%. In the Asymmetry ratio of VEMPs in patients who presented with
VEMPs, there are 6 (28.5%) patients out of 21 (100.0%) whose test showed normal.
We performed a comparative analysis to establish if there were some associations between
VEMPs and other tests and we found no clear association between the results of VEMPs
and the localization of a VS (Table 24).
Gender VEMPs Present VEMPs Absent Total
n PTA/
SD
Localization n PTA/
SD
Localization
Int Ext Int-
Ext
Int Ext Int-
Ext
Female 6 42,2
±15,9
2 0 4 5 60,55
±4,5
3 0 2 11
Male 6 45,2
±18,56
4 1 1 4 44,8
±21,3
2 1 1 10
Total 12 41,5
±15,9
6 1 5 9 55,5
±33,76
5 1 3 21
% 57,1 28,5 4,76 23,8 42,8 23,8 4,76 14,2 100
Table 13. Association between VEMPs, PTA regarding the localization of VS
From the information in Table 24, we can see that there is no relationship between the
VEMPs and the localization of a VS. Perhaps it is due to our small sample size of patients
who have undergone the VEMPs testing.
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Imaging Tests4.3.3
4.3.3.1 MRI
The results of the MRI analysis scans which determined the initial size of the VS in 106
(99.0%) patients was performed at the time of diagnosis and is presented in the following
Table 25.
Gender Total
number of
patients
Size of the tumor/mm
Mean Median Minimum Maximum Std. Dev
Female 57 14,96 12,00 2,00 50,00 10,16
Male 49 17,37 17,00 2,00 45,00 9,05
Total 106 16,08 15,00 2,00 50,00 9,69
Table 14. The size of tumor regarding the gender of the patient
We have observed that the mean size of the tumor is a little bit bigger in the cases of males
17.37 (±9.05) than in the cases of females 14.96 (±10.16). Particularly, this difference was
more pronounced in patients ≤ 40 years old (21.7 ±12.21 (6-50mm)) and this difference
was negatively correlated in older patients. Although the increased the age the tumor was a
determinant of size, statistical tests (t-Student) didn’t show any significant difference in the
size of the tumor between the two genders.
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Figure 55. Shows the initial size of the VSs in regard to the age of the patients
The above graph shows the relationship between age and the size of the tumor at the time
of diagnosis. Although the plotted samples are disperse, we can see a slight difference in
males in presenting with a relatively larger VS.
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Treatment4.4
Wait-and-watch4.4.1
The 67 (63.2%) patients were under a wait-and-watch scan. Among them, there were 36
(53.2%) females and 31 (46.3%) males. The average age of patients in this group were
59.21 ±14.35 (Range 24-85) and the average size of the VSs were 12.68 ±6.76 (Range 2-
35). The overall average PTA and size of the VS for the wait-and-watch group is presented
in the following table:
Average / ± Range
PTA 57,30 ±28,53 12-120
MRI 12,68 ±6,76 2-35
Table 15. The overall average PTA and size of VS in wait-and-watch group
The distribution of the patients regarding localization was the following: out of 67
(100.0%) patients, 35 (52.2%) presented with intracanalicular VSs, 10 (14.9%) patients
presented with extracanalicular VSs, and 22 (32.8) patients presented with intra-
extracanalicular VSs. Thus, the intracanalicular localization was a more frequent
localization among patients in the wait-and-watch group and it dominated over
extracanalicular and intra-extracanalicular types of VS localization.
Radiosurgery4.4.2
At the diagnostic stage, there were 27 (25.5%) patients directed to GK Radiosurgery.
Among them there were 15 (55.67%) females and 12 (44.4%) males. The average age of
patients in this group was 56.82 ±14.30 (Range 24.75-78.48). The overall average PTA and
size of the VS is presented in following table.
Average / ± Range
PTA 59.80 ±26,86 16,25-120
MRI 16,13 ±7,56 5-30
Table 16. The overall average PTA and size of VS in the GK Radiosurgery group
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We have compared the size of tumors between females and males, which was slightly
higher in females 14,86 ±8,06 than males 17,72 ±6,88 (p=0.064). The localization of a VS
among the GK Radiosurgery group was the following: intracanalicular tumors 7 (25.9%),
extracanalicular tumors 9 (33.3%), and intra-extracanalicular tumors were in 11 (40.74%)
of the cases.
Conventional neurosurgery4.4.3
In the group of patients under conventional neurosurgery, initially, there were 12 (11.32%)
patients, including 6 (50.0%) females and 6 (50.0%) males. The average age of patients in
this group was 43.78 ±9.28 (Range 29.16 –57.85) years. The overall PTA and size of the
VS is presented in the following table:
Average / ± Range
PTA 66.40 ±35.84 25.50-120
MRI 30.04 ±11.37 8-50
Table 17. The overall average PTA and size of VS in the Conventional neurosurgery group
Out of 12 patients, 5 (41.6%) presented with extracanalicular VSs and 7 (58.3%) patients
presented with an intra-extracanalicular VS.
Association between the wait-and-watch and radiosurgery treatment4.4.4
groups
As we see from the table above, the stated results of the data of patients in three different
groups slightly differs. The patients in the conventional neurosurgery group are younger
than the wait-and-watch and GK radiosurgery group p=0.03 (ANOVA). The average age
of patients in radiosurgery and the wait-and-watch group show no significant difference
(p = 0.19) (t-Student). We do not find significant differences between genders in the three
treatment groups. The overall average PTA in the wait-and-watch and GK radiosurgery
groups show no significant difference.
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As a main point of our objective, we compared only the wait-and-watch and HK
radiosurgery groups. The overall average size and PTA in the watch-and-wait and GK
radiosurgery treatment groups are presented in the following table below:
Treat. groups Mean ± 95% CI
Lower Upper
Age (y) Wait-and-watch 59,21 ±14,35 55,71 62,71
Radiosurgery 56,82 ±14,30 51,17 62,48
PTA (dB) Wait-and-watch 57,30 ±28,53 50,34 64,26
Radiosurgery 59,80 ±26,86 49,18 70,34
MRI (mm) Wait-and-watch 12,68 ±6,76 11,42 15,35
Radiosurgery 16,13 ±7,56 13,14 19,12
Table 29. Comparative characteristics of age, PTA, and size of VS among wait-and-watch and GK
radiosurgery groups
We found a significant statistical difference between the size of the tumor (p = 0.002;
95.0% CI of difference: -4.5602 <-2.75< -0.9398; two sided: 0.004) in the wait-and-watch
and GK radiosurgery groups, but we did not find a statistical difference in PTA between
the two groups (p= 0.33). The dot plot illustrates the comparative view of the overall
average PTA and size of the tumor in three treatment groups (e.g. see fig. 6). The dashed
line shows the average level (PTA and size of VS) for the three groups.
Figure 56. The value of MRI and PTA in three treatment groups
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Also, the majority of patients (52.2%) in the wait-and-watch group presented with an
intracanalicular VS. Although, there is a poor relationship between the two measurements
(R-squared = 0.079), the majority of patients under the wait-and-watch control group
presents tumors smaller than 15mm.
The initial average size of tumors in each group of treatment and the differences can be
seen in the following graph (e.g. see fig 57).
Figure 57. The average initial size of VS in 3 different treatment groups (p<0,001)
In order to find the differences for general comparison, we have used the two step ANOVA
methods.
First of all, we performed a global comparison of the groups (all groups were not equal)
and we have found that the differences between the groups were significant at the level of
p < 0.001 (one-way ANOVA).
The mean size of the VS in the wait-and-watch group (12.68 ±6.76) was smaller than the
size of the VS in the radiosurgery (16.13 ±7.56) group. This difference is statistically
significant at the level of p= 0.014. The mean size of the VS in the neurosurgery group
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(30.04 ±11.37) is much more significant than in both the wait-and-watch and radiosurgery
groups (p < 0.001) (Bonferroni test).
Complications of treatment4.5
By the last follow-up, overall, there were 42 (39.6%) patients who underwent GK
Radiosurgery and 16 (15.1%) patients who were treated with Neurosurgery and 48 (45.2%)
were still under the wait-and-watch control. The complications of a VS after Conventional
Neurosurgery was obvious; therefore, we have exclusively analyzed the complications of
GK Radiosurgery. According to the patient records and test results after first review (after
one month of GK Radiosurgery), there were 61.90% (26/42) who did not present with any
post-radiosurgery complications. However 38.1% (16/42) of the patients presented with
either type of complications. Among them, the 11.09% (5/42) of patients presented with
facial paresis, 2.3% (1/42) had facial palsy, 6.9% (3/42) became completely deaf, 2.3%
(1/42) suffered significant hearing loss (more than 10dB), and 4.76% of the patients (2/42)
complained of vertigo, which was not observed before the GK Radiosurgery. There were
4.76% (2/42) who complained of increased tinnitus after GK Radiosurgery. Also one
(2.3%) patient complained of a permanent holocraneal headache after one week of GK
Radiosurgery and later presented with atrophy of the cerebellar hemisphere in the revised
MRI. In addition to the main complications, all the above-mentioned patients presented
with headaches in varying intensities.
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Follow up4.6
As we mentioned before, after diagnosis and initial treatment, patients were under follow-
up control. The first follow-up review after diagnosis, or baseline, was in six months and
then one year, then three years and finally, five years, according to the follow-up stages. In
our surveillance, we analyzed the data of patients for each stage of follow-up. In the last
follow-up year, there were 6 (5.6%) patients who were lost before follow up. Including one
patient from the neurosurgery group who died because of postoperative complications and
severe postoperative infection. Two (1.8%) patients were lost before follow-up due to
being in advanced age and 3 (2.8%) patients were relatively recently diagnosed and did not
present data for the fifth year.
The overall average follow-up time for the three groups was 56.52 ±10.79 (Range 25.02-
71.74) months. In Table 38, the follow-up times for each group are presented separately.
Treatment groups Mean (±SD) 95% CI Range
Lower
Bound
Upper
Bound
Wait-and-watch 55,30 ±11,92 52,39 58,20 46,19
GK Radiosurgery 58,60 ±9,22 54,95 62,25 35,57
Neurosurgery 58,70 ±5,7 55,06 62,34 18,64
Total 56,52 ±10,79 54,21 58,56 46,72
Table 18. Duration of overall follow up times in different treatment groups
Our photos show the initial diagnostic tests and establishing of a diagnosis of a VS.
Usually, within the first 6 months, patients receive planned treatment and would be under
post-treatment follow-up. But sometimes, for example, after one year of being under the
wait-and-watch strategy, due to other factors (enlargement of the tumor, worsening of the
clinical picture or a patient's desire) the initial treatment (wait-and-watch) is changed to
radiosurgery, conventional surgery and/or from radiosurgery to conventional neurosurgery.
The majority of these cases in our study are considered as a risk group. Therefore, we
focused on the interval between diagnosis and treatment.
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During the five years of follow-up there were 20 (18.86%) out 106 (100.0%) patients who
had more than a six months interval from diagnosis to treatment (average 27.32 ±17.48
(Range 10.85-69.90) months) and we found changes from initial treatment. The average
age of patients in this group was 54.61 ±13.27 (Range 39.05-74.20) including 8 (40.0%)
female patients and 11 (55.0%) male patients.
The 12 (60.0%) out of 20 (100.0%) patients changed their treatment options because of
tumor enlargement and worsening of the clinical picture. Among them, the five (25.0%)
patients passed from wait-and-watch to conventional surgery and 8 (40.0%) patients passed
from wait-and-watch to GK radiosurgery. The five (25.0%) patients passed from wait-and-
watch to radiosurgery because of worsening of the clinical picture while the size of the VS
was steady. Three (15.0%) patients remained within the first and third years of follow up
and changed their treatment options by their own desires while having stable clinical
pictures and tumor size in the follow-up frame. The dynamics of follow-up of the above-
mentioned 20 patients is presented in Figure 58.
____________________________________________________________
0 1 year 3 years 5 years
Wait-and-watch Radiosuregry Neurosurgery
As we can see in the above figure, there is one (0.94%) patient within the first year from
the radiosurgery group and passed on to the neurosurgery group. This patient was a 48 year
old male with the initial size of his VS being 34mm, PTA was 75dB along with having
tinnitus and the absence of an ABR response to click stimuli. In the beginning, he was
under wait-and-watch control, but within the first year, he presented with tumor growth
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Figure 58. The dynamics of follow up of 106 VS patients
Results
180
(+35, 5mm), with a stable initial clinical picture and he was directed to conventional
neurosurgery. The conventional neurosurgery was complicated with a CSF leak, facial
palsy and complete hearing loss on the lesion side. In the postoperative review (third and
sixth months), the clinical picture was stable and in MRI there was a 3mm mass
compatible with a postoperative scar. However, after one year of postoperative review, the
patient complained of the worsening of his tinnitus and presented vestibular symptoms. In
the MRI, we detected the tumor growth, which measured 16mm, and the patient was
directed to GK radiosurgery. In the last two years of post-radiosurgery follow-up, the VS
remained steady (16mm) and the patient still occasionally feels the vestibular symptoms
along with tinnitus.
As we mentioned before, due to the above-mentioned changes in each follow-up stages, we
had a different number of patients in treatment groups; therefore, statistically, in addition
to the final treatment approach (As-treated), we have also used the initial treatment
approach (intention-to-treat), which allowed us to catch the risk groups.
We have exclusively compared the wait-and-watch and radiosurgery groups.
During the overall follow up period, there are a total of 42 (39.6%) patients who underwent
GK Radiosurgery (“As-treated”analysis). After one month, all of them were reviewed in
the Outpatient Unit of the Otolaryngology Department of CHUS. Among them there were
27 (64.2%) patients who do not show any complications related with GK Radiosurgery;
however, there were 15 (35.7%) patients who presented with either type of complication.
Among them, one (2.3%) had facial palsy, five (11.9%) had facial paresis, two (4.7)
experienced deafness, three (4.7%) had hearing loss (worsening of hearing more than 15
dB), four (9.5%) had tinnitus, two (4.7) experienced vertigo, and one (2.3%) patient
presented with atrophic changes of the cerebellar hemisphere.
Size of the tumor4.6.1
4.6.1.1 Watch-and-wait group
The mean tumor size at presentation in the wait-and-watch group was 12.68 ±6.76mm.
Among the 67 who had a VS, 11.9 (8/67) patients exhibited shrinkage, 58.2% (39/67) were
stable, with no growth over the follow-up course, and 28.3% (19/67) of the VSs grew.
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Among the 19 growing tumors, there were 13 (68.4%) males and 6 (31.57%) females and
the average growth rate was 0.51mm per year.
The overall VS growth rate for the wait-and-watch group was 0.12mm per year (range 0-
3). Among the patients with a tumor growth, there were 7.46% (5/67) of patients who
eventually went to conventional neurosurgery, 17.9% (12/67) went to GK radiosurgery and
one patient, due to minimal growth, preferred to remain under the wait-and-watch control.
The size of the VS measured in each follow-up period and the initial overall average sizes
of the VS in each follow-up period is presented in Table 31.
Follow up time n Average size of
VS ±
95% CI
Lower Bound Upper Bound
Initial 67 12,68 ±6,76 10,87 14,37
6 months 67 13,20 ±7,79 11,16 15,23
1 year 67 12,80 ±6,72 11,01 14,49
3 year 67 12,33 ±6,08 10,64 13,74
5 year 62 12,12 ±6,13 10,55 13,69
Table 19. The variation of tumor size of VS in a group of patients under wait-and-watch control
As we see from the above table, the average size of the VS slightly differs over the follow-
up years. The changes are especially more pronounced in the sixth month follow-up after
initial diagnosis, which in our case, corresponds to the treatment stage. However, with a
Repeated Measures ANOVA with a Greenhouse-Geisser (p=0.52) and Huynh and Feld
(p=0.52) correction, shows no difference was found between each measure (F=0.67). Even
with the Bonferroni, the multiple comparisons were not significant between the average
VS sizes. The difference between the means and the medians can be seen in the following
box plot illustration (e.g. see fig. 59).
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Figure 59. The evolution of VS size over the follow-up stages in a group of patients under the wait-and-
watch control
The box plot shows the third year follow-up results of the size of the tumor going down,
and in the fifth year, the average size of the VS became smaller than at initial examination.
There are some scattered cases in the wait-and-watch group as seen in the box plot.
4.6.1.2 Radiosurgery group
In the GK radiosurgery group, 66.0% (14/21) (“Intention-to-treat”statistical approach) of
the patients exhibited a VS shrinkage, 33.0% (7/21) were stable and 4.76% (1/21) of the
patients presented with growth of the VS even after GK radiosurgery. The overall average
size of the VS and its relative changes is presented in Table 32.
Follow up time n Average size of
VS ±
95% CI
Lower Bound Upper Bound
Initial 67 16,13 ±7,56 13,14 19,12
6 months 67 15,81 ±7,82 12,72 18,90
1 year 67 15,74 ±8,05 12,55 18,92
3 year 67 14,46 ±7,43 11,52 17,40
5 year 62 14,05 ±7,41 11,12 16,98
Table 20. The average size of the tumor over follow up years in a group of patients under radiosurgery
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A Repeated Measures ANOVA with a Greenhouse-Geisser (p=0.05) and Huynh and Feld
(p=0.05) correction determined that the overall average size of the VS differed statistically
significantly between time points (F=7,316). The graphical illustration of difference
between the averages of a VS in each follow up stage can be seen (e.g. see fig. 60).
Figure 60. Chart showing variations in tumor size in the follow-up years in a group of patients under GK
radiosurgery
From the figure above, we can observe that starting from the third year, there is a visible
change in tumor size. Therefore, as repeated measures ANOVA with a Greenhouse-
Geisser and Huynh and Feld was significant, we have performed another test (Bonferroni
post-hoc test) in order to know where exactly those differences occurred. In the Bonferroni
post-hoc test, we found it to be significant in the levels of baseline and the fifth year
(p=0.034), and between the second and fifth years (p=0.05) of follow up.
4.6.1.3 Statistical difference in size of tumor in radiosurgery and the wait-and-
watch group
The comparative study of tumor sizes between the wait-and-watch and radiosurgery groups
show that the course of tumor size in the two groups is different. The comparative
graphical illustration of VS sizes in the two groups presented (e.g. see fig. 61).
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Figure 61. Chart showing variations in tumor size over the follow-up years in the wait-and-watch and
radiosurgery groups
As we see from above-stated graphical illustration, the initial thick projection line between
the initial diagnosis and sixth months in both groups indicates the tumor evolution. In the
wait-and-watch cases, the tumor slightly enlarges, while in the GK radiosurgery group, the
tumor undergoes shrinkage. After one year, unlike the wait-and-watch group, in the
radiosurgery group, the shrinkage of the VSs was more pronounced. The shrinkage could
reflect the results of the applied Gamma radiation to the tumor tissue. On other hand, in
wait-and-watch group, the curve line descends, which means that during the initial periods,
some patients passed into the radiosurgery and/or neurosurgery groups due to tumor
growth.
Auditory function (PTA)4.6.2
4.6.2.1 Haring results in the wait-and-watch group
In the group of patients under the wait-and-watch control, the initial PTA average was
57.30 ±28.53. At the diagnostic stage, there were 32 out of 67 patients who presented the
overall average PTA ≤ 50dB, in six-months, one-year, three and five-years and the
information was retained 100.0%, 75.0%, 59.3% and 59.3% respectively.
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The overall average PTA in the follow up periods are presented in the following table (e.g.
see table 33):
Follow up time Average PTA ± 95% CI
Lower Bound Upper Bound
Initial 57,30 ±28,53 50,34 64,26
6 months 59,17 ±28,21 52,29 66,06
1 year 61,91 ±28,50 54,96 68,86
3 year 68,41 ±31,19 60,80 76,02
5 year 71,38 ±30,31 62,45 77,98
Table 21. Variations in the overall average PTA in the follow-up years of the wait-and-watch group
(Intention-to-treat cohort)
A repeated measures ANOVA with a Greenhouse-Geisser correction determined that the
mean PTA differed statistically significantly between time points (F = 21.96. P < 0.001).
The changes in PTA are illustrated with lines (e.g. see fig. 62).
Figure 62. A chart showing the evolution of the PTA overall average in the follow-up years of patients under
the wait-and-watch control group
Post hoc tests using the Bonferroni correction revealed that the mean PTA from the initial
diagnosis to after one year of follow up (57.30 ±28.53dB vs. 59.17 ±28.21dB,
respectively), was slightly different, but not statistically significant p = 0.061. However,
time points between the initial exam presenting a VS and all other (six months, one year,
three years and five years) time points was statistically and significantly different
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(p <0.001). The difference between the second time point (6 months) and all other time
points was statistically and significantly different (p <0.015). We did not find significant
associations in terms of audiometric configurations of the initial exam and other follow-up
points.
4.6.2.2 Hearing results in GK Radiosurgery group
The overall average initial PTA for the radiosurgery group was 59.80 ±26.86. After each
year, the hearing loss gradually increased. At the diagnostic stage, there are 20 out of 42
patients who presented the overall average PTA ≤ 50dB (useful hearing), after six months,
one year, three years and five years, the average was 75.0%, 60.0%, 50.0% and 35.0%,
respectively (As-treated cohort). Also, in the diagnostic stage, there were 30.9% (13/42) of
patients with flat/pantonal audiometric configuration, but at the end of the last follow-up
study, there were 50.0% (21/42) versus patients who presented flat audiometric
configurations p<0.0001(t-test). The comparative analyzes of the average in the follow-up
years is presented in the following Table 34.
Follow up time n Average PTA ± 95% CI
Lower Bound Upper Bound
Initial 27 59.80 ±26.86 49.18 70.43
6 months 27 69.18 ±26.28 58.78 79.58
1 year 27 74.71 ±24.42 86.04 84.37
3 year 27 78.96 ±24.95 69.09 88.83
5 year 27 81.58 ±23.66 72.22 90.94
Table 22. Variations of the PTA average over the follow-up years in a group of patients under GKR
As we see from table above, the average PTA in the GK Radiosurgery group over the
follow up times changes in a more pronounced way.
The graphical illustration of the overall average PTA can be seen (e.g. see fig. 13).
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Figure 63. The evolution of a PTA overall average in the follow-up years of patients who underwent GK
Radiosurgery
Figure 13 shows that the mean value of the PTA changes in each observation period.
Repeated Measures ANOVA detected that in six months after initial diagnosis, there is no
significant (p=0.19) change in the average PTA, but following after one year, the
difference of the PTA between the initial diagnosis was significant (p=0.013). In the same
way, in the third and fifth years after initial diagnosis, the hearing deterioration was more
expressed and the difference between each follow-up stage was statistically and
significantly different (p<0.001). Also the Bonferroni multiple comparison revealed that
there are more statistically and significantly differences between other follow-up levels,
including the six months versus the fifth year p< 0.000 and the third year versus the fifth
year p= 0.038.
4.6.2.3 Association of auditory functions in the radiosurgery and follow-up group.
Over the years, in both groups, the overall average PTA for each patient all that increases,
but the intensity of the increase in both groups are different.
We found that the PTA, at the initial point in both groups, does not differ significantly (p=
0.21). However, if we compare both groups in each of the follow-up levels, we can see
minimal differences between the mean PTA of two groups. For instance, the difference in
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the initial diagnosis and the six months time points is clear and this difference is
statistically and significantly different p=0.005 (Repeated Measures ANOVA). Following
difference between the initial point and one year is also statistically and significantly
different p=0.002 (Table 35).
Follow up
periods
PTA (dB)
Wait-and-watch Radiosurgery Difference
Initial 57,307 59,807 -2,5
6 months 59,179 69,185 -10,006
1 year 61,914 74,713 -12,79
3 years 68,414 78,963 -10,54
5 years 71,38 81,583 -10,20
Table 23. The rate of changes of the average PTA and/or hearing deterioration over the follow-up years in
the wait-and-watch and radiosurgery groups
According to multivariate test (Repeated Measures ANOVA), the PTA is statistically and
significantly different between the subjects in the two groups (Sphericity Assumed)
p=0.028. The level at which the differences are located between groups can be seen (e.g.
see fig. 13).
Figure 64. Image of the comparison of the mean PTA over the follow-up years between the patients under
the wait-and-watch and radiosurgery groups
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The plotted graph above shows the two groups after the initial diagnosis and shows the
lines being directed far apart. The test indicated that there is a significant time effect. In
other words, the wait-and-watch and radiosurgery groups do change over time. Both
groups increase over time, but the radiosurgery group shows a greater increase in the mean
PTA over time. Moreover, the interaction of time and group is significant, because the
groups do not have parallel lines that increase over the time periods. However, the lines are
more or less stable after the fourth and fifth years. Seemingly, the GK Radiosurgery does
negatively affect hearing. If we compare the mean PTA of groups at the initial time point
(Repeated Measures Contrast –Simple Comparison) and following each time point, we
can see the difference between the means to be only borderline (p=0.07), but not
statistically significantly (p>0.05) different (Bonferroni multiple comparison).
The difference in hearing preservation over the follow-up periods between the wait-and-
watch and GK radiosurgery groups is presented in the following table below:
Intention-to-treat cohort n
Patients with PTA≤50dB
Baseline 6M 1Y 3Y 5Y
Wait-and-watch 67 32 (100%) 32 (100%) 24 (75%) 19 (59,3%) 19 59,3%)
Radiosurgery 21 13 (100%) 8 (61,5%) 7 (53,8%) 6 (46,1%) 3 (39,0%)
As-treated cohort n Baseline 6M 1Y 3Y 5Y
Wait-and-watch 48 24 (100%) 22 (91,6%) 20 (83,3%) 17 (70,8%) 15 62,1%)
Radiosurgery 42 20 (100%) 15 (75%) 12 (60%) 10 (50%) 7 (35%)
Table 24. Outcome results of useful hearing preservation for “Intention-to-treat”and “As-treated cohort”
From the table above, we can see that the rate of useful hearing in the cases of the GK
radiosurgery group is affected more than the group of patients under the wait-and-watch
control. However, in general, the statistical differences between the overall average PTA in
the initial and last follow-up points of both groups are statistically significantly different
p<0.001(two tailed t-test).
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4.6.2.4 Hearing deterioration and tumor growth
In the period of follow-up, we have revealed that the rate of tumor growth and hearing
deterioration both in the wait-and-watch and GK radiosurgery groups were different. In the
cases of the wait-and-watch group, the overall mean hearing loss for all follow-up years is
7.93dB, but in the cases of the GK radiosurgery group it is 15.1dB. Nevertheless, this
difference is statistically not significant (p=0.070). The differences could be due to the
following factors: the first important factor is the difference in group size, but there are
also large differences in the standard deviations between the two groups, especially in the
last few time points. That could be minimizing the differences in the means. Also the wait-
and-watch group is becoming more variable as time progresses while the GK radiosurgery
group becoming less variable. Table 37 shows the average hearing loss and tumor growth
in two treatment groups and compares the outcome results for “Intention-to-treat”and “As-
treated”statistical approaches.
Intention-to-treat cohort Mean ±
Baseline 6M 1Y 3Y 5Y
PTA (dB) Wait-and-watch 57,30
±28,53
59,17
±28,21
61,91
±28,50
68,41
±31,19
71,38
±30,31
Radiosurgery 59,80
±26,86
69,18
±26,28
74,71
±24,42
78,96
±24,95
81,58
±23,66
Size of the VS
(mm)
Wait-and-watch 12,68
±6,76
13,20
±7,79
12,80
±6,72
12,33
±6,06
12,12
±6,13
Radiosurgery 16,13
±7,56
15,81
±7,82
15,74
±8,05
14,46
±7,43
14,05
±7,41
As-treated cohort
PTA (dB) Wait-and-watch 57,70
±27,85
59,43
±27,15
61,55
±27,69
64,86
±28,85
64,55
±26,26
Radiosurgery 55,82
±25,34
62,94
±26,39
68,04
±25,73
74,33
±27,73
78,44
±27,41
Size of the VS
(mm)
Wait-and-watch 11,25
±5,23
11,35
±5,09
11,39
±5,08
11,55
±5,10
11,24
±4,81
Radiosurgery 15,72
±7,23
15,71
±7,26
16,0
±7,59
15,45
±6,9
15,14
±7,09
Table 25. Outcome results of PTA and Size of the VS for “Intention-to-treat”and “As-treated cohort”
As we see from table above, both statistical approaches show that the mean size of the VS
tumor in both groups undergoes shrinkage. In the cases of the “Intention-to-treat”
approach, patients are expected to remain in the same group regardless of applied
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treatment, and on the other hand, the tumor shrinks as a result of applied treatment.
Similarly, for patients in the “As-treated”approach, the mean size of the tumor shrinks
over the follow-up points as an effect of applied treatment. Observing the patients under
the wait-and-watch and GK radiosurgery groups via the “Intention-to-treat” statistical
approach and the interval of time between diagnosis and treatment, enabled us to reveal the
risk group. Detecting the risk group is also important for the estimation of the two
treatment options. Figure 14 illustrates the rate of “survival”for “wait-and-watch”group.
Figure 65. The survival rate of the wait-and-watch approach (Kaplan-Meir)
As we mentioned before, during the five years of follow up there are 20 (29.8%) out of 94
(100.0%) patients had more than a six month interval from diagnosis to treatment (average
27.32 ±17.48 (Range 10.85-69.90) months) and we found the tumors were changed from
the time of initial treatment. The average age of these patients was 54.61 ±13.27 (Range
39.05-74.20) including eight (40.0%) female patients and eleven (55.0%) male patients.
The overall difference in the tumor size between the initial and last follow-up exam was
2.95 ±1.68 (range 1-6mm), with the average growth between each follow-up period being
0.98 ±0.57mm. The average hearing loss between the initial exam and the last follow-up
exam was 7.05 ±39.11 (range 0-110)dB. The 45.0% (9/20) of patients in this group initially
presented with useful hearing (PTA≥50), after one year the number of those who could
hear dropped to 6 (30.0%). After five years, 5 (25.0%) of them retained useful hearing.
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According to the ANOVA paired t-test, there are significant differences between the initial
PTA and the PTA after one year (p<0.001), and between the initial size of the tumor and
after one year p=0.001. The 17 (85.0%) patients initially had an abnormal ABR and absent
DPOAE responses.
Results of exploration of VS patient due to NF24.7
As we stated before, we had one male patient with a bilateral VS which has been
diagnosed in November 2005 at the age of 36.
The primary symptoms of this patient were hearing loss, tinnitus, imbalance and
holocraneal headaches. The audiometry at diagnosis showed SNHL in the right ear (PTA
51,25) and complete hearing loss in the left ear (PTA 120dB). The MRI shoved multiple
intracranial meningiomas and pure extracanalicular VSs in both ears with the maximal size
of 11mm in the right and 20mm in the left side. In February 2006, the patient underwent a
bilateral GK Radiosurgery with a 12Gy single dose, since the VS tumor was steady in size.
However, in the control review performed in June 2010, the patient presented tinnitus and
worsening vestibular symptoms with a long with left peripheral facial palsy. Also the MRI
revealed an enlargement of the VS size towards the internal acoustic canal. Subsequently, a
patient is directed to the Neurosurgery unit. In March 2013, the patient was operated on
with the retrosigmoid approach. In the postoperative review in the ENT department, the
patient presented a left-sided hemiatrophy of the tongue and a left-sided hypoglossal palsy
with a palsy of tensor veli palatine.
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5 Discussion
Population characteristics and epidemiological considerations of VS5.1
Sex distribution5.1.1
According to traditional opinions, VS is more common in females than in males, with the
ratio being around 2:1236 and 1:1.4.237-242 In our series, there is also a slight sex difference
at presentation with 57 (53.8%) females versus 49 (46.2%) males out of 106 VS patients.
But other studies with a larger sample size suggest a slight tendency towards a female bias,
but one study found a less significant bias than that suggested traditionally. In a series of
1000 surgically managed tumors, Samii (Germany, 1997) describes a sex distribution of
54.0% female and 46.0% male patients. Bakkouri (France, 2009) found a 53:47%
Female:Male ratio in conservatively managed patients. Jennifer, et al., (2005) studied the
epidemiology of a VS regarding age, gender, race, year and region and found the incidence
of VSs similar among males and females and higher in whites than in nonwhites.247 In spite
of many authors claiming to have found a slight tendency toward the female bias,
including Gal and his colleagues (USA, 2010), who found the VS tumor to be equally
distributed across gender and tumor laterality.280 But they found a significant tendency
towards having a VS in the Caucasian (84.0%) race.
Age at presentation5.1.2
As stated in the results section, the average age of our patients at presentation was 57.0
(range 24-86). Including the cases of females 57.51 (range 24-86) and in the cases of males
56.21 (range 24-85). Despite the fact that onset in the third decade is rare,236-240 there are
other studies reporting the VS being diagnosed between the ages 30 and 68.246 In our
series, we observed only 4 (3.0%) patients who presented with a VS in their third decade of
age and the majority of patients were distributed over the 5th - 7th decades.
In cases of Jennifer, et al., (2005) the incidence of a VS is lowest among the 0- to 19-year
age group, and highest among the 45- to 64-year age group.247 Gal and his colleagues
(USA, 2010) studied 1,621 VS patients, and in their series, the mean age of patients with a
VS was 51.3 years. The cases of a VS in pediatric patients is rare, and can deform part of
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NF2.236-247 It has been suggested that younger patients may be less sensitive to
cochleovestibular dysfunction because of greater reserves of baseline functions. Some
authors found that younger patients often presented with large tumors but with signs and
symptoms that were less severe than those of older patients.279 Also, the young patients
tolerate more tumor growth because of a greater neurological effect.
Clinical characteristics5.2
Symptoms at presentation5.2.1
In general, the primary signs of a VS can be otologic, vestibular, neurologic and
neurosurgical. The most common presenting otologic symptoms of a VS are considered to
be hearing loss.243-246 In our series, also, there are 68 (64.1%) patients who complained of
hearing loss as a presenting symptom of VS. Most literature reviewed is in agreement that
tinnitus is the second most common presenting symptom of a VS.240-246 In our series, there
were 24 (22.6%) patients who presented with a VS as a first sign, and 43 (40.5%) patients
who presented with tinnitus and with the other otologic or vestibular symptoms. Although,
all 24 patients presented with tinnitus as a first sign, with a diagnostic PTA, patients
presented with hearing loss in either level. Martin (Birmingham, 2013) has investigated
730 patients with a VS, and among them in 7.0% of the cases, patients were found with
tinnitus as a presenting symptom, and in 58.0% of patients, tinnitus was an accompanying
symptom. In our series, there is only one patient (0.9%) who presented with tinnitus as a
sole-reported complaint. Bakkouri (France, 2009) found that 4.0% of the patients with a
VS showed the symptom of tinnitus alone.
Side of lesion5.2.2
According to reviewed literature, in more than 90.0% of cases, the tumor is unilateral,
affecting the right and the left sides with equal frequency.248-249 In our series, a total of 55
(51.9%) patients presented with a right-sided VS and 51 (48.1%) patients presented with a
left-sided VS. We did not find a statistical correlation in terms of frequency of affection in
the right or the left ear. Edwards CG, et al., investigated 160 patients with a VS and in their
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their series, VS tumor location was more commonly on the right side (59 percent), more so
than on the left side (41 percent).250 A couple of other authors (Christensen, et al., 2004
and Takebayashi T., et al., 2006) also conducted research about the prevalence of a VS in
the right or left ear in long-time mobile phone users, and they didn’t find any significant
difference in either the right or the left side.251-252
Localization of VS5.2.3
The location of a VS is usually reflected in the clinical picture; therefore, there is always a
clinical, scientific and statistical interest associated with the localization of a VS. In our
series, we have found an intracanalicular VS in the cases of 41 (38.7%) patients. We found
40 (37.7%) intra-extracanalicular tumors, and 25 (23.6) extracanalicular VSs in the
patients. From the literature, we found only a few articles describing the rate or percentage
of VS localization. Kwan, et al., (2004) analyzed 54 VS patients, and they found 22
(40.0%) patients with a pure intracanalicular VS and 32 (59.2%) patients with an intra-
extracanalicular VS. They did not find VS cases presenting a pure extracanalicular
localization.253 Also, Haapaniemi (2000) and his colleagues found that 22.0% of the cases
were mainly an intracanalicular tumor and 78.0% of the cases were an extracanalicular
tumor. They did not clarify as to whether the cases were a pure intra- or extracanalicular
localization.254 Godefroy WP (2009), and his colleagues, conservatively observed 70
patients, and in their cases found 30 (43.0%) intracanalicular tumors and 40 (57.0%)
extrameatal tumors. But they also did not clarify as to whether the VS cases were an intra-
or extracanalicular localization.255
Exploration5.3
Audiometric assessment5.3.1
5.3.1.1 Pure Tone Audiometry
The audiometric assessment of VS patients at diagnostic stage is very important for the
further management in follow up stages. In our series at diagnostic stage there are
96(90,5%)patients presented hearing loss with the overall average PTA 58,8dB. Among
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them there were 51(53,1%) females with the mean PTA of 64,93dB and 45(46,8%) males
with mean PTA of 60,96dB. We didn’t find any association between PTA and gender of
patients. Hajioff (Canada, 2007) and his colleagues observed 72 cases of VS with the
duration of 10 years, and their series the baseline average overall PTA was 43.8 ± 17.5 and
they didn’t mention about age or gender prevalence, but they found prevalence regarding
the localization of VS.257 Hajioff described the average overall PTA for wait-and-watch
groups only. Woodson and his colleagues (USA, 2010) studied pre and post-treatment PTA
(500, 1,000, 2,000, and 3,000 Hz pure-tone thresholds) of 156 VS patients and in their
series the mean pretreatment PTA was 29 ± 13 dB259. But their baseline average overall
PTA much more differs than ours. In the literatures there are few articles describing
baseline average overall PTA for all VS patients before dividing them to treatment groups.
Walsh and his colleagues (Canada, 2000) retrospectively observed 72 VS patients and in
their cohort the baseline PTA was 49.4 dB258 which is also close to our baseline findings.
5.3.1.2 Audiometric configuration
Several authors described and classified the configuration of the pure tone audiogram in
their studies of VS, but very few authors described the prevalence of a VS associated with
each type of configuration.260-261 In our series, at the diagnostic stage, there are 63.5% of
patients who showed SNHL with a slopping audiometric configuration. The following
audiometric configurations were registered: 5.0% rising, 25.0% flat or pantonal and 9.3%
of cases of other (U-shaped/Basin-shaped, mountain-shaped etc.) audiometric
configurations. In the follow-up stage, the radiosurgery group presented interesting results
regarding the audiometric shape. Suzuki and his colleagues (Japan, 2010) performed a
retrospective study of 500 patients with asymmetric SNHL, and among them, they found 2.6%
(13/500) of patients with a VS.261 According to them, the pure tone audiogram configuration
associated with the highest prevalence of VS was the basin-shaped (“U”shapes) loss,
followed by a flat loss, total deafness, high-frequency sloping, and lastly, a high-frequency
steep. They suppose that compression neuropathy or a conduction block of the cochlear
nerve leads to a basin-shaped hearing loss.262 Although the main limitation of their work
was a small sample size, which made their work statistically insignificant.
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5.3.1.3 Auditory Brainstem Responses (ABR)
As mentioned before, in our series, we had 43 (40.5%) cases with an available ABR test
performed at the time of diagnosis. Among the 43 patients, we found 36 (83.7%) cases
with a pathologic ABR, and in 7 (16.2%) patients, the ABR results were completely
normal, regardless of whether the patient had a hearing loss and VS. In our series, we
found IA5 to be more sensitive for a VS.
There are enough controversial articles in the literature regarding the diagnostic value of
ABR for a VS. Some authors consider that there is no place for an ABR in the modern
management of a VS263-264 . Some studies, with large sample sizes, show credible
information about the utility of ABR testing..
Koors and his colleagues (2013) studied the role of ABR testing in the diagnosis of VS
patients.263 They analyzed 43 publications (1978-2009) which included 3,314 patients.
According to their results, the pooled sensitivity for ABR detection of vestibular
schwannomas was 93.4% (95% CI 92.6–94.3, P = 0.0000). For tumors that were less than
1 cm, sensitivity was 85.8%. For tumors greater than 1 cm, the pooled sensitivity was
95.6%. Unlike our results, the sensitivity of the ABR to detect extracanalicular tumors was
higher than that for detecting intracanalicular tumors, but according to the authors, their
pooled data was not statistically valid263.
Chien Shih and her colleagues (2009) described 30 cases of a VS with the average tumor
size of 2.48 ±1.31 cm. In their series they found 100% sensitivity of ABR265 which seemed
to us a little bit unreliable. Although, they believe the main limitations of their study are
that it was retrospective and included a relatively small number of patients.
5.3.1.4 Otoacoustic Emissions
In spite of hearing loss in a VS, it is an example of a retro-cochlear SNHL. The OAEs
could seem rather useless and not significant in an attempt to compare a VS with OAEs,
which conversely represent an investigative tool of the cochlea266.
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In our series, from 28 (26.1%) available reports of DPOAE testing, there are 15 (53.7)
patients who presented with OAE compatible and with hearing function. In the cases of 13
(12.1%) patients, the OAE was absent due to profound hearing loss. We found a
relationship between tumor size and OAE, but due to the small sample size and the
statistical test regarding localization, the size of a VS with OAE was not significant.
Although, apart from the direct compressive effect of a VS tumor to the hearing nerves,
there are many factors which interfere with the results of an OAE267. The VS tumor,
although located outside the cochlea, may influence hair cell activity in a more or less
significant measure; consequently, hearing loss induced by a VS will be somewhat
influenced by cochlear function266-267.
Ferri GG and his colleagues (Italy, 2009) studied the cochlear function in 183 patients with
a unilateral VS266. They also recorded OAE by means of DPOAE. In their series, with an
OAE present, the absent ratio was 80.9%:25.1%. Interestingly, they divided abnormal
OAE into two patterns, cochlear and retro-cochlear patterns. According to authors, SNHL,
due to a VS, can be of sensory and/or neural origin and they recommend DPOAEs as a
complementary auditory test. Kagoya and his colleagues (Japan, 2013) studied cochlear
function in 196 patients with a VS by DPOAEs268. They found DPOAEs to be predictive of
a cochlear schwannoma, with a 75.0% sensitivity and an 87.0% specificity. Retro-cochlear
hearing loss was detected in 5 patients and it was also predictive of a cochlear
schwannoma which showed a 25.0% sensitivity and a 97.4% specificity.
Vestibular Testing5.3.2
5.3.2.1 Craneocorpography
As we know the VS by its localization and nature may cause peripheral as well as central
vestibular symptoms. But almost always the central vestibular compensation almost always
takes place by means of neuronal plasticity mainly within the region of the vestibular
nuclei and also in the brain stem vestibular commissures.269
Our group, as mentioned before, has found 69 (65.0%) available CCG tests with a
difference in the results of the male and female patients, and it is as follows: There were 29
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(39.7%) male patients and 39 (57.3%) female patients. The average overall PTA was 55.04
±24.24 (Range 12.5-117.5) and the average overall size of the VS was 16.98 ±10.18
(Range 2-50mm). Patients with a CCG Type IV, corresponding to a VS, presented a
relatively larger tumor size (22 ±12.14) than those patients who presented a CCG Type I
(16.55 ±11.24), corresponding to a normal CCG.
There are only a few publications devoted to the role of CCG in the diagnosis of a VS.
Gomez and his colleagues (Spain 2000) studied the CCG in 21 VS patients, but the study
was performed in post-operative VS patients, which has not presented much diagnostic
value.269
Apart from Gomez, in the same way Claussen (by whom the CCG initially was described)
and his colleagues (Germany, 1989) also studied 20 post-operative VS patients270. They
concluded that, like other vestibular tests, the CCG in addition does not cover the whole
range of vestibular pathologies270-271. Due to their different locations in the IAC, the
superior and inferior vestibular nerves and the cochlear nerves all may give rise to various
symptoms270. Moreover, it is clear that the CCG would not be helpful in cases where a VS
is attached to the cochlear nerve or in cases where the vestibular lesion has been
compensated by the higher centers.
5.3.2.2 Computerized Dynamic Posturography
Although, the CDP does not provide localizing or lateralizing information, it does provide
functional information regarding how well VS patients can use their balance and an
indication of the importance of a patient's entire balance disturbance. CDP may be helpful
in the decision making process for choosing the appropriate type of management.
The 60 (56.6%) patients, who were analyzed in regard to balance in different conditions of
SOT, show that 38 (63.3%) had normal overall balance, and in the case of 22 (36.6%)
patients, the overall balance was pathologic. Following, we noticed Conditions 5 and 6 of
SOT. There were 26 (43.3%) patients who presented with normal results and 32 (53.3%)
patients who presented pathologic results. In the cases with Condition 6, there were 32
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(55.0%) normal results and 27 (45.0%) patients who presented with pathologic results. We
also performed a comparative analysis between the genders and found a significant
difference in Condition 6 (p= 0.005), VEST (p= 0.93), and in the overall balance (p= 0.19).
Gouveris and his colleagues (Germany, 2007) studied CDP in 216 VS patients with the
mean age of 54 years. According to their results, they found a significant difference in the
distribution of Condition 5 and 6 between VS patients with and without vestibular
symptoms272.
In our case, we did not find a clear correlation in the results of a CDP among patients with
and without vestibular symptoms. Nevertheless, in our series, we have found a significant
difference in Condition 6 between males and females among the VS patients. Authors
concluded, although patients with symptoms present a lower Condition 5 and 6 than
patients without symptoms, the results are not sufficient for reliable discrimination for all
patients272.
5.3.2.3 Caloric Testing
According to the medical literature reviewed for our work, we assumed that caloric tests
are frequently altered ones, showing vestibular hyporreflexia or arreflexia273.
In our group, we found 67 (63.2%) available caloric tests. Among the patients, there were
36 (53.71%) females with the mean age of 56.91 (Range 24.16-58.55) and 31 (46.2%)
males with the mean age of 57.82 (Range 29.03-81.33) years.
We found 37 (55.2%) pathologic and 30 (44.8%) normal bithermal caloric responses. The
overall percentage of normal:pathologic ratio was 44.8:55.2 with the higher number of
patients being predominately female (63.8%) over males (46.4%). In the female group, the
average overall PTA (61.79 ±30.69) was slightly higher than those in males (58.64
±28.39), but in the other hand, males presented a little bit higher overall size of a VS
(16.60 ±8.46) than females (14.82 ±10.36). Nevertheless, we did not find a clear
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correlation or influence of PTA, size and localization of a VS related to the results of
caloric testing.
Diallo and his colleagues (Senegal, 2006) studied the diagnostic value of caloric testing in
100 VS patients. In their series, they found 61.0% normal and 11.0% abnormal caloric
responses. In the cases of 28% of the patients, they could not analyze the caloric
response.274 Some authors believe the caloric tests are the most frequently altered ones
(77.0%) among other vestibular tests showing vestibular hyporreflexia or arreflexia273.
Iwasaki S. and his colleagues (Japan, 2005) performed an interesting study to investigate
clinical features of diseases showing abnormal VEMP responses with normal caloric
test responses. They studied 811 patients with balance problems who had undergone
both caloric response and VEMP testing. In the results, they found 40 (5.0%) (out 811
patients) to have abnormal VEMP responses with normal caloric test responses. Among
these patients there were 8 VS patients275.
An analogic study was conducted by Wang WQ and his colleagues (China, 2000) and they
also aimed at summarizing the outcome of neurootologic examination in the diagnosis of
13 VS patients. In their cases, 5 patients tested normal in the caloric test, but all were
abnormal in the visual-vestibular optokinetic response and in 90.9% of the cases, the ABR
were positive276. Another group of authors from Japan performed caloric testing in 78 VS
patients and in their series the 63 (80.8%) patients showed no caloric responses and the
remaining 15 (19.2%) patients showed normal caloric responses277. So far, there is no fully
comprehensive vestibular or audiologic test meeting the current diagnostic interests
of a VS.
5.3.2.4 Vestibular Evoked Myogenic Potentials
We had 21 (19.8%) VEMPs tests available. Including 11 (52.38%) females and 10
(47.61%) males. In 12 (57.14%) patients, the VEMPs were presented on the VS side, and
in cases of nine (42.8%) patients, the VEMPs were absent in the pathologic ear. Among the
patients with absent of VEMPs, there is one (4.7%) patient who showed no click VEMP
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response on the VS side. In the group of patients who presented a response, there were 5
(23.8%) females and 6 males (28.7%). Following in a group of patients with an absence of
VEMPs response, there were 6 (28.5%) females and 4 (19.0%) males. The average AR for
all 12 (57.1%) normal VEMPs stimuli was 33.94 ±24.0% (Range 87-6.2%). In the overall
result there were 6 (28.5%) patients (out of 21) who presented with a normal AR and a
normal VEMP.
Ushio and his colleagues (Japan, 2009) performed a comparative study of VEMPs and
caloric testing in 78 VS patients with the mean age of 50.4 ± 12.8 years. They found an
abnormal click VEMP in 46 (59.0%) patients. In eight (10.3%) cases, they found normal
responses on both sides and the following 24 patients (30.8%) showed a no click-VEMP
response on both sides277. In their series, the speciﬁcity of VEMP was 52.7%. In our series, 
the speciﬁcity of VEMPs was a little bit lower (42.8%) than their series. The main reason 
for the relatively low specificity of VEMPs and caloric testing is explained in many
comparative studies. For instance, unlike auditory brainstem response, which could be
specific for retrocochlear lesions such as a VS, abnormal VEMP and caloric test results are
not specific for retrolabyrinthine lesions277-278.
Imaging test5.3.3
5.3.3.1 MRI
The overall average size of a VS at the diagnostic stage for the 106 patients was 16.08
±9.69 (2-50mm). The males show a little bit bigger overall average size 17.37 ±9.05 of a
VS than females 14.96 ±10.16. Particularly, this difference was more pronounced in
patients ≤40 years (21.7 ±12.21 (6-50mm). Although, due to the difference in sample size,
the realized statistical test (t-Student) didn’t show a significant difference between the two
genders. Although this slight difference was not significant, it has been confirmed by the
other large sample-sized studies. For instance, Harun and his colleagues279 (USA, 2012)
performed a retrospective study in 1,296 patients diagnosed with a unilateral VS. In their
study, the male subjects had significantly larger tumors than female subjects at
presentation (18.23 versus 16.81mm, p = 0.031); interestingly, in their cases, this
difference was also particularly pronounced in patients younger than 40 years.
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With respect to age, we found that increasing age was negatively correlated with tumor
size and positively correlated with hearing loss, but did not predict the presence of
dizziness.
In our series, we found a difference between tumor localization and PTA. The overall
average PTA in intracanalicular localization was (48.87 ±25.47) different than both an
extracanalicular and an intra-extracanalicular localization.
Unlike our studies, Massick and his colleagues (USA, 2000) studied the influence of VS
size and location to the hearing function in the cases of 21 VS patients and they did not
find significant differences in the tumor characteristics and audiometric function281.
Moreover, they conducted their study in VS patients under the wait-and-watch policy.
The larger the sample size, the more likely the findings will be significant; therefore,
taking into account their small sample size perhaps we may not be able to precisely
estimate their results. In the literature, we did not find any article discussing the tumor
characteristics in a VS patient before applying either type of modern management.
Treatment5.4
After establishment of a VS diagnosis, patients have had several options for managing their
tumor. The most popular types of treatment modalities include the wait-and-watch or
conservative management, Gamma Knife Radiosurgery and Conventional Neurosurgery.
During the last few decades, the election of treatment modality by the patient is gaining
more popularity. But in some other cases, unfortunately, evidence suggests that a predictor
of treatment choice is the discipline of the attending physician283. This may be attributed
partly to the limited evidence-based guidelines for treating a VS282. In our series, applied
treatment modality, as usual, depended on the following conditions: tumor size, associated
symptoms and signs, patient age, patient health, and patient preference.
.
As we mentioned before, our cohort included the 67 (63.2%) patients under the wait-and-
watch scan. Of the 67 patients, there were 36 (53.2%) females and 31 (46.3%) males. The
average age of the patients in this group were 59.21 ±14.35 (Range 24-85), the average
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size of the VS was 12.68 ±6.76 (Range 2-35) and the overall average PTA was 57.30 ±28.5
(12.50-120).
In the Radiosurgery group, there were 27 (25.5%) patients who were directed to GK
Radiosurgery. Among them, there were 15 (55.67%) females and 12 (44.4%) males. The
average age of patients in this group was 56.82 ±14.30 (Range 24.75-78.48). In following
the results of the overall average PTA in the radiosurgery group, we found that they did not
differ significantly from the wait-and-watch group. The averages were 56.31 ±29.16 (3.75-
120)dB, but the overall average sizes of the VS slightly differs (15.72 ±7.19 (Range 2-
30mm). Following, the ratio of the intracanalicular, extracanalicular and intra-
extracanalicular VS was 26.1%:30.95%:44.85% respectively.
In the group of patients under conventional neurosurgery initially, there were 12 (11.32%)
patients, including 6 (50%) females and 6 (50%) males. The average age of patients in this
group were 43.78 ±9.28 (Range 29.16 –57.85) years, which was younger than both of the
above-mentioned treatment groups. The overall average size of the tumor in this group
(30.04 ±11.37mm and PTA 66.40 ±35.84dB) was significantly higher than that of both of
the above-mentioned groups.
Since the era of both Cushing and Dandy in the early 20th century, almost all patients with
a newly diagnosed VS have undergone attempts at surgical removal of their tumors.
Although outcomes in the era of microsurgery greatly improved the quality of life of
patients after surgery, the earlier diagnosis of these tumors prompted a comprehensive
evaluation of less invasive management strategies284. But there are still evidences of
serious perioperative, postoperative and long term complications of VS microsurgery.
Sarna and his colleagues (Italy, 2004) performed a retrospective study of 707 VS patients
and made a review of the complications other than those related to the facial nerve and
hearing, encountered in vestibular schwannoma surgery285. According to them, the only
preoperative complication in the cases of 707 patients was followings: abdominal
subcutaneous hematoma (site of fat harvest) which occurred in 23 patients (3.2%).
Cerebrospinal fluid leak was present in 20 patients (2.8%), 15 of whom needed revision
surgery. Other complications included VI cranial nerve dysfunction in 12 cases (1.68%),
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subdural hematoma in 3 cases (0.4%), CPA hematoma in 4 cases (0.6%), cerebellar edema
in 2 cases (0.28%), brainstem hematoma in 1 case (0.14%), transitory aphasia in 1 case
(0.14%), and lower cranial nerve dysfunction in 1 case (0.14%). Even mortality occurred
in one case (0.14%).
Follow up5.5
In the last decade due to no clinical parameters identified to correlate with VS growth the
growth of a VS is objectified by performing a consecutive MRI286. Therefore, the wait-
and-watch policy has gained popularity as an alternative or prelude to conventional
neurosurgery and radiosurgery. This can be justified, as growth is known to be extremely
variable with most VS remaining stable or showing minimal growth for many years.
As we mentioned before, in follow-up, our main focus was on the wait-and-watch and
radiosurgery patients. The overall average follow-up for the wait-and-watch group was
55.30 ±11.92 (Range 25.02-71.21) months, and for GK Radiosurgery it was 58.80 ±9.22
(36.16-71.74).
The most reviewed literature to current work255,257-258,281,287-289 described follow up study of
VS with conservative approach has an average 52,68 ±13,82 (Range 43,2-80) months
follow up times and their average number of patients in both groups included in the study
was 79,28 ±87,64 (Range 21-273). The majority of the above-mentioned authors in either
stage of follow-up faced the problem of lost cases255, 257-258,281, 288.
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Auditory function5.5.1
5.5.1.1 Wait-and-Watch group
In the literature there are only a few publications regarding hearing loss or audiovestibular
symptoms after wait-and-watch management of VSs255. The initial overall average PTA in
our wait-and-watch group was 57.30 ±28.53dB, and the initial number of patients was 30
(44.77%) out of 67 patients with useful hearing (PTA≤ 50 dB). In the first 6 months, after
initial diagnosis, there was no significant change (p=0.38) observed in the overall average
PTA. But after one year of initial diagnosis, the difference in PTA between the initial point
is significant (p=0.001) and in this stage, there were 28 (93.3%) out of 30 (100.0%)
patients who had useful hearing. In the third and fifth years after initial diagnosis, the
hearing deterioration was more significant (p<0.001) and in this stage, there were 21
(70.0%):17 (56.6%) patients who had useful hearing, accordingly. In the wait-and-watch
group, we did not find a direct relationship between tumor growth and hearing loss. Also,
in this group, the overall average hearing loss in the first, third and fifth years was
4.6:11.10:14.07 dB, accordingly.
Pennings and his colleagues (Canada, 2011) 289 reviewed 47 unilateral intracanalicular VS
and evaluated hearing function in the follow up period. The mean follow-up was 3.6 years.
In their series all patients showed hearing degradation during follow-up. The mean pure
tone average at the first audiogram was 37.5 dB, which diminished to 50.9 dB at the time
of the last audiogram. Despite the documentation of both tumor progression and hearing
deterioration in many patients, the authors continued to recommend observation rather than
intervention.
Godefroy and his colleagues (Netherlands, 2009) studied 70 VS patients who underwent
the wait-and-watch management. In their series, useful hearing was maintained in 57.0%
of patients after almost 4 years of follow-up255. Their results were very close to ours and
they also did not find a relationship between hearing loss and tumor growth.
There are some other authors also reported the evolution of PTA in VS patients under the
wait-and-watch control. In the series of Walsh and his colleagues (Canada, 2000) the
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hearing loss was observed in 50.0% to 67.0% of cases after conservative treatment,
regardless of tumor regression258.
In the series of Hafioff and his colleagues257 the audiometric follow-up in 40 patients at 80
months showed that most patients had significant hearing loss even in the absence of
measurable tumor growth. In their case the overall average hearing loss within 80 months
was 36dB. Also they found hearing loss to be worse in the presence of measurable tumor
growth.
According to Massick and his colleagues281 (USA, 2000) the auditory pathways have a
level of reserve when injured. When this reserve is expended, any increase in tumor
volume results in progressive deterioration in audiometric function. The initial overall
average PTA in their series was 34.71 ±20.8dB, and after 5 years of follow-up, this
average changed to 53.90 ±31.11dB. Within the five years, the group lost 19.2dB. They
revealed significant correlations of changes in tumor volume with changes in the pure-tone
average (p< 0.0001). Although the hearing loss is significant, the number of patients
included in the study is probably important for rightly estimating presented results of given
work..
Breivik and his colleague (2013, Norway)287 comparatively studied two treatment options
wait-and-watch and radiosurgery in 237 unilateral VS patients with the mean follow up
time of 55 month. They found that within the follow up time the useful hearing was lost in
76,0% of 71 (100,0%) wait-and-watch patients, which is significantly higher than our
observation.
Régis and his colleagues (France, 2010) also studied two treatment options, wait-and-
watch and radiosurgery, in 47 unilateral intracanalicular VSs with the mean follow-up time
of 43.8 ±40 months. In their group, at 3, 4, and 5 years, the useful hearing preservation
rates were 75.0%, 52.0%, and 41.0% in the wait-and-watch group. Wait-and-watch
management failed in 35 patients (74.0%) due to tumor growth or worsening of hearing288.
In our follow-up group, there are 30 (62.5%) out 48 (100.0%) patients who presented with
an intracanalicular tumor with the initial average PTA of 49.18 ±23.45 (Range 16.25-
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97.50)dB. After 5 years, there were 17 (61.5%) patients who presented with useful hearing
with an overall average PTA ≤ 50dB.
Author,
year (Ref. n)
Patients
(n)
Follow up
(months)
Tumor
growth
rate
Hearing
preservation
rate
Additional
treatment
needed
Breivik 2013 (287) 124 55 NR 24% 50,8%
Pennings 2011 (289) 47 43,2 17% 74% 17%
Régis 2010 (288) 47 43,8 77% 41% 74%
Godefroy 2009 (255) 70 43 36% 57% 39%
Sughrue 2010 (138)m 34 (982) 26–52 NR 54% 16%
Hajioff 2008 (257) 72 121 77,7% NR 35%
Massick 2000 (281) 21 45,6 66% 66,6% NR
Walsh 2000 (258) 25 43,8 32% 43% 12%
*NR not reported, m - meta-analyses
Table 26. Summary of the recent series of VSs managed with the wait-and-watch strategy
5.5.1.2 Radiosurgery group
GK Radiosurgery has often been cited as a safe and effective treatment for small and
medium sized VSs288,290 But sometimes this safety and effectiveness may be questioned
due to the lack of comparison with the natural course of other studies.
According to our follow-up results, the initial and final PTA average were significantly
different (p<0.001). At the diagnostic stage, there were 20 (41.6%) patients who presented
useful hearing (PTA ≤ 50dB), and the rate of useful hearing preservation in six months,
one, three and five years were at 75.0%, 60.0%, 50.0%, and 35.0% respectively. Also, in
diagnostic stage, there were 30.9% (13/42) (As-treated cohort) patients who presented the
flat audiometric configuration, but at the end of the last follow-up study, there were 50.0%
(21/42) VS patients who presented with a flat audiometric configuration p<0.0001. We
have observed statistically significantly different hearing degradation in all patients who
underwent GK radiosurgery, and the overall average PTA at the follow-up points were also
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statistically significantly different (initial vs. one year p=0.01, initial vs. third and five
years p<0.001). Of the 42 patients treated with GK radiosurgery, one (2.3%) patient failed
to complete the radiosurgery as a result of tumor growth after the GK radiosurgery. The
patient was then directed to Neurosurgery.
Hearing preservation is an important and critical issue for patients with VS undergoing
GKS. The literature to the topic contains controversies, and a large number of individual
results have been reported, but to date there have been few efforts to aggregate this
research to achieve statistical power291.
Unlike our studies, some GK Radiologists, in their studies, reported the useful hearing
preservation to be 61.0% to 80.0% in the third and five years after GK radiosuregry284.
But the results of large meta-analysis performed by Yang and his colleagues (USA, 2010)
are close to our results291. Yang and his colleagues performed a systematic literature
review of the results of GKS hearing preservation which included 45 articles from 4,234
patients who provided the data. The mean follow-up was 44 months. Overall, the hearing
preservation rate was 61.0% with a dose of 13 Gy or lower, and 50.4% at more than 13 Gy.
They concluded that neither patient age nor tumor volume correlated with hearing
preservation and an overall hearing preservation rate of approximately 51.0% can be
expected approaching 3-4 years after radiosurgical treatment. The analysis reveals that
patients treated with < or = 13 Gy were more likely to have preserved hearing than patients
receiving larger doses of radiation.
In the series of Régis and his collagues288 in the GK radiosurgery group, 66.0% (31/34)
had useful hearing at the time of diagnosis. Only 21 (68.0%) preserved useful hearing and
10 (32.0%) lost useful hearing during follow-up. Authors confirmed that tumor control and
functional hearing preservation rates were higher in patients who underwent early GK
radiosurgery, which in their series was 88.0%, 79.0%, and 60.0% at 1, 2, and 5 years,
respectively.
According to Kondziolka and his colleagues284 in a longer-term assessment of hearing at a
median of 6 years the hearing was preserved in 71.0% of patients, serviceable hearing was
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confirmed in 74.0% of patients, and any testable hearing was present in 95.0% of patients.
For intracanalicular tumors, these rates were 84.0%, 92.0%, and 100.0%, respectively.
The summary of results from anological studies of some authors are presented in Table 39.
Author,
year (Ref. n)
Pts (n) Follow up
mean
(months)
Tumor
control
rate
Hearing
preservation
rate
Additional
treatment
needed
Arthurs 2011 (282)m (84)
1,850
72 91–95% 60% 3,9%
Régis 2010 (288) 34 43,8 3% 64% 3%
Yang 2010 (291) m 45
(4,234)
44,4 NR 51% NR
Yang 2009 (179) m 74
(5,825)
41 94% 57 (=2,083) NR
Paek 2005 (293) 25 45 0% 52%. 0%
Carlson 2012 (294) 44 111,6 NR 23% NR
Yamakami 2003
(183)m
9
(1,475)
46 92,6% 66% 4,2%
* NR –not reported, m -Meta-analysis.
Table 39. Summary of recent series of VSs managed with GK Radiosurgery
Timmers and his colleagues (USA, 2011) performed a prospective study in 100 patients
treated with GK radiosurgery. Eight patients needed additional treatment after a mean
follow-up period of 38 months. One patient experienced a temporary facial nerve deficit.
In their series, based on the measurements of the largest extrameatal diameter, the tumor
size decreased or remained stable in 94.0% of the patients.
Some other authors reported the negative effects of GK radiosurgery to overall hearing,
and they believe the reason for the hearing deterioration after GK radiosurgery in patients
with vestibular schwannoma has not been documented clearly. However, there are several
hypothetical causes of hearing deterioration proposed in the literature. One of those causes
could be the direct radiation of the brainstem, which is believed to be a significant
prognostic factor for hearing deterioration after GK SRS. Interestingly, the cochlear
nucleus may be one of the other sensitive structures to be damaged by radiotherapy293.
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Size of the tumor5.5.2
5.5.2.1 Wait-and-watch group
During the overall observational period, the VSs seemed to be non-growing in a majority
of cases (70.2%). However, as we mentioned before, there are 29.8% (20/94) patients who
presented the tumor growth. Among them 28.3% (19/67) of the patients were under the
wait-and-watch strategy.
Like many authors we also did observe the tumor shrinkage after GK Radiosuregry287-288,
however, unlike some other authors we did not observe the protective effect of GK
Radiosurgery on hearing287,290-291.
Rosenberg and his colleagues (2000, USA)295 conducted a retrospective study of 80
patients with unilateral vestibular schwnnoma who had conservative treatment with the
average duration of 57,6 months by serial imaging studies. In their series, the overall
growth rate, with conservative treatment, was 0.91mm per year, and in 42.0% of the cases,
they found the VS to be non-growing or regressing in size. According to them, neither
auditory nor vestibular testing was a reliable measure for determining tumor growth. The
percentage of non-growing tumors in their series was a little bit smaller than ours.
However, other authors stated the percentage of non-growing tumors to be higher. For
instance, in the series of Godefroy 255 the percentage of non-growing tumors in
conservatively managed patients was 63.0% (44/70), and the percentage of patients who
required treatment was 39.0% (27/70). Following Régis and his colleagues (2010,
France)288 found the percentage (ratio) of growing and nongrowing VSs to be 74:26.
Another study based on a review of 47 patients with unilateral intracanalicular
schwannomas was performed by Pennings and his colleagues289 to evaluate hearing
function during a period of observation. The mean follow-up was 43,2 months. Nineteen
patients (40.0%) had tumor growth greater than 2mm (8 patients underwent treatment), 24
(51.0%) had stable tumors, and 4 (9.0%) had slight tumor regression. All patients showed
hearing degradation during the follow-up stages. In spite of the documentation of both
tumor progression and hearing deterioration in many patients, the authors continued to
recommend observation rather than intervention.
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5.5.2.2 Radiosurgery group
According to more recent studies conducted by Breivik and his colleagues (2013, Norway)
the GK Radiosurgery reduces the tumor growth rate and prevents the new treatment about
tenfold287. According to the long-term results of GK Radiosurgery for VSs the tumor
control rate varies from 93.0% to 100.0% after radiosurgery288,292,296-297.
In our series, a total of 42 patients (As-treated cohort) underwent GK Radiosurgery and
among them, only one (2.8%) patient presented the tumor growths after they were treated
with GK Radiosurgery. In 26.1 % (11/42) of cases, we have observed negative growth
after GK Radiosurgery and in all other cases, the tumor remained steady.
Kondziolka and his collagues290studied 5 to 10 year outcomes in 162 patients with a VS
who had undergone radiosurgery. In this study, a long-term 98.0% tumor control rate was
reported. In another study performed by the same authors in 157 patients, there was a
decrease in tumor size in 114 patients (73.0%), no change in 40 patients (25.5%), and an
increase in 3 patients who later underwent resection (1.9%). In their series, only 2.0% of
patients required tumor resection after radiosurgery.
Kim and his colleagues (2007, Korea)298 observed 59 post-radio surgery patients with the
duration of at least 5 years, and in their series, the tumor control rate was 97.0%. They also
classified the patterns of change in tumor volume into three categories. Transient increases
in tumor volume were detected in 29.0% of the patients, and the maximum transient
increase in tumor volume was identified at 6 to 30 months after GK Radiosurgery. The
report stated that the hearing was preserved in 4 of the 12 patients who had serviceable
hearing prior to treatment. They concluded that the tumor control after GK Radiosurgery
depends on the dosage of radiation, and they believe that with an average of 12 Gy, the
tumor control would be between 86.0% and 98.0%.
Some studies have reported about malignant transformation of VS after performed GK
Radiosurgery299, has been performed, but in our series, we did not observe cases of a VS
transforming into a malignant tumor. According to certain authors, after fractionated
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external-beam radiation therapy, the risk of malignant transmission may be as high as
2.0%, as has been reported many years after such radiation therapy for pituitary tumors300.
Delayed oncogenesis following radiosurgery is rare because the target and regional tissue
volume irradiated are small. The procedure results in a single radiation exposure, and the
high central dose more than likely leads to cell death rather than cell transmutation290.
Case of NF25.6
The NF2 is a less frequent among VS patients and its low incidence contributes to the
difficulty in obtaining an accurate diagnosis301. Although the NF2 is less frequent but it
causes dramatic clinical outcomes281,301. Patients with NF2 are routinely treated and
controlled by neurosurgeons since they usually have a VS as well as meningiomas in other
parts of the CNS. However, due to the importance of periodic monitoring of hearing and
vestibular functions, patients with NF2 should be controlled by otolaryngologists as well.
In the last few years, the hearing rehabilitation for NF2 patients by means of auditory
brainstem implantation (ABI) is gaining more popularity because an ABI after tumor
removal is a safe procedure and is the best means of hearing rehabilitation if the cochlear
nerve is not preserved.
Final considerations5.7
Over the past few years, the wait-and-watch strategy in the management of VSs is
increasingly adopted as an initial treatment option for a VS. As shown in previous reports,
our study shows that a wait-and-watch strategy serves as a screening tool for the
management of VSs because there aren't any effective criteria to consider GK
Radiosurgery or Conventional Neurosurgery at the diagnostic stage.
Wait-and-watch management does not seem to worsen the patient's overall quality of life
over time and useful hearing is preserved in wait-and-watch control much better than GK
Radiosurgery. Thus, in our group, patients with non-growing small tumors and with a
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stable clinical picture were prospectively continued in follow-up under the
wait-and-watch plan.
We have observed the hearing loss to be more pronounced in case of GK Radiosurgery,
and by comparing with other similar studies, we were brought to the conclusion that the
radiation dose is perhaps the most important contributing factor. Nevertheless, no definite
guideline for determining the appropriate radiation dose for GK SRS has been established.
At times, it appears to be that there are other issues related with a patient's individual
resistance to radiation; however, a satisfactory hearing preservation and tumor control rate
could not be achieved using a low radiation dose.
Our study demonstrates that a trial of the wait-and-watch approach is reasonable in the
majority of selected patients with a small-sized VS and outcomes are not adversely
affected in those patients who ultimately failed in the wait-and-watch management.
Our guidelines on clinical management of a VS –protocol of treatment5.8
Choosing the treatment option for a VS continues to be a challenging issue for more than
100 years because of their benign nature and potentially significant surgical morbidity and
mortality related to the complex anatomy of the CPA. However, in recent years,
development of new diagnostic modalities such as the CT, the MRI and the auditory evoke
potentials has resulted in the drastic decrease in the average size of a VS at diagnosis.
Using the serial MRI also enables the control of non-growing VSs, thereby warning of
possible complications of Conventional Neurosurgery and/or Radiosurgery.
The following Table 31 presents the main factors for consideration of treatment
options for a VS.
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Factors Influencing
to the treatment
Treatment options
Wait-and-
watch
Radiosurgery Neurosurgery
Tumor size ≥20mm + ++
10-15 + +
≤10 ++ +
Age ≥60 + + +
45-60 + ++ +
≤45 + +
Tumor
localization
Intracanalicular + ++ +
Extracanalicular ++ ++ +++
Intra-
Extracanalicular
+ ++ ++
PTA≥50dB Yes ++ +
Not + ++ +
Table 27. The plus signs show factors which influence VS treatment options
There are also some other important factors which may influence the decision of either
treatment options and one of those factors could be the clinical presentation. Although the
predictive value was limited, the symptoms of vertigo, facial paralysis and hearing loss
may be the indicators which predict tumor growth.
Limitations of this study5.9
Although this research was carefully prepared, we are still aware of its limitations and
shortcomings.
First of all, not all VS’s were histologically confirmed because many patients were
diagnosed with an MRI; therefore, it is possible that our sample included individuals with
other diagnoses such as meningioma or facial nerve schwannoma.
Second, due to the fact that our study was retrospective in almost all cases, the size of the
tumor was considered according to the maximal diameter. In our awareness nowadays in
many centers, volumetric measurement becomes more popular and the measurement of a
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tumor by its volume gives more reliable information for comparing the tumor size in the
follow-up periods.
Third, not all patients may have reported all relevant symptoms because there are
differences in the willingness to report certain symptoms or differences in provider
interviews. Also, our study did not include some important information, in our opinion.
Tests like the Speech Recognition Test (SRT) and the results of the stapedial reflex (SR)
may have made our study more reliable. The SRT is especially important for the
comparison of hearing preservation rates with other analogic works used, like the Gardner-
Robertson Classification; however, the works used for this scale does not include
frequencies higher than 2000 Hz.
In addition, in the last follow-up time, we lost some patients. Also, over each follow-up
time, some patients in our series changed treatment options which complicated comparing
groups in follow-up points. Therefore we used “Intention-to-treat” and “As-treated
statistical approaches”.

Conclusions
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6 Conclusions
The first conclusion in our series is that the vestibular schwannoma affects both genders
equally at all ages, and its peak incidence is in the sixth decades of life.
Secon, in our patients, the percentage of affection of the intra- and extracanalicular
components of vestibulococlear nerve is similar.
Third, the most common presenting symptom at the time of diagnosis is the hearing loss.
Fourthly, the usual type of hearing loss we meet in our patients is the sensorineural high-
frequency hearing loss with the sloping audiometric configuration.
The fifth conclusion is that the severity of audiometric alteration is related with the
localization of the vestibular schwannoma and the hearing is more affected in
intracanalicular tumors than extracanalicular tumors.
Sixth, the instrumental tests for vestibular functions tend to show abnormal results in those
patients who presented with vestibular symptoms at the diagnostic stage and the tests are
usually normal in those patients who do not present with vestibular symptoms at the time
of diagnosis.
Seventh, in small tumors, the two compared therapeutic approaches (wait-and-watch and
GK Radiosurgery) are effective in controlling the growth of the vestibular schwannomas.
Eighth, in those patients who underwent GK Radiosurgery, the hearing deterioration
observed during follow-up is higher than those included in the wait-and-watch group.
Ninth, in patients who underwent GK Radiosuregry, over the follow-up years, show tumor
shrinkage more that those patients included in the wait-and-watch group.
Tenth, the complications experienced as a result of GK Radiosurgery were not significant.
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Eleventh, in patients with a small vestibular schwannoma, the wait-and-watch protocol is a
correct therapeutic approach which does not worsen the medium-term prognosis.
Twelfth and finally, we consider the wait-and-watch therapeutic approach to be a
“screening tool” for vestibular schwannomas in the early stages after diagnosis.
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